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1. INTRODUCTION 
 
 In this thesis, the sensitivity of four methods for the detection of mycoplasma 
contamination and the effects of mycoplasmas on the germ line transmission (GLT) 
of murine embryonic stem (mES) cells and the phenotypes of the chimeras were 
investigated. 
 
I. Sensitivity of the detection of mycoplasma contamination in cell cultures  
 
 Since the first report of the presence of mycoplasmas in cell cultures in the 
mid 1950’s (Robinson 1956), a consolidation of information has been published, 
concerning new mycoplasma species, their habits, properties and their interaction 
with cells in vitro (Sethi 1972, Barile 1979, McGarrity 1985, Muhlradt 1991, Tsai 
1995, Baseman 1997, Razin 1998, Deiters 1999, Rottem 2003, Zhang 2004, 
Yavlovich 2001, Yavlovich 2006, Zhang 2006). The presence of mycoplasmas can 
influence the growth and effect morphological, biochemical, immunological and 
genetically properties of the cells, and therefore endanger the interpretation of the 
results of biological experiments, as well as the quality of biopharmaceutical products 
thus resulting in a loss of time, materials and products (Tully 1996). For this reason, 
European Pharmacopoeia and Federal Drug Administration recommend frequent 
examination of cell cultures for mycoplasmas, in order to provide quality and safety of 
products (CBER/FDA 1993, Pheur 2004). In cell cultures, the incidence of single 
mycoplasma contamination is still high, being 15 to 35% worldwide with extreme 
incidences of 65 to 80%, whereas multiple mycoplasma infections with 2 or more 
mycoplasma species are between 7 and 60% (Drexler 2002, Uphoff 2002, 
Timenetsky 2006). Sources for mycoplasma contaminations in cell cultures are 
laboratory personnel, contaminated serum, media and already contaminated cell 
cultures. Among the 20 mycoplasma species that have been isolated from 
contaminated cell cultures, the species that are found in human are responsible for 
more than half of all mycoplasma infections (Drexler 2002). These include M. 
hominis, M. fermentans and M. orale. Mycoplasmas differ from other bacteria found 
in cell cultures. They could be present without causing any visible changes in cell 
cultures such as turbidity or change of colour of the media. Due to their lack of a rigid 
cell wall they are resistant to penicillin and streptomycin, two of the most common 
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antibiotics used for routine cell culture work. In addition due to their small size 
conventional microscopy does not detect them. 
 Over the years, a number of techniques for the detection of mycoplasmas 
have been developed. These include agar culture, culture of samples on indicator 
cell lines and DNA fluorochrome staining, biochemical cytotoxicity assay, enzyme-
linked immunosorbent assay (ELISA), DNA-RNA hybridization, one step- and nested-
PCR, PCR-ELISA, and real-time PCR (McGarrity 1985, Johansson 1990, Uphoff 
1992, Uphoff 1992, Hopert 1993, Tully 1996, Uphoff 2002, Uphoff 2002, Garner 
2000, Harasawa 2005, Ishikawa 2006). Many of these methods are time-consuming, 
complex, subjective, detect only a restricted number of mycoplasma species, and 
some of them appear to be marginally useful (Uphoff 1992, Uphoff 1992). 
 An ideal detection method should not only be highly sensitive but also simple, 
rapid, efficient, and cost effective. As such there is still a lack of a suitable method 
which fulfils all the criteria for routine diagnostic work (Drexler 2000, Drexler 2002, 
Uphoff, 2002). 
 In the first part of the thesis, the objective was to determine the sensitivity of 
two commercial assays, the newly developed MycoAlertTM and MycoSensorTM QPCR 
assays in detecting M. hominis, M. fermentans and M. orale and to compare the 
results with those obtained by agar culture and an in-house established gel-based 
PCR. Ten-fold serial dilutions of fresh supernatants and cell suspensions of L929 
fibroblast cells were analyzed for this purpose. This step was important for reliable 
detection of mycoplasmas in the ES cell cultures. 
 
II. The influence of mycoplasma species on the germ line transmission of 
murine embryonic stem cells and phenotypic analysis of chimeras 
 
 The use of pluripotent mES cells increased within the last years. In biomedical 
research, mES cells are used for the production of transgenic and knock-out mice 
which serve as animal models for human and animal diseases, in studies for 
investigating embryonic development and for in vitro studies of cell systems 
established after their spontaneous differentiation into well-defined somatic cell types 
(Rohwedel 1996, Wobus 2005). Additionally, mES cells are used for studies in 
pharmacology, embryotoxicology, and cell transplantation and replacement therapy 
(Wobus 2005, Cormier 2006). Due to the high demand of mES cells which results in 
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extensive and uncontrolled exchange between laboratories worldwide, the risk of 
contaminations may be high. In contrast to human ES cell lines which are tested for 
pathogens prior to their use, animal ES cell lines are often used without 
determination of their microbiological status. As a result, contaminated mES cell lines 
could lose their pluripotential properties and the ability to contribute to the germ line, 
becoming worthless for studies, or they could lead to contamination of other 
laboratories and animal facilities (Nicklas 2000, Nagy 2003). 
 In the second part of the thesis, the objective was to determine the effects of 
mycoplasmas on the TBV2 mES cell line (129/SvPas) during in vitro culture, the 
ability to contribute to the germ line, the phenotype of chimeras and their progeny. As 
such, TBV2 mES cells in the 13th passage (P13) were inoculated with the human 
species M. hominis, M. fermentans and M. orale to establish a multiple mycoplasma 
infection. The mES cells were cultured over 20 passages and the growth rate, the 
viability and the susceptibility of mES cells to mycoplasmas were determined. The 
karyotype and the differentiation status of mycoplasma-infected and control mES 
cells were determined at different passages via Spectral Karyotyping (SKY) and 
Fluorescence Activated Cell Sorting (FACS), respectively. Furthermore, 
mycoplasma-infected and control mES cells were injected into Crl:CD1 (Icr) 
blastocysts for the production of chimeras. The phenotype of the resulting chimeras 
from mycoplasma-infected litters was described based on clinical, morphological, 
histological, and immunological examinations. The contribution to the germ line was 
evaluated after mating chimeras produced with C57BL/6 mice and scoring the 
number of germ line pups. 
 
 
 
 
 
Literature review/Mycoplasmas  4 
2. LITERATURE REVIEW 
 
2.1 Mycoplasmas 
 Mycoplasmas were reported for the first time in 1898 by Nocard and Roux 
after the successful cultivation of the causative agent of contagious bovine 
pleuropneumonia (Nocard 1990). The name “mycoplasma” (from the greek words 
“mykes” which means fungus and “plasma” which means formed) was coined in the 
1950s by Edward and Freundt (Edward 1956) replacing the term “pleuropneumonia-
like organisms” (PPLO). It was used to describe the only known mycoplasma at that 
time, the bovine species M. mycoides, which has a fungus-like growth pattern, being 
unique for this mycoplasma species. In 1937, Dienes and Edsall isolated from a 
gland abscess the first human mycoplasma species, probably the now known M. 
hominis (Dienes 1937, Tully 1996, Waites 2005). The first mycoplasma infection in 
cell cultures was reported by Robinson et al. in 1956, in which mycoplasmas were 
detected in negative control cell cultures (Robinson 1956). 
 
2.1.1 Taxonomy of mycoplasmas 
 Mycoplasmas are one of the eight genera that constitute the class of 
Mollicutes, and with more than 120 recognized species they are the largest group of 
all (Figure 1) (http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi). 
 Phylogenetic studies involving sequence analysis of the highly conserved 16S 
mRNA revealed that mycoplasmas are closely related to Gram-positive Clostridia, 
Bacillus, and Lactobacillus. According to the current molecular biological taxonomy, 
based on sequence similarities and phenotypic properties, mycoplasmas are 
reclassified into three groups, the hominis, the pneumoniae and the spiroplasma 
group (Weisburg 1989, Drexler 2000). 
 
2.1.2 General characteristics and properties of mycoplasmas 
 Mycoplasmas are 0.3 to 0.8 µm large and are the smallest self-replicating 
organisms known (Robertson 1975, Razin 1978, Drexler 2000). They lack a rigid cell 
wall, and are surrounded by a single plasma membrane (Rottem 2003, Razin 1998). 
As such, mycoplasmas are pleiomorphic, demonstrating a variety of forms, including 
spherical, pear- and flask-shaped, rod-like and filamentous (Kim 1966, Razin 1998). 
On solid agar, they build colonies after 3 to 5 days, with a characteristic “fried-egg” 
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appearance and a diameter of 100 to 400 µm, but in some cases, they grow very 
slowly and are not recognizable until 1 to 3 weeks or more (Drexler 2002). 
 
 
 
Class: Mollicutes 
 Order I: Mycoplasmatales 
 Family I: Mycoplasmataceae 
  Genus I: Mycoplasma 
   Genus II: Ureoplasma 
 Order II: Entomoplasmatales 
  Family I: Entomoplasmataceae 
   Genus I: Entomoplasma 
   Genus II: Mesoplasma 
  Family II: Spiroplasmataceae 
   Genus I: Spiroplasma 
 Order III: Acholeplasmatales 
  Family I: Acholeplasmataceae 
   Genus I: Acholeplasma 
 Order IV: Anaeroplasmatales 
  Family I: Anaeroplasmataceae 
   Genus I: Anaeroplasma 
   Genus II: Asteroplasma 
 
Figure 1 Conventional classification of Mollicutes 
 
 
 Mycoplasmas have a double-stranded DNA and divide by binary fusion. The 
procedures of cytoplasmic division and genome replication are asynchronous, 
resulting in the formation of filaments and transformation into chains of cocci until 
division is completed (Razin 1998, Drexler 2000). Their generation time is between 1 
to 9 hours and they have a relative long lag phase (Drexler 2002). The mycoplasma 
genome ranges from 580 (M. genitalium) to 2.220 kb (Spiroplasma), and it contains 
24 to 33 mol% G+C and approximately 500 genes (Dybvig 1996, Pollack 1997, Razin 
1998, Drexler 2000, Rottem 2003). This number of genes represents only around 
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one-fifth of the number of genes found in other bacteria (Drexler 2000). As a result, 
mycoplasmas lack many enzymatic pathways, such as the pathway for cell wall 
production and de novo biosynthesis of purines, a functional tricarboxylic acid cycle 
and a cytochrome-mediated electron transport-system, while their energy-yielding 
pathways are inefficient (Dybvig 1996). 
 Mycoplasmas are characterized as fermentative and non-fermentative 
species, based on their ATP-producing abilities. Fermentative mycoplasmas produce 
ATP by carbohydrate fermentation via the glycolytic pathway, whereas in non-
fermentative mycoplasmas, ATP production is achieved by arginine hydrolysis via the 
arginine-dihydrolase pathway. Some mycoplasma species, such as M. fermentans 
produce ATP, using both metabolic pathways. Furthermore, a mechanism based on 
ATP production from enzymes commonly found in both groups of mycoplasmas was 
proposed as a complementary way of ATP production (Razin 1978, Razin 1998, 
Drexler 2000). 
 Mycoplasmas are found in humans, animals and in cell cultures, where they 
live commensally or as pathogens. As parasites, mycoplasmas exhibit host and 
tissue specificities. As such, they are able to enter the host cells in which they 
multiply and survive for a long period of time, they develop mechanisms of mimicry 
against host antigens in order to deal with the host immune system, and they survive 
within phagocytic and non-phagocytic cells generating phenotypic plasticity (Razin 
1998, Rottem 2003). 
 
2.1.3 Mycoplasmas in cell cultures 
 Mycoplasmas can very easily contaminate in vitro cell cultures. They can be 
present without causing any visible changes, like turbidity or changes of the colour of 
cell media, and they remain undetectable under conventional microscopy. Their 
plasticity allows them to pass through commonly used antimicrobiological filters of 
0.45 µm in diameter (Drexler 2000). Furthermore, mycoplasmas are gram-negative 
and show resistance to commonly used antibiotics such as penicillin and 
streptomycin (Drexler 2002, Uphoff 2005). 
 Contaminated cell lines, reagents and laboratory equipment often serve as 
sources for mycoplasma contaminations (McGarrity 1985, Drexler 2002). The ease of 
droplet generation from mycoplasma contaminated cell lines during cell handling, the 
high concentration of mycoplasmas in infected cultures and their resistance to 
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dehydration (up to 7 days on working surfaces) play an important role in the tenacity 
and transmission of mycoplasmas to cell cultures (McGarrity 1985, Drexler 2000, 
Drexler 2002). Furthermore, laboratory personnel significantly contribute to spreading 
of contaminations (Tully 1996, Uphoff 2002, Drexler 2002). 
 Infection of cells by mycoplasmas depends on the dosage of mycoplasmas 
and the type of cells involved. Generally, mycoplasmas grow very well in cell 
cultures. One mycoplasma cell could result in 106 CFU/ml in 3 to 5 days in an 
infected cell culture giving titers of 106 to 108 organisms/ml. In heavy infections, 
approximately 100 to 1000 mycoplasmas are attached to each cell (Drexler 2002). 
 
2.1.3.1 Frequency and common mycoplasma contaminants in cell cultures 
 The frequency of mycoplasma contaminations in vitro varies worldwide, 
depending on the number of cell cultures examined, the detection methods used by 
the individual laboratories, and the geographic area in which these frequencies were 
recorded (McGarrity 1985, Tully 1996). Primary cell cultures and cell cultures of early 
passages are less frequently contaminated with reported incidences of 1 and 5%, 
respectively. In contrast, continuous human or animal cell lines are the most 
frequently contaminated with a prevalence of 15 to 35% (Drexler 2002). 
 Animal mycoplasma species like M. arginini, M. hyorhinis, and Acholeplasma 
laidlawii used to be the most common mycoplasma species found in cell cultures due 
to the use of contaminated serum (McGarrity 1985). Currently data, are classifying 
the human species M. orale as the most common contaminant species with a 
frequency of 20 to 40%, followed by M. hyorhinis (10 to 40%), M. arginini (20 to 
30%), and M. fermentans and M. hominis with 10 to 20% (Drexler 2002). Multiple 
infections involving 2 or more mycoplasma species vary between 7% (Uphoff 2002) 
and 62% (Timenetsky 2006) of mycoplasma contaminations in cell cultures. 
 
2.1.3.2 Effects of mycoplasmas on cell cultures 
 Mycoplasmas affect several cell parameters in vitro, influencing growth, 
morphology, metabolism, the genome, and the antigenicity of the cells (Stanbridge 
1971, Barile 1979, McGarrity 1984, McGarrity 1985, Drexler 2000, Drexler 2002). 
These effects depend on the infecting mycoplasma species, the infected cell type, 
the culture conditions, the intensity and duration of the infection (Drexler 2002). 
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 Effects on growth, morphology and metabolism. The requirement of 
mycoplasmas for nucleic acid precursors and their competitive use of amino acids 
and other nutrients result in cytopathic effects on the cells. The production of 
hydrogen peroxide, acidic conditions, depletion of arginine and other nutrients induce 
increased granularity, cytotoxicity, lysis and cell death (Stanbridge 1971, Barile 1979, 
McGarrity 1985, Drexler 2000). Mycoplasmas alter the levels of proteins, RNA and 
DNA synthesis and metabolism of the cells (Drexler 2000, Drexler 2002). 
Consequently, cells undergo degeneration showing pyknotic nuclei, margination of 
chromatin, nucleolar segregation and nuclei with condensed chromatin (leopard 
cells) (Stanbridge 1971, Drexler 2000). The addition of proper nutrients in culture 
media can reverse some of the above-mentioned effects, but others remain 
irreversible (Stanbridge 1971, Drexler 2000). Furthermore, mycoplasmas influence 
the growth rate of infected cells (Stanbridge 1971). Abnormal, stunted growth pattern 
with rounded degenerated cells and detachment of monolayers could be obtained 
due to mycoplasma contamination (Barile 1979, Drexler 2000). 
 Effects on the genome. Mycoplasmas induce chromosomal aberrations in 
cultured cells, which consist mostly of achromatic gaps, chromatid breaks, 
translocations, and rearrangements, dicentrics, and pulverization. A further gradual 
reduction on the number of chromosomes and appearance of new chromosome 
varieties could be induced by mycoplasmal infections (Stanbridge 1971, Barile 1979, 
McGarrity 1985, Drexler 2000). 
 Effects on antigenicity and immunology. Interactions of mycoplasmas with 
cultured cells result in changes in cell membrane composition thus affecting the 
expression of surface antigens and receptors (Drexler 2000). In addition, the 
presence of mycoplasmas influences the propagation of virus in cell cultures. Non-
fermentative species decrease the propagation of arginine-dependent DNA virus due 
to arginine depletion. The mycoplasmal presence could induce or inhibit the 
production of interferon-γ in cell cultures, resulting in the reduction or increase of 
virus propagation, respectively (Barile 1979, McGarrity 1985, Drexler 2000). 
Mycoplasmas affect haematopoietic cells in vitro, stimulate or inhibit their activation, 
proliferation and differentiation. They enhance immunoglobulin secretion of B-cells 
and induce expression of cytokines and growth factors such as IL-1β, IL-2, IL-6 and 
TNF-α (McGarrity 1985, Razin 1998, Drexler, 2000). 
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2.1.3.3 Methods for detection of mycoplasmas in cell cultures 
 Cell cultures are used extensively in biomedical research and for the 
production of biological products. Mycoplasmas can affect various cell parameters 
leading to misinterpretation of experimental results and contamination of biological 
products. As such, cells should be screened for mycoplasmas prior to their use. 
 Several techniques that have been developed for the detection of 
mycoplasmas in cell cultures are summarized in Figure 2 (Drexler 2000). 
 Mycoplasmologists developed direct and indirect methods for mycoplasma 
detection in cell cultures. The term “direct” is referred to the classical microbiological 
colony growth on agar which detects directly viable mycoplasma cells, whereas the 
term “indirect” refers to procedures that measured gene products of mycoplasmas or 
they are based on mycoplasmal enzymatic, metabolic and other properties (Drexler 
2000). 
 Most of these methods are complex, difficult to interpret, involve subjective 
assessments, are lengthy, and expensive. An ideal method should be highly 
sensitive, specific, simple, rapid, easy to interpret, efficient, and cost effective (Uphoff 
1992, Uphoff 1992, Drexler 2000, Drexler 2002, Uphoff 2002). The criteria which 
methods are based on are sensitivity (detection of true positives), specificity 
(detection of true negatives), accuracy (detection of true positives and true 
negatives), predictive value (probability of correct results) and reproducibility 
(concordance of interpretation of results) (Drexler 2000, Uphoff 2002). 
 Today, the most reliable methods used for mycoplasma detection in cell 
cultures are culture in broth and agar, and the PCR method (Drexler 2002). There 
are several broth and agar media developed for cell-free growth and culture of 
mycoplasmas including Friis, PH-Hayflick (modified or not), SP4 and DM-1 medium 
(Hayflick 1965, Uphoff 1992, Uphoff 1992, Tully 1996). For proper and better quality 
control, results obtained with culture should be confirmed by a second method. For 
mycoplasma species that cannot be cultured in artificial media, an indicator cell line 
is proposed as the method of choice (Tully 1996). The PCR method with protocols 
based on 16S rRNA sequence regions and the 16S-23S intergenic regions of 
mycoplasma species includes single or nested PCRs, genus or species-specific, gel-
based or real-time PCRs (van Kuppeveld 1992, Blanchard 1993, Blanchard 1993, 
Harasawa 1993, van Kuppeveld 1994, Razin 1994, Dussurget 1994, Rawadi 1995, 
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Harasawa 1996, Harasawa 1999, Tang 2000, Garner 2000, Kong 2001, Uphoff 2005, 
Harasawa 2005, Ishikawa 2006, Timenetsky 2006, Sung 2006, Bruchmuller 2006). 
 
 
Histological staining: Histochemical stains and light microscopy 
Electron microscopy: Transmission/Scanning electron microscopy 
Microbiological culture: Broth/Colony formation on agar 
DNA fluorochrome staining: DAPI/Hoechst 33258 stain 
Biochemical methods: Enzyme assays 
       Gradient electrophoresis separation of labeled RNA 
       Protein analysis 
Immunological procedures: Fluorescence/enzymatic staining with antibodies 
      ELISA, Autoradiography 
RNA hybridization: Filter/Liquid hybridization 
Polymerase chain reaction: Species-/genus–specific PCR primers 
      Universal PCR primers 
 
Figure 2 Methods for detection of mycoplasma in cell cultures (Drexler 2000) 
 
 
2.1.3.4 Elimination and eradication of mycoplasmas in cell cultures 
 For routine laboratory work, mycoplasma-positive cell cultures should be 
discarded and replaced with new mycoplasma-free cell stocks. However, for 
irreplaceable, valuable cells, attempts to eradicate mycoplasmas and render cells 
mycoplasma-free can be made (McGarrity 1985, Uphoff 1992, Uphoff 2005). 
 Over the years, several techniques have been proposed for this purpose 
including the use of antimycoplasma sera, exposure to detergents selectively toxic 
for mycoplasmas, induction of chromosomal damage in mycoplasmas using 5-
bromouracile and visible light, in vivo passage of continuous cell lines through nude 
mice, co-cultivation of infected cells with macrophages, and antibiotic treatment 
(Schmidt 1984, McGarrity 1985, Schmitt 1988, Drexler 2000, Drexler 2002, Uphoff 
2005). Many of the above techniques are unreliable, ineffective, impracticable, 
cannot be applied in every situation, are time- and cost-ineffective, and change 
characteristics and properties of the cells subsequent to treatment (McGarrity 1985, 
Schmitt 1988, Uphoff 1992, Drexler 2002). Today, the antibiotic treatment is the most 
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promising, reliable, and effective method for the treatment of mycoplasma-infected 
cell cultures (Schmidt 1984). 
 Many antibiotics such as tetracycline, kanamycin, lincomycin, erythromycin, 
tylosine or spectinomycin have been used in different protocols and combinations for 
the eradication of mycoplasmas but resistance was induced to several of them 
(Schmidt 1984, Schmitt 1988). Tiamutin and minocyclin were effective when they 
were used consecutively for weeks without causing any effects on cell properties 
followed by cell cloning for the establishment of mycoplasma-free cell line (Schmidt 
1984). Optimal results presented ciprofloxacin and other quinolones in respective 
experiments (Schmitt 1988, Uphoff 1992). 
 Today, the most prevalent antibiotics with high effectiveness against 
mycoplasmas in vivo (veterinary/human medicine) as well as in vitro (cell cultures) 
are tetracyclines, macrolides, and quinolones. They could be applied in low 
concentrations, having low or no effects on eukaryotic cells, and the possibility of 
developing resistance seems to be very unlikely. The antibiotics of choice from these 
3 categories are tiamutin, minocyclin, quinolones (ciprofloxacin and enrofloxacin) and 
Mycoplasmal Removal Agent (MRA) (Uphoff 2005). The macrolide tiamulin (BM-
cyclin 1) and the tetracycline minocyclin (BM-cyclin 2), which bind to the 30S and the 
50S ribosomal units, inhibit protein synthesis. Quinolones and MRA inhibit the 
bacterial DNA gyrase, which is essential for DNA replication (Uphoff 2005). 
 Generally, antibiotic treatment should last between 2 and 4 weeks. However, 
the treated cells should be monitored for 4 to 6 weeks post treatment (Schmidt 1984, 
Schmitt 1988, Uphoff 1992, Drexler 2000, Drexler 2002, Uphoff 2005) and should be 
negative in order to be declared mycoplasma-free. Absence of mycoplasmas should 
be regularly confirmed by examinations with highly sensitive detection methods 
(Uphoff 2005). 
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2.1.4 Mycoplasma species 
 For the work presented in this thesis, 3 human mycoplasma species were 
used: M. hominis, M. fermentans, and M. orale. These are described in details below. 
 
2.1.4.1 Mycoplasma hominis  
 M. hominis was the first human mycoplasma species isolated from a gland 
abscess (Dienes 1937, Tully 1996, Waites 2005). The genome size of different M. 
hominis strains varies between 704 to 825 kb (Ladefoged 1992, Dybvig 1996). 
Usually, they are round or rod-like (Kim 1966) (Figure 3), but under in vitro 
suboptimal growth conditions produce aberrant forms and show low viability 
(Robertson 1975). It belongs to the non-fermentative species and uses arginine for 
the production of ATP (Schimke 1966). 
 It is located primarily in the human urogenital tract being pathogenic for both 
males and females (Waites 2005), while it was also found at high prevalence in the 
urogenital tract of asymptomatic healthy people (Blanchard 1993, Serin 2001, 
Baczynska 2004, Waites 2005). Clinical studies showed that M. hominis could be the 
causative agent or associated with several inflammatory diseases of the reproductive 
system of adults and be implicated in conditions directly related to perinatal 
infections, which could lead to infertility and spontaneous abortions in women. 
Furthermore, M. hominis could show vertical transmission to the foetus or neonate 
and be implicated with respiratory, neurological, and other systemic infections or 
septic conditions in newborns (Cassell 1991, Waites 2005). Finally, M. hominis could 
cause extragenital and systemic infections in people suffering from immunodeficiency 
syndromes (Waites 2005). 
 Studies in human reproduction and in vitro fertilization showed that M. hominis 
adheres to or invades the human sperm cells, showing no apparent damage and 
significant effects on sperm count, motility and fertilization (Hill 1987, Diaz-Garcia 
2006). In addition, in vitro washing of infected sperm did not result in eradication of 
M. hominis, whereas this procedure managed to eradicate Ureoplasma ureolyticum, 
another genital mycoplasma (Hill 1987). In experimental animal infections, M. 
hominis persisted for 1 day to 4 months in mice and up to 4 weeks in guinea pigs 
after subcutaneous inoculation (Kraus 1977). Vaginal colonization of M. hominis 
persisted for more than 200 days in BALB/c mice after direct inoculation, spreading 
to the uterine horns, ovaries, and oropharynx but not to other organs (Furr 1989). 
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 Under in vitro situations, M. hominis attaches to the host cell surface or 
invades the cells (Waites 2005, Taylor-Robinson 1991). A protein called P50 which 
belongs to Vaa (Variable adherence-associated) antigen was suggested to be 
involved in adherence of M. hominis to the cells (Henrich 1993). Furthermore, P50 
undergoes variations and mutations, giving M. hominis the chance to evade the host 
immune system. In vivo, the p50 gene of a clinical isolate of M. hominis expressed 
the main form of the respective adhesin protein expressed in vitro, suggesting that 
this is the most stable form of expression. Nevertheless, the p50 gene shows great 
variability going through point mutations, truncations or duplications. As a result, this 
protein is highly immunogenic in humans and implicated in arthritis caused by M. 
hominis (Henrich 1998, Razin 1998, Boesen 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Photo of M. hominis in rod-like or round forms attached to a cell, observed in 
infected cell cultures under an electron microscope at 20000 x magnification. (Kindly provided 
by Dr. C.C. Uphoff, Department of Human and Animal Cell Cultures, DSMZ, German Collection 
of Microorganisms and Cell Cultures, D-38124 Braunschweig, Germany) 
 
 
 
 
2 µm x 20000
Literature review/Mycoplasmas  14 
2.1.4.2 Mycoplasma fermentans 
 M. fermentans was first isolated from the human urogenital tract in the 1950’s 
(Ruiter 1952), has a genome size of 1160 kb (Dybvig 1996), and a spherical or 
filamentous form (Kim 1966) (Figure 4). It ferments sugars and hydrolyses arginine 
for the production of ATP, using both metabolic pathways found in mycoplasmas 
(Özkan 1999). 
 M. fermentans inhabits the human respiratory and urogenital tract and was 
considered to be a commensal. The interest in this organism has increased because 
of its possible role as a pathogen or as an opportunistic co-factor accelerating the 
progression of human immunodeficiency virus disease (HIV) (Lo 1992, Yavlovich 
2001, Waites 2005). Furthermore, M. fermentans was possibly involved in the 
pathogenesis of inflammatory arthritis forms and chronic arthritic conditions (Johnson 
2000, Gilroy 2001, Yavlovich 2001, Waites 2005, Yavlovich 2006). 
 In vitro, M. fermentans attaches to or invades the host cells. It possesses a 
urokinase-type plasminogen activator which binds plasminogen, activating it into 
plasmin, thus entering the host cell (Yavlovich 2001, Rottem 2003). It has a high 
reducing antioxidant capacity, serving as a defense mechanism and gives M. 
fermentans the ability to fight against oxidative stress within the host cell, resulting in 
cell habitation for prolonged period of times (Yavlovich 2006). Furthermore, it is 
highly fusogenic, capable of fusing with a variety of cells (Franzoso 1992, Rottem 
2003), and interacts with haematopoietic cells, inducing production of interleukins 
and Tumor Necrosis Factor-α (TNF-α) (Muhlradt 1991, Rottem 2003). As previously 
described, M. fermentans induced apoptosis of mouse spleenic T-cells initiated by 
concanavalin A (Shibata 1997). Induction of malignant transformation and 
chromosomal abnormalities were obtained in murine embryonic cells after inoculation 
with M. fermentans, correlating to the duration of infection (Tsai 1995).  
 M. fermentans possess a Macrophage Activating Lipopeptide-2 (MALP-2), 
which is located in its plasma membrane. This 2 kDa lipopeptide differs from 
conventional bacterial lipopeptides, carrying only two ester-linked fatty acids, and 
lacking the N-terminal third fatty acid enhancing a high biological activity (Deiters 
1999, Luhrmann 2002). It was capable of liberating chemoattractant chemokines and 
initiating an inflammatory effect in vitro and in vivo after intraperitoneal and 
pulmonary application of MALP-2 lipopeptide in mice, respectively (Deiters 1999, 
Luhrmann 2002). The mice presented a maximal leukocyte infiltration within 72 hours 
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returning to normal levels within 10 days, whereas monocytes and macrophages 
were increased after 3 days (Deiters 1999, Luhrmann 2002). The synthesis of MIP-
1α (Macrophage Inflammatory Protein-1α), MCP-1 (Monocyte Chemoattractant 
Protein-1) increased in the first 6 hours after inoculation, respectively, remaining 
elevated for 24 to 48 hours, whereas MIP-2 (Macrophage Infiltration Protein-2) 
reached maximal production within the first 2 hours (Deiters 1999, Luhrmann 2002). 
Furthermore, MALP-2 induced cross tolerance in mice (Deiters 1999, Luhrmann 
2002, Deiters 2003). Additionally, M. fermentans suppressed the interferon-γ (INF-γ) 
expression of major histocompatibility complex (MHC) class II molecules on 
macrophages and resulted in impaired antigen presentation to helper T-cells in an 
animal model (Frisch 1996).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Photos of M. fermentans observed in infected cell cultures under an electron 
microscope at 30000 and 20000 x magnifications, respectively. Left photograph: a filament 
form of M. fermentans in an interaction with the host cell membrane. Right photograph: Forms 
of M. fermentans undergoing binary division and constructing chains of cocci. (Kindly 
provided by Dr. C.C. Uphoff, Department of Human and Animal Cell Cultures, DSMZ, German 
Collection of Microorganisms and Cell Cultures, D-38124 Braunschweig, Germany) 
 
 
 
 
 
 
 
1 µm x 30000 2 µm x 20000
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2.1.4.3 Mycoplasma orale 
 M. orale is a common inhabitant of the oral and pharyngeal cavity of humans 
(Taylor-Robinson 1964). It has a characteristic filamentous morphology and uses the 
arginine-dihydrolase pathway for ATP production (Kim 1966, McGarrity 1985) (Figure 
5). M. orale is considered to be a non-pathogenic species in immunocompetent 
persons, but could be responsible for secondary infections in case of 
immunodeficiency (Paessler 2002, Waites 2005). 
 In vitro, M. orale is mostly found free in medium, between the cells (McGarrity 
1984). Whole cells of M. orale induced macrophage-mediated cytolysis of 
fibrosarcoma A9HT (Loewenstein 1983), produced chromosomal aberrations in a 
human diploid and the WI-38 fibroblast cell lines (McGarrity 1985), induced TNF-α 
production in a murine tumor cell line; (Gallily 1989) and stimulated lymphocytes for 
high cell proliferation (Mizushima 1985).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Photo of M. orale observed in infected cell cultures under an electron microscope 
at 18000 x magnification showing filamentous forms. (Kindly provided by Dr. C.C. Uphoff, 
Department of Human and Animal Cell Cultures, DSMZ, German Collection of Microorganisms 
and Cell Cultures, D-38124 Braunschweig, Germany) 
 
 
 
2 µm x 18000  
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2.2 Murine embryonic stem (mES) cells 
 The embryonic development begins with the first entity of life, the zygote, and 
continues with several cell divisions, the morula and the blastocyst stage, constituting 
the preimplantation embryonic stages. With respect to embryonic development, a 
stem cell hierarchy which is described below in Figure 6 characterizes each 
embryonic stage. mES cells originate from the inner cell mass (ICM) of day 3.5 
preimplantation embryos (blastocyst). They are pluripotent which means that they are 
undifferentiated and capable of forming the 3 primary germ layers (ectoderm, 
mesoderm, endoderm) and the primordial germ cells (PGCs) (Evans 1981, Martin 
1981, Bradley 1990, Smith 2001, Wobus 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Stem cell hierarchy (Wobus 2005). Zygote and early cell division stages 
(blastomeres) to the morula stage are defined as totipotent, because they can generate a 
complex organism. At the blastocyst stage, only the cells of the inner cell mass (ICM) retain the 
capacity to build up all the three primary germ layers, the endoderm, mesoderm, and ectoderm 
as well as the primordial germ cells (PGCs), the founder cells of male and female gametes. In 
adult tissues, multipotent stem and progenitor cells exist in tissues and organs to replace lost 
or injured cells. At present, it is not known to what extent adult stem cells may also develop 
(transdifferentiate) into cells of other lineages or what factors could enhance their 
differentiation capability (dashed lines). Embryonic stem (ES) cells, derived from the ICM, have 
the developmental capacity to differentiate in vitro into cells of all somatic cell lineages as well 
as into male and female germ cells. 
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 Embryonic stem cell research dates back to the 1970’s with the establishment 
of the first embryonic carcinoma (EC) cell line from tumor stem cells (Jakob 1973, 
Gearhart 1974). Evans and Kaufman (Evans 1981) and Martin et al. (Martin 1981) 
isolated and cultured the ICM in vitro, establishing the first mES cell lines (Wobus 
2005) (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 From blastocyst stage embryos to ES cells (Turksen 2002). (A) Blastocyst stage. (B) 
Blastocyst embryo hatching from the zona pellucida. (C) Blastocyst embryo attached to a PEF 
feeder layer 2 d after hatching, ICM is apparent inside the blastocyst. (D) Blastocyst embryo 
attached to tissue culture plastic without a PEF feeder 2 d after hatching, ICM is apparent 
inside the blastocyst. (E) ICM is distinctive and extends above the flat trophoblasts and PEF 
feeders. (F) ICM is distinctive and extends above the flat trophoblasts without PEF feeders. (G) 
ES cell colonies on PEF feeders. (H) ES cell colony on tissue culture plastic without PEF 
feeders. 
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 mES cells are capable of self-renewal. They show a high proliferative activity 
in vitro remaining undifferentiated (pluripotent) even after a long period of time in 
culture (Smith 2001, Faherty 2005, Wobus 2005). They possess a large nucleus, little 
cytoplasm and 1 or more nucleoli (Tielens 2006). They are injected into blastocysts 
which are transferred to recipients and can contribute to the production of chimeric 
mice (Gossler 1986, Bradley 1990, Longo 1997, Wobus 2005). Spontaneous 
differentiation of the mES cells results in a wide range of well-defined differentiated 
somatic cell lines (Smith 2001, Wobus 2005). 
 
2.2.1 Genetic background of mES cell lines 
 Mouse strains used for the production of mES cell lines are chosen based on 
their genetic background. mES cells should be capable of contributing to the germ 
line. As such, the 129 inbred mouse strain has been used mostly for the 
establishment of mES cell lines, while mES cell lines were also isolated from the 
C57BL/6 (B6) mouse strain (Nagy 2003). 
 The 129 strain is homozygous for the white-bellied agouti allele (Aw/Aw) of the 
Agouti locus (Nagy 2003). The 129 substrains show great genetic variation, 
especially in coat and eye colour due to the fact that they were generated by crosses 
with other inbred lines (Nagy 2003). Currently, there are many established mES cell 
lines provided by laboratories, commercial sources or research centers. These 
include R1, AB1 and AB2.1, J1, CCE, W9.5, W4, RW4, E14 derived from 
129x1/SvJx129S1/SV-+p+Tyr-cKitlSl-J/+, 129S7/SvEvBrd, 129S4/SvJae, 129S6/SvEv, 
129X1/SvJ, 129S6/SVEvTac, 129X1/SvJ, 129P2/Ola on a 129 strain background 
(Nagy 2003, http://www.imgen.bcm.tmc.edu/molgen/labs/bradley/cell.htm,  
http://www.healthsystem.virginia.edu/internet/transgenic-mouse/aboutESC.cfm). 
 The C57Bl/6 ES cell lines are considered less stable in maintaining the ability 
to contribute to the germ line due to possible genetic alterations that occur during 
gene-targeting procedures (Nagy 2003). The MPI 65-3, WB6, MES-1, 4A4, Bruce4 
(Thy1.1 congenic C57BL/6 strain) and B1 (C57BL/6J-Tyrc-2J) are some mES cell 
lines that originated from C57Bl/6 mice (Auerbach 2000, Liu 2003, 
http://www.healthsystem.virginia.edu/internet/transgenic-mouse/aboutESC.cfm). 
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2.2.2 In vitro culture of mES cells 
 The main components of ES cell media are D-MEM medium, foetal calf serum 
(FCS) pretested for ES-cell culture, β-mercaptoethanol, glutamine, pyruvate, and 
Leukemia Inhibitory Factor (LIF) (Nagy 2003). 
 The culture conditions for ES cells are demanding. They often influence the 
cell properties when they are suboptimal (Nagy 2003). ES cells are sensitive to pH 
and temperature changes (Turksen 2002); they should be cultured at reasonably 
high densities and passaged every 2 to 3 days since they have a very short 
generation time, approximating 12 to 15 hours (Rohwedel 1996, Turksen 2002, 
Wobus 2005). Culture at low densities, the lack of essential substances, and 
unstable incubation conditions could lead to production of embryoid bodies, which 
are mES cell aggregates at the first stage of differentiation, or to chromosomal 
aberrations and further loss of the germ line competence (Nagy 2003). 
 Culture of mES cells on feeder cell layers offers an environment for optimal 
continued proliferation without differentiation allowing and enhancing growth of 
pluripotent, multicellular, compact, and well-shaped colonies (Nagy 2003, Tielens 
2006). The feeder cell layers consist of murine embryonic fibroblast cells (MEFS) 
which are inactivated prior to their use via irradiation or chemical treatment with 
Mitomycin C (MMC) (Turksen 2002, Nagy 2003). Culture on feeder cell layers was 
originally considered a necessity for the in vitro culture of mES cells to prevent 
differentiation (Smith 2001). This consideration was revised after the successful 
culture and support of mES cells in feeder-free dishes in the present of conditioned 
media to which LIF (see below) was added (Smith 1987, Smith 1988, Williams 1988). 
Nevertheless, the culture of mES cells on feeder cells is still widely practiced in stem 
cell laboratories (Nagy 2003). 
 mES cells can also be cultured in gelatin-coated dishes. The colonies are 
flatter than those obtained on feeder layers while their margins appear extensively 
differentiated (Nagy 2003). 
 The Leukemia Inhibitory Factor (LIF) or Differentiation Inhibiting Factor (DIA) is 
essential for the in vitro maintenance of mES cell pluripotency. LIF is a cytokine of 
the interleukin (IL)-6 cytokine family. It supports self-renewal and inhibits 
differentiation of the mES cells (Smith 1988, Williams 1988) by binding to a 2-part 
receptor complex, LIF and gp130 receptors, and activating the transcription factor 
STAT3 (Niwa 1998, Matsuda 1999). LIF is produced by the feeder cells, which are 
Literature review/Murine embryonic stem cells 21 
stimulated by the presence of mES cells (Rathjen 1990, Smith 2001, Nagy 2003). In 
current protocols for stem cell culture, LIF is added even in co-culture with feeder 
cells (Nagy 2003). 
 
2.2.3 Markers for determination of pluripotent mES cells 
 The pluripotent mES cells are characterized by high levels of cellular alkaline 
phosphatase (AP) (Thomson 1998), high telomerase activity (Tielens 2006), 
expression of the cell surface glycoprotein Stage-Specific Embryonic Antigen 
(SSEA)-1 (Knowles 1978), by the presence of the transcription factor Oct 3/4, and 
other factors (Scholer 1989, Pesce 1999, Wobus 2005, Tielens, 2006). 
 AP is localized mainly in the plasma membrane (Johnson 1977) of the ES 
cells and is characteristic but not specific for pluripotent ES cells (Tielens 2006). The 
AP activity is first expressed between the 8- (Izquierdo 1975) and the 16-cell 
embryonic stage, and then at the morula stage. Later, at the blastocyst stage, AP is 
found only in the cells of the ICM (Johnson 1977). It can be detected by cell staining 
with a dye containing an AP-specific substrate, and depending on the dye used, the 
cells appear red or dark/blue violet. 
 Telomerase is a ribonucleoprotein enzyme, which elongates telomeres by 
adding DNA telomeric sequences onto the 3´ ends of chromosomes (Thomson 1998, 
Niida 2000), resulting in the maintenance of the telomere length and the replicative 
life-span of the cells, respectively (Thomson 1998). The telomerase activity of murine 
and human ES cells is high but not specific for pluripotent cells. It is expressed with 
lower activity by other somatic cell lines as well (Thomson 1998, Armstrong 2000, 
Prelle 2000, Wobus 2005). 
 The expression of the stage-specific embryonic antigen (SSEA)-1 begins at 
the 8-cell embryo stage, continues at the ICM, and becomes restricted to the 
embryonic ectoderm and visceral endoderm, respectively (Knowles 1978, Fox 1981, 
Knowles 1982). Its antigenic determinant is a carbohydrate, whose structure is 
related to the antigen I of the human blood group (Knowles 1982). It can be detected 
immunohistochemically using a monoclonal antibody anti-SSEA-1, which reacts with 
a carbohydrate similar but not identical to antigen I (Nudelman 1980, Gooi 1981, 
Hakomori 1981). In adult mice, cells of the oviduct, the endometrium, the epididymis, 
as well as brain areas and the kidney tubules react positively to anti-SSEA-1 
antibody (Fox 1981). 
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 The mouse transcription factor OCT-4 (also called OCT-3) is a maternally 
expressed octamer-binding protein, having 352 amino acids and is encoded by the 
Oct 4 gene. It belongs to the class V of the POU (Pit-Oct-Unc) family which regulates 
gene expression by binding to the octamer motif ATGCAAAT (Scholer 1989, Herr 
1995, Pesce 1999, Tielens 2006). The OCT-4 factor is expressed in totipotent and 
pluripotent ES cells, and is downregulated upon differentiation (Pesce 1998, Pesce, 
2001), whereas by the PGCs, it is restricted after the 8th day of gestation (Rosner 
1990, Scholer 1990, Tielens 2006). This property is retained in vitro (Niwa 2000, 
Tanaka 2002, Tielens 2006). Its unique RNA expression pattern suggests its 
involvement in the early embryonic events such as the initial formation, self-renewal 
and maintenance of the pluripotential nature of mES cells (Nichols 1998, Pesce 
1999, Niwa 2001, Tielens 2006). The loss of OCT-4 expression has been correlated 
with the loss of pluripotency, induction of differentiation, and difficulties in delivering 
pluripotent cells (Buehr 2003, Tielens 2006). 
 
2.2.4 Genetic manipulation and use of embryonic stem cells 
 The ability of altering the genome of mES cells by homologous recombination 
and contribution to the germ line (Gossler 1986, Thomas1987, Koller 1989) makes 
mES cells an attractive tool for studies investigating gene function (Turksen 2002). 
 mES cells are used for the production of transgenic (insertion of a new gene in 
mouse genome) and knock-out (inactivation of genes in the mouse genome) mice 
which serve as animal models for human and other mammalian diseases, in studies 
of embryonic development, or in vitro studies of cell systems, established after their 
spontaneous differentiation into well-defined somatic cell types (Rohwedel 1996, 
Wobus 2005). Additionaly, mES cells are used for studies in pharmacology, 
embryotoxicology, and for experiments concerning cell transplantation and 
replacement therapy (Wobus 2005, Cormier 2006). 
 
2.2.5 Production and methods for determination of chimeras 
 The first experimental chimera was created in 1961 (Tarkowski 1961) by 
placing 2 zona pellucida-free 8-cell stage embryos in contact and transferring the 
blastocysts afterwards into recipients. The first chimera produced by blastocyst 
injection was performed in 1968 (Gardner 1968). 
 Two methods are established for the production of chimeras. The first and the  
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most common method is the injection method during which mES cells are directly 
injected into the blastocoel (Gardner 1968) for the production of germ-line chimeras 
(Bradley 1984) (Figure 8). The aggregate method is the second one where mES cells 
aggregate with morula stage embryos (Wagner 1985, Nagy 1990, Wood 1993). Both 
methods have advantages and disadvantages. The injection method requires 
expensive equipment and time. The aggregate method is simpler, technically less 
demanding and less expensive than the injection method. A great number of 
aggregated and injected embryos could be produced daily with both methods but 
more time is needed for development of aggregated embryos in culture before 
embryo transfer (Nagy 2003). 
 Various factors affect the production of germ line chimeras. These include the 
number and the size of mES cells injected or aggregated, the stage of the 
aggregated embryos cultured, the genetic background of host blastocysts compared 
to mES cell line used (Nagy 2003). The number of mES cells injected into a 
blastocyst is recommended to be 10 to 15 (Bradley 1987, Nagy 2003) depending on 
the mES cell line used. Too many or too few mES cells could lead to reduction of 
embryo vitality or failure in producing chimeras (Brown 1992, Nagy 2003). 
Furthermore, small round mES cells should be chosen for blastocyst injection (Brown 
1992). The genetic background of the host blastocysts should be different but 
compatible with that of the ES cell line in order to obtain chimeras competent for 
germ line transmission and distinguishable chimeras based on coat colour markers 
(Nagy 2003). 
 Chimeras can be distinguished by several ways. The simplest way to evaluate 
the contribution of mES cells to somatic tissues is the pigmentation markers. It can 
be scored by simple observation of the coat and eye colour. In this way, 
distinguishable chimeras can be obtained when 129 agouti mES cells are injected in 
C57BL/6 or CD-1 Cr host blastocysts or when 129 chinchilla mES cells are injected 
into C57BL/6 blastocysts (Bradley 1987, Nagy 2003) (Figure 9). Isoenzyme analysis 
is used to determine chimeric mice in case of undistinguishable coat and eye color. 
Glucosephosphate Isomerase (GPI) enzyme is detected via electrophoresis and gel 
analysis (Bradley 1987). Currently, molecular methods like PCR and Southern blot 
hybridization are used for DNA analysis of chimeras (Nagy 1993, Floss 2002). 
Finally, the germ line transmission is determined by mouse breeding and simple 
genetic laws (Bradley 1987) (Figure 9).  
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2.2.6 Factors influencing germ line transmission 
 The genetic background significantly influences the germ line competence of 
mES cell lines. As mentioned above, some mES cell lines are less stable than others 
and undergo genetic alterations, arising from gene targeting procedures (Nagy 1993). 
Even though mES cells have the ability for self-renewal and are highly proliferative 
their long period in culture often leads to development of abnormalities, which 
influence their germ line competence. These include chromosomal aberrations, 
abnormal structures in the cytoplasm, changes in metabolism, low replicative 
efficiency or poor growth, apoptosis or tumorigenicity (Rubin 2002, Kanatsu-
Shinohara 2005). 
 The karyotype of mES cells plays a very important role in their ability to 
contribute to chimeric tissues and the germ line. Aneuploidy is the main reason for 
failure of germ line transmission. When a total of 50 to 100% of euploid metaphases 
was present, mES cells contributed to the germ line, whereas ES cells with 
metaphases less than 50% euploidy did not (Longo 1997). Other studies revealed 
that trisomy 8 occurred frequently in mES cell lines during gene targeting, resulting in 
contribution to somatic tissues but not to the germ line (Liu 1997). Other trisomies 
like trisomy 11 also occurred in mES cell lines (Sugawara 2006). Therefore, 
karyotypic analysis of the mES cell lines should be performed prior to their use and 
lines with 50 or 70% and more of euploid metaphases should be chosen for use only 
(Turksen 2002, Nagy 2003). 
 The number of passages influences the germ line competence of the mES 
cells. Previous studies showed that the contribution to the germ line declined when 
the number of passages increased correlating to increased aneuploidy which 
influences the percentage of chimera born and the percentage of chimerism (Nagy 
1993, Longo 1997). 
 The presence of pathogens in mES cell cultures could influence several cell 
parameters and reduce the germ line potential. The presence of Mouse Hepatitis 
Virus (MHV) was reported in 2 studies (Okumura 1996, Kyuwa 1997), whereas the 
E14-1 mES cell line (Hooper 1987, Nagy 2003) reported to be infected with M. 
hominis, showed a relative low frequency (40%) of germ line transmission 
(http://tikus.gsf.de/ggtc/info/faqs.php). Previous experimental studies using 
mycoplasma-infected mES cells, showed reductions in the percentage of embryos 
born, the percentage of chimeric mice and in the contribution to chimeric tissues 
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compared to results obtained from non-infected mES cells (Bradley 1987). 
Furthermore, use of mES and feeder cells infected with pathogens could introduce 
infections into pathogen-free mouse facilities (Nicklas 2000). As a result, screening of 
mES and feeder cells for pathogens prior to their use is essential, especially when 
the microbiological status of the cells is unknown (Nicklas 2000, Nagy 2003). 
 The contribution of mES cells to the germ line can be further influenced by 
factors such as the number of mES cells injected into a blastocyst, the size and the 
proliferation of mES cells injected (Brown 1992). 
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Methods 
 
3.1 Cell culture and preparation of samples for the sensitivity detection 
 M. hominis, M. fermentans and M. orale stocks were kindly provided by Dr. 
C.C. Uphoff, Department of Human and Animal Cell Cultures, DSZM, German 
Collection of Microorganisms and Cell Cultures, Braunschweig, Germany and were 
stored at -80°C.The number of viable mycoplasmas in stocks was determined before 
inoculation of the cells by plating on Friis agar and counting the number of CFUs 
after two weeks of incubation.  
 The mouse fibroblast L929 cell line (CCL-1 ATCC, Manassas, VA, USA) was 
grown in antibiotic-free DMEM supplemented with 10% inactivated fetal calf serum in 
75 cm2 cell culture flasks at 37°C in a moisture-saturated atmosphere of 7% 
CO2/93% air in an incubator. A total of 6x105 cells was seeded per 75 cm2 cell culture 
flask and was inoculated with M. hominis, M. fermentans, or M. orale at a dose of 1 
CFU/12 cells (5x104 CFUs/75 cm2 flask) (Tsai 1995). Negative control L929 cells 
were free of mycoplasmas. After 4 passages of the L929 cells over 15 days, 
supernatants from the mycoplasma-infected and the control cell cultures were 
collected and the number of cells therein was determined with a haemocytometer 
FAST-READER 102®. Serial 10-fold dilutions with DMEM up to 10-10 from the fresh 
cell-containing supernatants were made and used for analyses by agar culture, the 
MycoAlertTM Assay, gel-based PCR, and MycoSensorTM QPCR assays. In addition, 
for PCR analyses and agar culture, cell suspensions containing 104 trypsinized cells 
from the monolayer/ml DMEM and serial 10-fold dilutions thereof up to 10-10 were 
prepared. 
 
3.2. Agar culture 
 Friis agar medium contained 128 ml Solution I, composed of 0.82 g Bacto 
brain heart infusion, 0.87 g DifcoTM Bacto PPLO-Broth, 50 ml Hank’s BSS (balanced 
salt solution, see below) and 78 ml dH2O, 37.3 ml Solution II composed of 33.2 ml 
heat-inactivated porcine serum, 3.32 ml sterile filtrated yeast extract solution 25%w/v, 
0.133 ml sterile filtrated Phenol red solution 1% and 0.343 ml dH2O, 1.14 g Agar No.1 
and 1.6 ml sterile filtrated DEAE-Dextran solution 1%. Hank’s BSS composed of 25 
ml Solution A, 25 ml Solution B and 450 ml sterile H2O. Solution A contained 80 g 
NaCl, 4 g KCl, 1 g MgSO4x7H2O, and 1 g MgCl2x6H2O dissolved in 400 ml dH2O. 
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Solution B contained 1.5 g Na2HPO4x2H2O and 0.6 g KH2PO4 dissolved in 500 ml 
dH2O. Solutions A and B were autoclaved separately and then combined with dH2O. 
Solution I was stabilized to pH 7.4 with 1M NaOH and together with agar was 
autoclaved at 121°C. Before mixing and plating in 6-cm Petri dishes, both Solutions I 
and II were kept in a water bath at 60°C. 
 PH-Hayflick Agar medium contained 100 ml Solution I composed of 3.5 g 
DifcoTM Bacto PPLO-Agar, and 100 ml dH2O and 25 ml Solution II containing 23.36 
ml heat-inactivated horse serum, 1.7 ml sterile filtrated yeast extract solution 25%w/v, 
0.324 ml DNA-solution, and 0.234 ml dH2O. Solution I was stabilized to pH 6.5 with 
1M HCl and autoclaved at 121°C. Before mixing and plating in 6-cm Petri dishes, 
both Solutions I and II were kept in a water bath at 60°C. 
 From the undiluted and diluted cell-containing supernatants and cell 
suspensions, 100 µl were pipetted directly onto Friis- and PH-Hayflick agar plates, 
without first culturing them in the respective broths to accommodate quantification 
(Uphoff 1992, Uphoff 1992, Hopert 1993). Culture was performed at 37oC and 7% 
CO2 in a moisture-saturated atmosphere. After 14 days, agar plates were evaluated 
by counting the number of typical colonies having a fried-egg appearance under the 
inverted microscope (Zeiss, Göttingen, Germany).  
 
3.3 Biochemical luminescence assay  
 The MycoAlertTM assay kit was obtained from Cambrex Bio Science, Lonza, 
Verviers. It is a biochemical luminescence assay based on the presence of 
mycoplasmal enzymes, and energy pathways that result in ATP generation. A 
bioluminescent luciferin/luciferase reaction converts the ATP produced into light. The 
emitted light intensity was measured by a luminometer connected to a computer with 
the WinGlow program (Berthold Technologies).  
 In order to assess the sensitivity of the luminometer, dilutions of 1:2, 1:4, 1:8, 
1:16, 1:32, 1:64, and 1:128 of the MycoAlertTM Assay Control Set were made. From 
each dilution, 100 µl were pipetted into a 96-well white microplate and 100 µl of the 
MycoAlertTM Reagent were added to each sample. The emitted light intensity was 
measured after 5 min (Reading A). Immediately afterwards, 100 µl of the MycoAlertTM 
Substrate were added. After further 10 min, the second measurement was made 
(Reading B). The ratio B/A of each sample was calculated. According to the 
manufacturer’s instructions, a luminometer is sufficiently sensitive when it produces a 
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ratio less than 1 for the negative control and a ratio more than 1 for definite positive 
results with the MycoAlertTM Assay Control Set at dilutions of at least 1:8. 
For detection of mycoplasma, the cell-containing supernatants were 
centrifuged for 5 min at 1500 rpm according to the manufacturer’s instructions. Serial 
dilutions up to 10-10 of the cell-free supernatant were made. From each dilution, 100 
µl were analyzed as described above. The ratio B/A of each sample was calculated 
based on the 2 measurements. According to the manufacturer’s instructions, ratios 
less than 1 indicate mycoplasma-negative samples; ratios greater than 1.2 indicate 
mycoplasma-positive samples. An aliquot of the MycoAlertTM Assay Control Set was 
used as the positive control at a dilution of 1:10. For analysis of each mycoplasma 
species, 5 replications with serial dilution samples were performed. 
 
3.4 Gel-based Polymerase Chain Reaction  
 Undiluted and diluted cell-containing supernatants and cell suspensions were 
centrifuged for 6 min at 13.000 rpm. Supernatants were discarded and cell pellets 
were washed twice with phosphate buffered saline (PBS), resuspended in 100 µl 
PBS and incubated for 15 min at 95°C. DNA was extracted with the Wizard Clean-Up 
System according to the manufacturer’s instructions and eluted from the column with 
50 µl dH2O at 80°C. Extracted DNA was stored at -20oC and analyzed within 1 week. 
The degenerated primers Myco-5’ and Myco-3’ (Uphoff 2002, Uphoff 2005) were 
used with the following sequences: 5’ primers: cgc ctg agt agt acg twc gc, tgc ctg rgt 
agt aca ttc gc, cgc ctg agt agt atg ctc gc and cgc ctg ggt agt aca ttc gc, 3’ primers: 
gcg gtg tgt aca ara ccc ga, gcg gtg tgt aca aac ccc ga. The PCR with 1 µl DNA was 
performed in a final volume of 25 µl with 3.5 µl 10xPCR buffer, 1.6 µl 50 mM MgCl2, 1 
µl dNTP mix 10 mM each, 1 µl Myco-5’ and 1 µl Myco-3’ primers (mix of each single 
primer at 5 µM) (Uphoff 2005), 1.5 U Platinum Taq DNA Polymerase and 15.6 µl 
dH2O. The thermal cycler was programmed to perform a hot-start initial cycle carried 
out at 96°C for 2 min, 65°C for 1 min and 72°C for 1 min. Further 35 cycles were 
performed with a denaturation time of 94°C for 20 s, annealing time of 65°C for 20 s 
and amplification time of 72°C for 40 s with 2 s extension time per cycle. Ten 
microliters of the PCR product were mixed with 2 μl loading buffer, electrophoresed 
on a 1.4% agarose gel, stained with ethidium bromide, visualized under UV light, and 
photographed. Internal and positive controls for the PCR were provided as described 
(Uphoff 2005). M. orale stocks were used as the positive control. Mycoplasma-
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positive samples show a band at 502-520 bp, depending on the mycoplasma species 
present. For analysis of each mycoplasma species, 5 replications with supernatant 
samples and 3 replications with cell suspensions were performed. The mycoplasma 
species were identified by digestion of the PCR products with the restriction enzymes 
Xba I, Hpa II, and Hae III using React® 2 buffer, React® 8 buffer and React® 2 
buffer, respectively. One microliter of the diluted enzyme (1:10 in 1x diluted buffer) 
and 1 µl of the corresponding 10x buffer were added to 8 µl of the PCR reaction mix 
containing the PCR products and incubated at 37°C for 1 h. The restriction fragment 
patterns were determined by electrophoresis on a 1.4% agarose gel, staining with 
ethidium bromide, and then visualized under the UV light and photographed. The 
DNA from M. hominis was digested by Xba I and Hae III enzymes, that of M. 
fermentans by Hpa II and Hae III and the DNA from M. orale was digested by Xba I 
and Hpa II enzymes. Xba I produced fragments of 253 bp or 265 bp for M. hominis 
and M. orale, respectively, Hpa II produced fragments of 288 bp and 230 bp for M. 
orale and 357 bp, 111 bp and 48 bp for M. fermentans. Hae III produced fragments of 
336 bp or 180 bp and 356 or 160 bp for M. hominis and M. fermentans, respectively 
(Uphoff 2002, Uphoff 2005). For determination of each mycoplasma species, PCR 
products from 2 replications were analyzed.  
 
3.5 Real-time Polymerase Chain Reaction  
 The MycoSensorTM QPCR Assay kit was obtained from Stratagene. In order to 
directly compare the results from the gel-based PCR and real-time PCR methods, 
extracted DNA from the same aliquots was used for both analyses. The 
MycoSensorTM QPCR Assay was performed by analyzing 5 µl DNA in a final volume 
of 50 µl with 2xMycoSensorTM QPCR Master Mix containing SureStart® Taq DNA 
polymerase, dNTPs and optimized buffer components, mycoplasma primer mix 
provided with the kit, SYBR® green reference dye, diluted 1:50, and PCR-grade H2O. 
Amplification and detection were performed with the Applied Biosystems 7500 Real-
time PCR System using the following settings: initial cycle at 50°C for 2 min and 95°C 
for 10 min followed by 40 cycles of 95°C for 15 s, 60°C for 1 min and 79°C for 30 s. 
Subsequently, a melting curve analysis was performed at 95°C for 15 s, 60°C for 1 
min and 95°C for 15 s. Fluorescence was emitted at 520 nm. According to the 
manufacturer’s instructions, negative controls give no peaks or have amplification 
curves with a melting temperature (Tm) of ~ 74°C due to a primer dimer formation, 
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whereas positive controls give amplification curves with a melting temperature (Tm) of 
~82°C. 
 Standard curves for each real-time PCR run were constructed using dilutions 
containing 50, 100 and 1000 copies of M. orale-positive control provided with the kit 
at a concentration of 200 copies/µl. For real-time PCR with each mycoplasma 
species, 3 to 5 replications with supernatant samples and 3 replications with cell 
suspensions were performed. 
 
3.6 Preparation of primary murine embryonic fibroblast feeder cells  
 For the production of primary murine embryonic fibroblast feeder cells 
(EMFI), pregnant C57BL/6J-Tg(pPGKneobpA)3Ems/J inbred mice were sacrificed 
13.5 days post coitus (dpc) by cervical dislocation. The uteri were removed with 
sterile surgical instruments, placed in 10 cm Petri dishes containing phosphate 
buffered saline (PBS) without Ca+2 and Mg+2, and the foetuses were collected. Their 
membranes, heads, and the internal organs were removed, and discarded. The 
carcasses of 10 embryos were collected in a 50 ml Falcon tube containing 35 ml PBS 
and washed in order to remove as much blood as possible. The washed carcasses 
were minced with a scalpel in a Petri dish placed on ice for about 5 min. Minced 
tissues were collected in 10 ml 0.05% Trypsin/0.02% EDTA solution (w/v) in PBS 
without Ca+2 and Mg+2, 200 µl DNase I (100 mg) were added and the tissues were 
incubated for 15 min at 37°C. With the use of a syringe plunger, the tissues were 
pressed through a sterilized mesh into an Erlenmeyer flask. A total of 50 ml 
Trypsin/EDTA solution was added to flush the remaining tissue clumps on the mesh. 
In case of a viscous liquid, 200 to 600 µl DNase I were added directly onto the mesh. 
The liquid was incubated thereafter for 45 min at 37°C by shaking. The cell 
suspension was distributed evenly into two 50 ml Falcon tubes, filled up with 
1xDMEM medium enriched with 4.5 g/L glucose, L-glutamine and pyruvate and 
centrifuged for 5 min at 1500 rpm. Cell pellets were washed twice with DMEM (1x), 
resuspended in a volume of 10 ml DMEM (1x) and the number of viable cells was 
determined using 1:10 trypan blue dye (100 µl trypan blue, 100 µl cell suspension 
and 800 µl PBS) and a haemocytometer (FAST-READER 102®). A total of 5x106 
cells was seeded into 15 cm Petri dishes containing 25 ml DMEM medium (1x) and 
200 µl of Penicillin-Streptomycin, and cultured overnight. The next day, the medium 
was replaced with antibiotic-free feeder cell medium. Feeder cell medium contained 
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100 ml DMEM (1x) medium enriched with 4.5 g/L glucose, L-glutamine and pyruvate, 
11.4 ml inactivated fetal calf serum (FCS), 1.14 ml 200 mM glutamine and 1.14 ml 
non-essential amino acids (100x). Cells were cultured for 3 days at 37°C in a 
moisture-saturated atmosphere of 7% CO2/93% air in an incubator (Binder), splitted 
1:5, and cultured for 3 more days until they were confluent. They were frozen in vials 
(NuncTM Cryo tube vials) containing 5x106 cells/ml freezing medium consisting of 
70% DMEM medium (1x), 20% FCS and 10% Dimethyl Sulfoxide (DMSO). After 1 
day storage at -80°C, vials were stored at -160°C. 
 For the production of inactivated EMFI, cells were quickly thawed at 37°C in a 
water bath, placed in a 15 ml Falcon tube, filled up with 5 ml feeder cell medium and 
centrifuged (Hettich Universal 30 F) at 1200 rpm for 5 min. The cell pellet was 
resuspended in 5 ml feeder cell medium, distributed in five 15 cm Petri dishes, each 
containing 19 ml feeder cell medium, and incubated at 37°C in a moisture-saturated 
atmosphere of 7% CO2/93% air in an incubator for 3 days, followed by a 1:3 split and 
further culture until confluence was observed. A total of 20 ml fresh feeder cell 
medium containing 200 µl Mitomycin C (1 mg/ml) was given to the confluent cells 
followed by incubation at 37°C in a moisture-saturated atmosphere of 7% CO2/93% 
for 2 to 2.5 hours. Then they were washed twice with 5 ml PBS, 5 ml of 
Trypsin/EDTA solution were added, and cells were incubated for a few minutes at 
37°C until they detached from the bottom of the plates. A cell suspension was made 
by repeated pipetting and the cells were transferred into a 15 ml Falcon tube. The 
plate was washed with 5 ml DMEM, and then the medium containing cells was added 
to the Falcon tube to stop enzymatic activity. The number of cells was determined 
using a haemocytometer. Cells were frozen in vials containing 3 to 5x106 cells/ml 
freezing medium. After 1 day storage at -80°C, vials were stored at -160°C. 
 For preparation of plates for ES cell culture frozen inactivated EMFI cells were 
thawed quickly at 37°C in a water bath, placed in a 15 ml Falcon tube, filled up with 5 
ml of feeder cell medium and centrifuged at 1200 rpm for 5 min. The cell pellet was 
resuspended in 5 ml fresh feeder cell medium and the number of cells was 
determined using a haemocytometer. A total of 2.5x105 and 7 to 7.5x105 inactivated 
feeder cells was seeded with 4 ml in 6 cm and with 8 ml in 10 cm feeder cell medium 
in Petri dishes, respectively. 
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3.7 Mycoplasma species 
 The number of viable mycoplasmas in stocks was determined before 
inoculation of the mES cells by plating on Friis agar and counting the number of 
CFUs after 2 weeks of incubation. 
 
3.8 Murine embryonic stem cell culture 
 In this study, the murine embryonic stem cell line ES TBV2 which was 
produced from the 129/SvPas strain of mouse (Institute of Developmental Genetics, 
Helmholtz Zentrum München, HMGU), was used in the 13th passage (P13). They 
were free of mycoplasmas and FELASA (Federation of Laboratory Animal Science 
Associations)-relevant pathogens and contributed to the germ line transmission at 
P13+1. At P13+2, the karyotype of the ES cells was normal (40, XY). 
 TBV2 mES cells (P13) were thawed quickly at 37°C in a water bath, placed in 
a 15 ml Falcon tube, filled up with 5 ml of Embryonic Stem cell (ESC) medium and 
centrifuged (Eppendorf 5804) at 1200 rpm for 5 min. The ESC medium consisted of 
100 ml DMEM (1x) enriched with 4.5 g/L glucose, L-glutamine and pyruvate, 15 ml 
fetal calf serum pre-tested for ES cells, 0.2 ml β-Mercaptoethanol (50 mM), 1 ml 
glutamine (200 mM) and 18 µl LIF (107 I.U/ml). The cell pellet was resuspended in 5 
ml fresh ESC medium and the number of cells was determined using a 
haemocytometer. A total of 4.14x105 ES cells (2x104 ES cells/cm2) was seeded in 6 
cm Petri dishes on inactivated feeder cells together with 4 ml ESC medium. 
 For the establishment of a multiple mycoplasma infection, frozen stocks of M. 
hominis, M. fermentans and M. orale were thawed quickly at 37°C in a water bath 
and added to the freshly seeded ES cells at a dose of 1 CFU/12 cells (Tsai 1995). A 
total of 1x104 CFUs of each mycoplasma species was added to 4.14x105 freshly 
seeded ES cells and were cultured for 2 days. Control cells were not inoculated with 
mycoplasmas. 
 For the following passages, a total of 1.134x106 mycoplasma-infected and 
control mES cells (2x104 ES cells/cm2) was seeded in separate 10 cm Petri dishes 
with 10 ml ESC medium, cultured over 20 passages on inactivated EMFI cells at 
37°C and 7% CO2/93% air in an incubator (Queue Systems), and passaged every 2 
days. At each passage, mES cells from each experimental group were cultured in 
four to eight 10 cm Petri dishes. The supernatants were collected and the mES cells 
were washed twice with 3 ml PBS and once with Trypsin/EDTA solution and 
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incubated with 3 ml Trypsin/EDTA solution at 37°C for a few minutes until they 
detached from the bottom of the plates. A cell suspension was made by repeated 
pipetting and the ES cells were transferred into a Falcon tube. Each plate was 
washed with 3 ml ESC medium and the medium containing cells was added to the 
Falcon tube with the trypsinized cell suspension to stop enzymatic activity. For each 
experimental group, the supernatants, the washing solutions containing detached 
cells and the cell suspensions were pooled together, respectively. 
 The morphology, the number and the viability of mycoplasma-infected and 
control mES cells were determined at all 20 passages. The morphology of the ES 
cells was determined by observing the confluence, the size of the mES cell colonies, 
and the development of embryoid bodies. The total number of mES cells at each 
passage was determined by calculating the number of cells in the supernatant, the 
washing solution and the cell suspension using a haemocytometer. The viability of 
mES cells in the cell suspension was determined using 1:10 Trypan blue dye (100 µl 
cell suspension, 100 µl Trypan blue, 800 µl PBS). 
 The remaining mES cells were frozen in 1.8 ml vials with ESC freezing 
medium consisting of 65% DMEM (1x), 25% FCS and 10% DMSO, stored 1 day at  
-80°C and then at -160°C. 
 
3.9 Detection of mycoplasmas in stem cell cultures 
 The ability of M. hominis, M. fermentans and M. orale to grow in ES TBV2 cell 
cultures was determined at all 20 passages by agar culture, the MycoAlertTM assay, 
the in-house established PCR, and the MycosensorTM QPCR assay. 
 For agar culture, aliquots of 100 µl fresh supernatant from mycoplasma-
infected and control ES cells were inoculated on Friis and PH-Hayflick agar plates at 
passages P13+5, P13+10, P13+15 and P13+20. Results were evaluated after 2 
weeks of incubation in a moisture-saturated atmosphere of 7% CO2/93% air at 37°C. 
Three aliquots of 1 ml supernatant from the 20 passages of mycoplasma-infected 
and control mES cell lines were collected in 1.5 ml Eppendorf tubes stored at -80°C 
and examined subsequently. Supernatants from all passages were tested with the 
MycoAlertTM assay and the gel-based PCR, while only mycoplasma-infected samples 
from the passages P13+5, P13+10, P13+15 and P13+20 were tested with 
MycosensorTM QPCR assay. Additionally, a total of 1x104 mycoplasma-infected mES 
cells prepared for blastocyst injection was tested with the MycosensorTM QPCR 
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assay in order to determine the number of mycoplasmal genomes injected into a 
blastocyst. The identification of mycoplasma species found in each passage was 
determined by digestion of the PCR products with restriction enzymes (Restriction 
Fragment Length Polymorphism, RFLP). 
 
3.10 Spectral Karyotyping (SKY) 
 The karyotype of mycoplasma-infected and control mES cells was determined 
by Spectral Karyotyping at passages P13+5, P13+10, P13+15 and P13+20. The 
analyses were performed in the Institute of Molecular Radiation Biology, HMGU. 
 A total of 100 µl Colcemid (Colcemid stock solution 10 µg/ml) was added to 
mES cells in a 10 cm Petri dish (10 ml ESC medium), in order to capture 
metaphases. The ES cells were incubated at 37°C in an incubator (Queue Systems) 
for 2 to 2.5 hours. Then the cells were washed twice with 3 ml PBS and trypsinized 
with 3 ml EDTA/Trypsin solution. The supernatant, the washing solution and the cells 
were collected in a 50 ml Falcon tube and centrifuged at 1100 rpm for 5 min. The 
supernatant was discarded and the tube was flicked with the finger to distinguish the 
cell pellet. A total of 10 ml KCl (75 mM) hypotonic solution (0.56% in dH2O) (KCl 
M=74.56 g/mol) was added dropwise while the tube was gently flicked with the finger. 
The cells were left for 10 min at room temperature and centrifuged afterwards at 
1100 rpm for 10 min. The supernatant was discarded and the tube was flicked with 
the finger to distinguish the cell pellet. A total of 10 ml fresh cold methanol/acetic acid 
fixative (3:1 vol/vol) was added dropwise to the cells, stored for 30 min at -20°C and 
centrifuged at 1500 rpm for 10 min. The same procedure was repeated 3 times. The 
cells were finally resuspended in a final volume of 2 ml fixative and stored overnight 
at 4°C. The next day, 10 to 20 µl of fixed metaphases were dropped onto super frost 
object slides and aged for a week at room temperature. The slides were stored under 
a nitrogen atmosphere at -20°C until used. 
 Metaphase preparations were thawed in a humid chamber at 37°C for 20 min 
and treated thereafter with 100 µl RNase solution (0.05 mg RNase A stock solution/1 
ml 2xSSC), covered with plastic foil, and incubated in a humid chamber for 20 min at 
37°C in an incubator (Memmert). They were washed twice in 2xSSC (100 ml of 
20xSSC in 1 liter dH2O) for 3 min, placed in denaturating solution (70 ml formamide, 
10 ml 20xSSC, and 20 ml dH2O) for 2 min at 72°C and dehydrated in a 70% (kept at -
20°C), 90% (kept at 4°C) and 100% (kept at 4°C) ethanol series for 2 min, each. The 
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20xSSC solution consisted of 175.3 g NaCl, 88.2 g sodium citratex2H2O in 1 liter 
dH2O (autoclaved).They were subsequently hybridized with 5 µl/slide probe mixture 
(Mouse Spectral Karyotyping Reagent Lot Nr. 0666, Applied Spectral Imaging), 
which was denaturated before for 7 min at 80°C and incubated for an hour in the dark 
at 37°C on a heated block. The denaturated metaphases with the hybridization 
solution were covered with 18x18 mm coverslips, sealed with rubber cement 
(Fixogum, Marabu) and incubated for 46 to 48 hours in a humid chamber at 37°C. 
Post hybridization washes were performed twice in 2xSSC at 37°C for 5 min, once in 
0.5xSSC at 75°C for 5 min and once in 4xSSC/0.1% Tween (80 ml dH2O, 20 ml 
20xSSC and 0.1 ml Tween® 20) for 2 min at room temperature. After a short wash 
with dH2O, 100 µl of PNM blocking reagent were added onto the slides, covered with 
plastic foil and incubated in a humid chamber at 37°C for 30 min. PMN consisted of 
500 ml PN buffer, 25 g of Blotting Grade Blocker Non-Fat Dry Milk 5% and 0.1 g 
sodium azide. PN solution contained 1 liter solution A (17.79 g Na2HPO4 M = 177.99 
g/mol, in 1 liter dH2O), 62.5 ml solution B (0.86 g NaH2PO4 M = 137.99 g/mol, in 62.5 
ml dH2O) and 0.1% Nonidet P40 which was added after the stabilization of the final 
volume at pH 8.0. The detection of digoxigenin-labelled and biotinylated probes was 
carried out by the addition to the slides of 50 µl of Anti-digoxigenin solution diluted in 
PMN (5 µl Anti-digoxigenin solution in 1245 ml PMN) followed by 50 µl mixture 
solution of a goat anti-mouse antibody conjugated to Cy-5 and Cy-5.5, respectively (5 
µl of each antibody+245 µl PMN, mixed together 1:1). The slides with the antibody 
solutions were incubated at 37°C for 45 min and washed 3 times afterwards in 
4xSSC/0.1% Tween at 45°C for 5 min. The chromosomes were then stained with 30 
µl DAPI-antifade solution (5 µl DAPI 1 mg/ml, 30 µl Vectashield mounting medium, 
100 ml 2xSSC) and covered with 24x50 mm coverslips. 
 Metaphases were observed under an epifluorescence microscope (Axioplan 2, 
Carl Zeiss GmbH) connected to a interferometer-CCD Camera Combination 
(SpectraCube, Applied Spectral Imaging) and analyzed with the SKY View imaging 
software. A total of 15 to 20 metaphases from each cell passage was evaluated for 
chromosomal aberrations such as translocations, deletions, numeric aberrations, 
insertions and chromosome breaks using a mouse cytogenetic nomenclature. An 
alteration was characterized “clonal” when it appeared 2 or more times in 15 
metaphases and “non clonal” when it appeared only once. Numeric aberrations were 
only of importance when they appeared 3 or more times in 15 metaphases. 
Methods  36 
3.11 Fluorescent Activated Cell Sorting (FACS) of the ES cells 
 The differentiation status of mycoplasma-infected and control ES TBV2 cells 
was determined via flow cytometric analysis (FACS) by evaluation of OCT-4 and 
SSEA-1 markers. mES cells at passages P13+6, P13+11, P13+16 and P13+21 were 
analysed at the Institute of Molecular Immunology, HMGU.  
 Frozen mycoplasma-infected and control mES cells at passages P13+5, 
P13+10, P13+15 and P13+20, were thawed and cultured for 2 days. The mES cells 
were harvested and collected in 4 ml ESC medium after 2 and 1 washing steps with 
PBS and Trypsin/EDTA solution, respectively, and short incubation with 
Trypsin/EDTA solution. They were centrifuged at 1700 rpm for 7 min (Heraeus 
Megafuge 2.0) and the cell pellets were washed with 1 ml Hank’s Balanced Salt 
Solution (HBSS). In order to discriminate live from dead cells, the cell pellets were 
resuspended in 2 µl ethidium monoazide (EMA 500 mg/ml), transferred in 2.5 ml 
tubes, incubated in the dark for 10 min and then illuminated for further 15 min. Then, 
they were washed with 1 ml HBSS, centrifuged at 1700 rpm for 5 min and 
resuspended in 100 µl mouse buffer. The mouse buffer consisted of 1 ml HBSS, 50 
µl mouse serum and 10 µl NaN3 (NaN3 0.1%). Aliquots of 50 µl cell suspension were 
prepared for double staining, isotype controls, and single staining controls, 
respectively. A total of 3 µl Anti-SSEA-1 and Mouse IgM coupled with APC was 
added to the samples prepared for double and single staining, and isotype control, 
respectively, and incubated by shaking on ice. After 1 hour incubation time, the 
samples were washed twice with 1 ml HBSS, centrifuged at 1900 rpm for 5 min, 
resuspended in 0.5 ml 1:3 Fixation/Permeabilization solution (Foxp3 Staining Buffer 
set), incubated in the dark at 4°C for 40 min to allow fixation of the cells, and washed 
twice with 1 ml permeabilization buffer solution (1 ml 10xPermeabilization buffer/9 ml 
dH2O). Furthermore, 2 µl of Fc block solution (2 mg/ml FCR G Rat 2b in 0.1% NaN3) 
were added to the samples. A total of 3 µl of Anti-OCT-3/4 and Anti-mouse CD4 
coupled with PE (L3T4) was given to samples prepared for double and single 
staining, and isotype control, respectively, and incubated by shaking at room 
temperature for 45 min. They were washed twice with 1 ml permeabilization buffer 
solution and resuspended in 250 µl HBSS. Measurements were performed with a 
FACS LSR II and results were evaluated with the FloJo software (TreeStar, Inc. 
USA). 
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3.12 Mice and husbandry 
 Outbred Crl:CD1 (Icr) and inbred C57BL/6J-Tg(pPGKneobpA)3Ems/J mice 
used for the production of blastocysts and embryo transfer recipients, and the 
production of murine embryonic fibroblasts (feeder cells), respectively, were bred in a 
full barrier unit at the HMGU animal facilities and kept in filter-topped Type II 
Makrolon cages at a temperature of 20 to 24oC, humidity of 50 to 60%, 20 air 
exchanges per hour and a 12/12-hour light/dark cycle. They were free of FELASA-
relevant infectious agents. Wood shavings were provided as bedding. Mice were fed 
a standardized mouse diet (1314, Altromin) and provided sterilized drinking water ad 
libitum.  
 Animal manipulations were performed in a mouse room. Before 
entering the area, staff were clothed in a clean garment and wore disposable gloves, 
bonnets and face masks. During routine weekly changes of cages including wire bar 
lids and water bottles in class II laminar flow changing stations, mice were transferred 
to new cages with forceps padded with silicone tubing. Forceps were disinfected after 
each cage change with 70% ethanol. All materials, including individually ventilated 
cages (IVCs, VentiRacks™), Makrolon® cages, lids, feeders, bottles, bedding and 
water, were autoclaved before use. 
 Experimental mice were kept in IVCs under positive pressure and the 
conditions stated above. All animal studies were approved by the HMGU Institutional 
Animal Care and Use Committee and the Government of Upper Bavaria, Germany 
(211-2531-8/02). 
 
3.13 Production of blastocysts and pseudopregnant recipients  
 Female outbred Crl:CD1 (Icr) mice aging 6 to 8 weeks were used as 
blastocysts donors. They were induced to ovulate by intraperitoneal injections of 5 IU 
equine Chorionic Gonadotropin (eCG) (Intergonan® 1000 I.U) followed 48h later by 5 
IU human Chorionic Gonadotropin (hCG) (Ovogest® 1500 I.U). They were mated 
immediately thereafter with males of proven fertility. The presence of vaginal plugs 
indicating successful mating was determined the following morning. 
 For the collection of blastocysts, pregnant mice were sacrificed with CO2 3.5 
days post coitus (3.5 days after plug checking), the uteri were removed with sterile 
surgical instruments and they were placed in 8-cm Petri dishes (Nunc IVF Product 
line) containing filtered M2 medium pre-tested for embryos. Then, they were flushed 
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with the respective medium and the blastocysts were collected thereafter under a 
stereoscopic microscope (Leica MZ75). They were placed in 3.5 cm sterile tissue 
culture dishes, and washed through 4 drops of 100 µl M2 medium each. The washed 
blastocysts were kept in a 3.5 cm Petri dish in a 100 µl drop of M2 medium, covered 
with mineral oil on a heated block at 37°C until used.  
 Female outbred Crl:CD1 (Icr) mice aging 8 to 12 weeks were used as 
pseudopregnant recipients. They were mated with vasectomized males and used for 
embryo transfers 2.5 days after the vaginal plug was detected. 
 
3.14 Blastocyst injection, embryo transfer and production of chimeras 
 Mycoplasma-infected and control TVB2 mES cells at passages P13+5, 
P13+10, P13+15 and P13+20 were used for blastocyst injection and embryo 
transfers. The ES cells were prepared as previously described. However, incubation 
of the cells with Trypsin/EDTA solution was shorter in order to obtain feeder-free 
mES cells. The cell suspension was then centrifuged at 1200 rpm for 5 min, and the 
cell pellet was resuspended in a final volume of 0.5 ml to 1 ml ESC medium and kept 
on ice until used. 
 Blastocyst injection and embryo transfer were performed as described (Nagy 
2003). Blastocyst injection was performed using a microinjection manipulator (Leitz 
DM IRB) on a super frost object slide covered with filtered M2 medium using injection 
pipettes GC100T-15, size 38, straight with spike (BioMedical Instruments) and hand-
made blastocyst-holding pipettes. After uptake of the mES cells into the injection 
pipette, the blastocysts were held in the correct position and a total of 15 to 20 mES 
cells was injected in each blastocoel (Figure 8). The injected blastocysts were 
collected afterwards into a drop of M2 medium covered with mineral oil and left on a 
heated block to recover and re-expanded until used. Injection of blastocysts with 
control mES cells was performed first, followed by the injection with mycoplasma-
infected mES cells. 
 The pseudopregnant recipients were anaesthetized with 0.15 ml of Ketamin 
(0.39 ml Ketavet® 100 mg/ml), Xylazine (0.39 ml Sedaxylan 20 mg/ml), and 
Acepromazinemaleat and chlorobutanol (0.12 ml Vetranquil 1%) mixture solution 
diluted in 2.1 ml Sodium Chloride (0.9%). The mice were dissected laterally in the 
abdominal area with sterile surgical instruments and the uteri horns were taken out of 
the cavity gently and held with a clamp. A 27 gauge injection needle was inserted 
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near the utero-tubal junction into the endometrial stroma under a stereoscopic 
microscope, and immediately after the removal of the needle, a glass micropipette 
containing the injected blastocysts and a very small amount of M2 medium was 
inserted and embryos were deposited into the uterus. A total of 7 injected blastocysts 
was transferred to each uterus horn. The abdominal muscles were sutured with 
sterile absorbable Vicryl 4-0 and the skin was closed with 9 mm auto clips. Embryos 
injected with control mES cells were transferred first, followed by the transfer of 
blastocysts injected with mycoplasma-infected ES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Procedure of blastocyst injection, Photograph from Nagy et al., Manipulating the 
mouse embryo, 2003. A: Collection of ES cells, White arrow: ES cell, Black arrow: Fibroblast 
cell, B: Immobilization of blastocyst by holding pipette in the right position (inner cell mass 
positioned at 6 or 12 o´ clock), C: Insertion of injection pipette into the blastocoel, D: Release 
of ES cells into blastocoel, E: Slowly withdrawal of the injection pipette, F: Collapse of 
blastocysts, resulting in close contact of the ES cells with the surface of the inner cell mass. 
Blastocysts are re-expanded after 1 to 3 hours of culture. 
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 After the operation, pseudopregnant recipients received one drop of analgesic 
(Vetalgin® 500 mg/ml) orally. They were kept singly in IVCs. 
 A total of 8, 14, 14 and 16 embryo transfers was performed with mycoplasma-
infected mES cells from the passages P13+5, P13+10, P13+15, and P13+20, 
respectively, whereas 6, 8, 11, and 7 embryo transfers were performed from the 
respective passages with control TBV2 mES cells. 
 The number of litters, pups, and chimeric pups of each respective passage, as 
well as clinical signs of the recipients and pups were protocolled. Furthermore, the 
weight and length of a total of 108 and 69 pups coming from litters produced with 
mycoplasma-infected and control mES cells, respectively, were scored weekly until 
the 13th week of age.  
 
3.15 Determination of chimeras and germ line transmission (GLT) 
 For determination of mES cell contribution to the germ line, chimeras obtained 
were mated with C57BL/6 mice (Charles River Laboratories, Inc., Germany). The 
litter size, color and gender of the mice were recorded. Progeny were either agouti 
with a light-coloured belly (GLT, originating from the 129/SvPas strain) or black in 
colour (wild type, originating from the C57BL/6 strain) (Figure 9). 
 
3.16 Histological examination and stains  
 A total of 6 and 3 clinically affected and healthy male chimeras, respectively, 
was sacrificed at 2 (n=2 and 1), 7 (n=1 and 1) and 16 weeks of age (n=3 and 1). The 
heads, the internal organs, the femurs and the humerus were investigated 
histologically. A total of 2 male chimeras, 2 and 7 weeks old, respectively, from 
control litters and 3 male outbred wild type Crl:CD1 mice (pathogen-free from the 
core breeding unit of the HMGU), 7 week old, were sacrificed and served as control 
mice (additionally to the clinically healthy chimeras obtained after blastocyst injection 
with mycoplasma-infected mES cells). The weight and length of mice, as well as the 
size of the internal organs of the 7- and 16- week old mice were scored whereas their 
carcasses were x-rayed in order to determine the structure of the skeleton. 
Histological examinations were performed at the Institute of Pathology, HMGU. 
 Internal organs were fixed in 10% buffered formalin for 1 to 2 days and 
embedded in paraffin. For histological examination, 2-5 µm thick sections were 
prepared (Microm 355), mounted on super frost plus slides and dewaxed in xylol for 
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5 min. This was followed by dehydration in a 70%, 96% and 100% ethanol series for 
3 min, respectively, and washing with dH2O for 30 sec. The slides were then stained 
for 2 min with Mayer`s hematoxylin solution, and washed with running water for 5 to 
10 min until the water appeared clear. Hematoxylin solution consisted of 1 g 
hematoxylin, 0.2 g NaJO3, 50 g KAl(SO4)12H2O, 50 g chloral hydrate and 1 g of citric 
acid, diluted and filtered in 1 liter dH2O. The samples were dipped for 1 second in a 
1% alcoholic eosin solution (1g Eosin Y/100 ml 100% ethanol), dehydrated through a 
70%, 96% and 100% ethanol series and placed in xylol for about 5 min. The slides 
were then covered with Eukitt mounting medium and then with 24x50 mm coverslips. 
Hematoxylin-Eosin stains the cytoplasm of the cells red, and the nuclei blue. 
 After 7 days of fixation in formalin, the head, the femurs and the humerus of 
the respective mice were decalcified in EDTA for 6-8 weeks at room temperature or 2 
weeks at 58°C, washed, dehydrated, prepared in Tissue-Tek® VIPTM 5 (Vacuum 
Infiltrations Processsor) and embedded afterwards in liquid paraffin. For histological 
examination, 4 µm thick sections were prepared, mounted on super frost plus slides, 
dewaxed in xylol, dehydrated through a 70%, 96% and 100% ethanol series for 3 min 
and washed with dH2O for 30 sec. For examination of the bone structure, the 
samples were stained for 10 min with Weigert´s Fe-Hematoxylin stain. The Fe-
Heamatoxylin consisted of 1 part solution A (10 g Hematoxylin in 1 liter ethanol) and 
1 part solution B (11.6 g FeCl3, 7.8 ml 32% HCL in 992 ml solution A). The sections 
were washed for 10 min in dH2O and then they were stained for 5 min in Van Gieson 
solution saturated with picric acid, rinsed in dH2O and ethanol, respectively, and 
mounted in Eukitt mounting medium. The Van Gieson´s stain consisted of 400 ml 
picric acid and 10 ml 1% acid violet. Van Gieson stains mineralised bones black, 
ostoid and collagen red, and bone marrow and muscles yellow. 
 
3.17 Flouresence Activated Cell Sorting of peripheral white blood cells 
 The immunological status of chimeras obtained after blastocyst injection with 
mycoplasma-infected and control mES cells, was determined. Immunoglobulin levels, 
Anti-DNA Abs, rheumatoid factor and peripheral blood leucocytes were investigated 
via multiplex bead array based assay, ELISA, and flow cytometric analysis (FACS), 
respectively. Analyses were performed in the Immunological Screening Module of the 
German Mouse Clinic, HMGU. 
 A total of 200 to 300 µl blood was collected with a 24-gauge needle from the  
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lateral veins of the mouse tail in 1.5 ml Eppendorf tubes containing 10 µl Heparin 
(25.000 I.U). The tubes were inverted several times to distribute the blood to 
anticoagulant and kept at room temperature for maximal 3 hours. The blood samples 
were centrifuged at 7.5x103 rpm for 3 min at 10°C, and 50 to 100 µl of plasma were 
taken for determination of the IgG1, IgG2a, IgM, IgG3, IgA levels, anti-DNA 
antibodies (abs) and rheumatoid factor.  
 A total of 25 µl/well of plasma diluted 1:1000 in FACS buffer, and 25 µl of 7-
fold serial dilutions of unlabelled mouse IgG1, IgG2a, IgM, IgG3 and IgA standard 
mixture (100=2.5 µl/ml) were added in duplicate in 96-well plate. The FACS buffer 
consisted of 1 liter filtered PBS, 5 g BSA, and 660 µl NaN3 30%, stabilized at pH=7.5. 
A total of 5 µl/well beads mixture was added and the plate was covered with 
aluminium foil and incubated at room temperature on a shaker for 10 min at 300 rpm. 
The bead mixture contained luminex beads of five different regions, coupled with 
antibodies specific for mouse IgG1, IgG2a, IgM, IgG3, and IgA. A mixture of 
biotinylated IgM, IgG1, IgG2a, IgG3 and IgA standards (200 ng/ml in FACS buffer) 
was prepared and 25 µl/well were added to the samples, covered with aluminium foil 
and incubated for further 20 min at room temperature on a shaker at 300 rpm. 
Afterwards, the samples were washed three times with 100 µl/well FACS buffer using 
a vacuum manifold and then 50 µl/well of streptavidin-PE (1 µl/ml) were added and 
incubated in the dark on a shaker for 10 min at 300 rpm. The washing step with the 
FACS buffer was repeated 3 more times and the samples were resuspended in 100 
µl/well FACS buffer/0.05% Tween 20 and shaken for 30 seconds at 1000 rpm. 
Results were obtained on a Bio-Plex reader (100 beads/region/analyte). 
 The DNA plate was incubated for an hour at room temperature with 50 µl/well 
Poly L-Lysine (50 µg/ml) and washed with the TECAN washer program, dried upside 
down on tissue paper to remove remaining liquid and 50 µl of single- and double- 
stranded DNA (1:1) mixture were added per well. The plate was covered with 
aluminium foil and stored at 4°C overnight. The wash buffer consisted of 2.5 l PBS, 
12.5 ml Tween® 20, and 5 ml 10% NaN3. For the rheumatoid factor, the plate was 
incubated with 50 µl/well rabbit IgG, covered with aluminium foil and stored at 4°C 
overnight. A total of 60 µl of plasma diluted 1:5 in PBS was added per well in the 
respective plates in duplicate. Coated-blocked plates were washed with the 
TOMTEC-Robot Quadra 3 system after 30 min of incubation at room temperature, 
and dried on tissue paper until there was no liquid in the wells. The washing solution 
Methods  43 
of Quadra 3 constisted of 10 l PBS and 0.01% Tween® 20. A total of 200 µl of DNA 
(diluted 1:100 in PBS) and RH (diluted 1:200 in PBS) dilutions was added per well in 
the respective plates, whereas serial 7-fold dilutions of control DNA (100 = 1 µl in 
1250 µl PBS) and RH standard controls (100 = 3.2 µl in 800 µl PBS) were made and 
200 µl of each serial dilution were added per well in the respective plates. The plates 
were incubated for 1 hour in a moist chamber at room temperature, washed and 
dried as previously described. A total of 100 µl of the appropriate detection antibody 
(Anti-mouse Polyvalent Immunoglobulins-AP diluted 1:3000 in PBS) was given in 
each well and the plates were incubated for more 1.5 hours in a moist chamber at 
room temperature. Wash and dry steps were repeated as previously described. 
Furthemore, 100 µl of p-Nitrophenyl Phosphat tabs/substrate buffer dilution (20 mg in 
20 ml) were added per well and incubated for exactly 17 min at room temperature 
and washed thereafter with the TECAN washer program. The substrate buffer 
consisted of 1 l dH2O, 97 ml Diethanolamine, 2 ml 10% NaN3, 200 mg MgCl26H2O, 
stabilized of pH 9.5. Measurements were performed on a TECAN SUNRISETM reader 
(TECAN GmbH, Crailsheim, Germany). 
 Peripheral blood leucocytes were collected after resuspension of the 
remaining cell pellet in 500 µl NH4Cl-Tris solution (lysis buffer) at room temperature 
which led to lysis of the red blood cells, followed by filtration of the cell suspension 
through a nylon net into a 1.5 ml Eppendorf tube and shaking for 10 min at room 
temperature. The Lysis buffer consisted of 45 ml solution A (1 liter dH2O and 9.1 g 
NH4Cl, filtered) and 5 ml solution B (1 liter dH2O and 28.8 g Tris-HCl, pH=7.5, 
filtered). A total of 200 µl/well of the cell suspension was added to 2 wells of a 96-well 
plate with a U-bottom and the plate was centrifuged at 10°C for 3 min at 7.5x103 rpm. 
The cells were washed twice in 200 µl NH4Cl-Tris/well and 200 µl FACS buffer/well, 
respectively, and centrifuged at 10°C for 3 min at 7.5x103 rpm. Peripheral blood 
leucocytes were then incubated with 20 µl Fc block solution (anti-mouse 
CD16/CD32) (1µl Fc block stock solution 2 mg/ml, in 499 µl FACS buffer) for 20 min 
on ice, 150 µl FACS buffer were added to the samples and centrifuged thereafter at 
10°C for 3 min at 7.5x103 rpm. The cells were resuspended in 50 µl Antibody mix 
(Panel 1 and Panel 2), incubated in the dark on ice for 15 min, then 50 µl Propidium 
Iodide solution/well (1 µl PI stock solution 2 mg/ml, in 99 µl PBS, stored at -20°C) (PI 
2 mg/ml) were added therein, and the cells were incubated for further 5 min in the 
dark on ice. They were washed and centrifuged repeatedly in 100 and 200 µl FACS 
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buffer 5 times, respectively. The Panel 1 mixture consisted of the following 
antibodies: 1:400 of 0.5 mg/ml FITC-conjugated rat anti-mouse CD44, 1:100 of 0.2 
mg/ml PE-conjugated armenian hamster anti-mouse γδTCR and APC-conjugated rat 
anti–mouse CD25, respectively, 1:1000 of 0.2 mg/ml PerCpCy55-conjugated rat anti-
mouse CD4, 1:100 of 0.2 mg/ml PE-Cy7 conjugated rat anti-mouse CD62L and 0.2 
mg/ml PB-conjugated rat anti-mouse CD3, 1:400 of 0.1 mg/ml APC-Alexa 750-
conjugated rat anti-mouse CD8a and 1:200 of 0.5 mg/ml Alexa Fluor 700-conjugated 
rat anti-mouse CD45, whereas the Panel 2 antibody mixture contains 1:1000 of 0.5 
µl/ml FITC-conjugated rat anti-mouse IgD, 1:200 of 0.2 mg/ml PE-conjugated Rat 
anti-mouse NK-T/NK, 1:800 of 0.2 mg/ml PerCPCy55-conjugated rat anti-mouse Gr1, 
1:1000 of PECy7-conjugated rat anti-mouse CD19, 1:2000 of 1 mg/ml APC-
conjugated rat anti-CD5, 1:800 of 0.1 mg/ml PB-conjugated rat anti-mouse CD11b, 
0.1 mg/ml APC-Alexa 750-conjugated rat anti-mouse B220 and 1:2000 of 0.5 mg/ml 
Alexa fluor 610-conjugated rat anti-mouse CD45. On the same plate, single color 
controls (SCC) containing single antibodies and PI were run parallel using the rest of 
the blood samples and 1:100 of 0.1 mg/ml PE-Alexa Fluor 610-conjugated rat anti-
mouse CD4, as well as an unstained sample containing only PI. 
 Data were obtained with a FACS LSR II and were analyzed using the FlowJo 
software (TreeStar, Inc. USA). Discrimination between live and dead cells was 
performed using the PI versus PE ratio. The minimum number of living cells was 
expected to be ≥ 30.000. The CD45+ cells were then defined versus the single colour 
controls and were taken for further analysis. T-cells were defined with the Panel 1 
antibodies, whereas Panel 2 detected B- and NK- cells. Subtypes of these cells were 
defined after subsequent subgatings of the respective cell population.  
 Blood samples were collected and tested from 56 male mice, aging 13 to 18 
weeks, and were divided into 5 groups. Group A constituted 9 chimeric mice obtained 
after the blastocyst injection with control mES cells, group B constituted 13 clinically 
healthy chimeric mice obtained after the blastocyst injection with mycoplasma-
infected mES cells, group C constituted 13 affected chimeric mice with clinical signs 
obtained after the blastocyst injection with mycoplasma-infected mES cells, group D 
constituted 10 control CD-1 wild type mice from the HMGU core breeding unit, and 
group E constituted 11 non-chimeric mice obtained after the blastocyst injection with 
mycoplasma-infected mES cells. All mice were housed under the same conditions in 
IVCs. 
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Figure 9 Determination of the germ line transmission based on the coat colour of the germ 
line pups. A. Offspring chimeras coming from CD-1 blastocysts injected with ES TBV2 cells. B. 
When ES cells show germ line transmission (GLT), the offspring appear agouti with light-
coloured belly. C. When ES cells do not show GLT, the offspring appear black. (Kindly 
provided by Dr. Michael van der Waal) 
ES cells contribute to germ line transmission (GLT)
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B
x CD-1/agouti chimeraF0
F1
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CD-1 blastocyst as ES cell acceptor
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4. RESULTS 
 
Detection of mycoplasma species  
 The presence of mycoplasmas in serial 10-fold dilutions of cell culture 
supernatants and cell suspensions was determined using agar culture, MycoAlertTM, 
gel-based PCR, and MycoSensorTM QPCR assays. The number of cells contained in 
the supernatant was 1x104/ml for M. hominis, 1.2x104/ml for M. fermentans, and 
2x104/ml for M. orale, whereas 1x104 trypsinized cells/ml DMEM were in the 
undiluted cell suspensions. The results are shown in Tables 1 to 3. 
 
Detection of M. hominis  
 The results for the comparison of agar culture, MycoAlertTM, gel-based PCR 
and MycoSensorTM for the detection of M. hominis are shown in Table 1. Plating of 
M. hominis from the undiluted cell-containing supernatant led to growth on both Friis 
and PH-Hayflick agar plates. Since the colonies were too dense they were not 
counted. With respect to the dilutions of the cell-containing supernatants, M. hominis 
colonies were detected up to the 10-5 dilution on Friis agar plates with 2x101 CFUs/ml 
and up to the 10-4 dilution on PH-Hayflick agar plates with 7x101 CFUs/ml. The limit 
of detection (LOD) of M. hominis in the cell suspensions was the 10-2 dilution with 
6x102 CFUs/ml and the 10-3 dilution with 4x101 CFUs/ml on Friis and on PH-Hayflick 
agar plates, respectively. The MycoAlertTM assay produced positive results with the 
undiluted M. hominis aliquots (5/5) and with the 10-1 dilution (5/5). All gel-based PCR 
runs (5/5) from the undiluted cell-containing supernatants were positive. Positive runs 
were obtained up to the 10-2 dilutions (3/5) (Figure 10). The gel-based PCR gave 
positive results for M. hominis only with the undiluted cell suspension in 2 out of 3 
runs. The MycoSensorTM QPCR detected M. hominis in the undiluted cell-containing 
supernatant (8x107 copies/ml) and up to a dilution of 10-3 (1.3x105 copies/ml) in all 
runs. Positive runs were obtained up to the 10-6 dilution (1/5), corresponding to 8x101 
copies/ml and 8 copies per reaction mixture (Figure 11). The MycoSensorTM QPCR 
detected M. hominis in the undiluted cell suspension (1.6x106 copies/ml) and up to a 
dilution of 10-2 (1.9x104 copies/ml) in all runs. Positive runs were obtained up to the 
10-4 dilution (1/3), corresponding to 6x101 copies/ml and 6 copies per reaction 
mixture. The cycle threshold (Ct) value for the standard sample of 50 copies was an 
average of 32 cycles for the M. hominis runs (data not shown), and the melting 
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temperature (Tm) was between 80.1°C and 82°C. The negative control gave no 
amplification curves and the Tm was between 65°C and 73°C. As such, it was judged 
as negative. The standard curves for run 1 to run 5 with M. hominis cell-containing 
supernatants and dilutions were linear with an average correlation coefficient (r2) of 
0.99 and an average slope of -3.29, corresponding to a PCR efficiency of 2 (100%) 
(Figure 11). Likewise, the standard curves for run 1 to run 3 with M. hominis cell 
suspensions and dilutions were linear with an average correlation coefficient (r2) of 
0.99 and an average slope of -3.35, corresponding to a PCR efficiency of 1.99 (99%). 
 
Detection of M. fermentans 
 The results for the comparison of agar culture, MycoAlertTM, gel-based PCR 
and MycoSensorTM for the detection of M. fermentans are shown in Table 2. Plating 
of M. fermentans from the undiluted cell-containing supernatant led to the growth of 
4.5x104 CFUs/ml on Friis agar plates but no colonies were observed on PH-Hayflick 
agar plates. With respect to the dilutions of the cell-containing supernatants, M. 
fermentans colonies were detected up to the 10-4 dilution on Friis agar plates with 
1x101 CFUs/ml. Plating of cell suspensions led to the growth of colonies up to the 10-
4 dilution with 5x101 CFUs/ml on Friis agar plates while growth on PH-Hayflick plates 
with 3x101 CFUs/ml was observed up to the 10-2 dilution. The MycoAlertTM assay 
produced positive results for the undiluted aliquots (5/5). All gel-based PCR runs 
(5/5) with the undiluted M. fermentans cell-containing supernatants were positive. 
Positive runs were also obtained with the 10-1 (3/5) dilutions (Figure 10). M. 
fermentans was detected in the undiluted cell suspension in all 3 runs and up to the 
10-1 dilution (2/3) with the gel-based PCR. The MycoSensorTM QPCR detected M. 
fermentans in the undiluted cell-containing supernatant (3x105 copies/ml) and up to 
the 10-1 dilution (2.9x104 copies/ml) in all runs. Positive runs were obtained up to the 
10-3 dilution (1/5), corresponding to 6.8x101 copies/ml and 7 copies per reaction 
mixture (Figure 12). The MycoSensorTM QPCR detected M. fermentans in the 
undiluted cell suspension (1.6x105 copies/ml) and up to a dilution of 10-2 (2.4x103 
copies/ml) in all runs. Positive runs were obtained up to the 10-3 dilution (2/3), 
corresponding to 2.4x102 copies/ml and 24 copies per reaction mixture. The cycle 
threshold (Ct) value for the standard sample of 50 copies was an average of 32 
cycles (data not shown) and the melting temperature (Tm) was between 80.1°C and  
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Figure 10 Gel-based PCR analyses of supernatant and 10-fold serial dilutions for the three 
human mycoplasma species. The PCR products of the mycoplasma-positive samples gave 
bands of about 510 bp. The internal control gave a 986 bp product. A.: M. hominis showed 
detectable bands up to the 10-2 dilution, B.: M. fermentans showed detectable bands up to the 
10-1 dilution, C.: M. orale showed detectable bands up to the 10-4 dilution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Amplification curves of the standard sample and serial dilutions of supernatant up 
to the respective dilution limit for M. hominis samples. SC: Standard curve. The standard 
samples gave Ct values of 31.75, 30.9, and 27.37 for 50, 100, and 1000 copies per 5 µl reaction 
volumes, respectively. 1-7: 100-10-6 dilution. M. hominis gave Ct values of 13.5 (1), 15.25 (2), 
17.6 (3), 22.05 (4), 25.2 (5), 30.66 (6) and 34.35 (7) with 1.64x107, 4.75x106, 9.3x105, 4.1x104, 
4.5x103, 1x102 and 8 copies per reaction, respectively. 
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Table 1 Comparison of agar culture, MycoAlertTM, gel-based PCR and MycoSensorTM QPCR assays for detection of M. hominis 
  Agar culture (CFUs/ml) 
Dilutions 
 Friis PH-Hayflick 
MycoAlertTM 
Positives/ 
total runs  
Gel-based PCR 
Positives/total runs 
MycoSensorTM QPCR 
Positives/total runs 
(copies/ml) 
  
Supernatant 
(1x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Supernatant 
(1x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Cell-free 
supernatant  
Supernatant 
(1x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Supernatant 
(1x104) 
cells/ml 
Cell 
suspension 
(1x104) 
cells/ml 
100  n.c. n.c.  n.c. n.c.  5/5  5/5 2/3  3/3 (8x107) 3/3 (1.6x106) 
10-1  n.c. 4x103  n.c. 5x103  5/5  3/5 0/3  3/3 (1.7x107) 3/3 (9x104) 
10-2  8.7x103 6x102  6x103 3.6x102  0/5  3/5 0/3  3/3 (3.4x106) 3/3 (1.9x104) 
10-3  7x102 0  5x102 4x101  0/5  0/5 0/3  5/5 (1.3x105) 2/3 (4.5x102) 
10-4  8x101 0  7x101 0  0/5  0/5 0/3  4/5/ (1.6x104) 1/3 (6x101) 
10-5  2x101 0  0 0  0/5  0/5 0/3  2/5 (1.8x103) 0/3 
10-6  0 0  0 0  0/5  0/5 0/3  1/5 (7.6x101) 0/3 
10-7*  0 0  0 0  0/5  0/5 0/3  0/5 0/3 
n.c.: not counted because the colonies were too dense 
*dilutions from 10-7 to 10-10 gave negative results with all methods
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82°C. The negative control gave no amplification curves and the Tm was between 
65°C and 73°C. As such, it was judged as negative. The standard curves for run 1 to 
run 5 with M. fermentans cell-containing supernatants and dilutions were linear with 
an average correlation coefficient (r2) of 0.99 and a slope of -3.38, corresponding to a 
PCR efficiency of 1.98 (99%) (Figure 12). Likewise, the standard curves for run 1 to 
run 3 with M. fermentans cell suspensions and dilutions were linear with an average 
correlation coefficient (r2) of 0.99 and an average slope of -3.35, corresponding to a 
PCR efficiency of 1.99 (99%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Amplification curves of the standard sample and serial dilutions of supernatant up 
to the respective dilution limit for M. fermentans samples. SC: Standard curve. The standard 
samples gave Ct values of 31.75, 30.9, and 27.37 for 50, 100, and 1000 copies per 5 µl reaction 
volumes, respectively. 1-4: 100-10-3 dilution. M. fermentans gave Ct values of 20.57 (1), 24.3 (2), 
30.77 (3) and 33.4 (4) with 8x104, 6.8x103, 9.3x101 and 7 copies per reaction, respectively. 
 
 
 
 
 51 
Table 2 Comparison of agar culture, MycoAlertTM, gel-based PCR and MycoSensorTM QPCR assays for detection of M. fermentans 
  Agar culture (CFUs/ml) 
Dilutions 
 Friis PH-Hayflick 
MycoAlertTM 
Positives/ 
total runs  
Gel-based PCR 
Positives/total runs 
MycoSensorTM QPCR 
Positives/total runs 
(copies/ml) 
  
Supernatant 
(1.2x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Supernatant 
(1.2x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Cell-free 
supernatant  
Supernatant 
(1.2x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Supernatant 
(1.2x104) 
cells/ml 
Cell 
suspension 
(1x104) 
cells/ml 
100  4.5x104 n.c.  0 3x103  5/5  5/5 3/3  3/3 (3x105) 3/3 (1.6x105) 
10-1  4.4x103 2x104  0 1.5x102  0/5  3/5 2/3  3/3 (2.9x104) 3/3 (1.6x104) 
10-2  3.8x102 5x103  0 3x101  0/5  0/5 0/3  2/3 (2.2x103) 3/3 (2.4x103) 
10-3  2.5x101 7x102  0 0  0/5  0/5 0/3  1/5 (6.8x101) 2/3 (2.4x102) 
10-4  1x101 5x101  0 0  0/5  0/5 0/3  0/5 0/3 
10-5  0 0  0 0  0/5  0/5 0/3  0/5  0/3 
10-6  0 0  0 0  0/5  0/5 0/3  0/5  0/3 
10-7*  0 0  0 0  0/5  0/5 0/3  0/5 0/3 
n.c.: not counted because the colonies were too dense 
*dilutions from 10-5 to 10-10 gave negative results with all methods 
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Detection of M. orale 
 The results for the comparison of agar culture, MycoAlertTM, gel-based PCR 
and MycoSensorTM for the detection of M. orale are shown in Table 3. Plating of M. 
orale from the undiluted cell-containing supernatant led to growth on both Friis and 
PH-Hayflick agar plates. With respect to the dilutions of the cell-containing 
supernatants, M. orale colonies were detected up to a dilution of 10-6 on Friis agar 
plates with 10 CFUs/ml and up to a dilution of 10-6 on PH-Hayflick agar plates with 5 
CFUs/ml. Plating of the cell suspension led to growth on both Friis and PH-Hayflick 
agar plates. M. orale colonies were detected up to a dilution of 10-4 with 60 CFUs/ml 
on Friis agar plates and up to a dilution of 10-4 with 1.3x103 CFUs/ml on PH-Hayflick 
agar plates (Figure 13). The MycoAlertTM assay produced positive results for the 
undiluted supernatants (5/5) and up to a dilution of 10-2 (5/5) in all runs. All gel-based 
PCR runs (5/5) with the undiluted M. orale supernatant and up to the 10-3 dilution 
were positive. Positive runs were also obtained with the 10-4 (1/5) dilution (Figure 10). 
M. orale was detected in the undiluted cell suspension in all 3 runs. Positive runs 
were also obtained up to the 10-2 dilution (1/3) with the gel-based PCR. The 
MycoSensorTM QPCR detected M. orale in the cell-containing supernatant (1x108 
copies/ml) and up to a dilution of 10-3 (1.2x104 copies/ml) in all runs. Positive runs 
(1/5) were also obtained up to the 10-5 dilution, corresponding to 8x102 copies/ml and 
80 copies/reaction mixture (Figure 14). The MycoSensorTM QPCR detected M. orale 
in the undiluted cell suspension (4.6x105 copies/ml) and up to a dilution of 10-2 in all 3 
runs, corresponding to 3.2x103 copies/ml and 320 copies per reaction mixture. The 
cycle threshold (Ct) value for the standard sample of 50 copies was an average of 32 
cycles (data not shown) and the melting temperature (Tm) was between 80.1°C and 
82°C. The negative control gave no amplification curves and the Tm was between 
65°C and 73°C. As such, it was judged as negative. The standard curves of M. orale 
cell-containing supernatants and dilutions for run 1 to run 5 were linear with an 
average correlation coefficient (r2) of 0.99, and an average slope of -3.24, 
corresponding to a PCR efficiency of 2 (100%) (Figure 14). Likewise, the standard 
curves for run 1 to run 3 with the M. orale cell suspensions and dilutions were linear 
with an average correlation coefficient (r2) of 0.99 and an average slope of -3.35, 
corresponding to a PCR efficiency of 1.99 (99%). 
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Figure 13 Typical colonies of M. orale with “fried egg appearance” on Friis agar, observed 
under a Zeiss inverted microscope. Scale bar = 10mm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Amplification curves of the standard sample and serial dilutions up to the 
respective dilution limit for M. orale samples. SC: Standard curve. The standard samples gave 
Ct values of 31.75, 30.9, and 27.37 for 50, 100, and 1000 copies per 5 µl reaction volumes, 
respectively. 1-6: 100-10-5 dilution. M. orale gave Ct values of 12.86 (1), 19.20 (2), 25.12 (3), 25.86 
(4), 29.35 (5) and 31.29 (6) with 1.98x107, 3.13x105, 5.2x103, 3.1x103, 3x102 and 8x101 copies per 
reaction, respectively. 
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Table 3 Comparison of agar culture, MycoAlertTM, gel-based PCR and MycoSensorTM QPCR assays for detection of M. orale 
  Agar culture (CFUs/ml) Dilutions 
 Friis PH-Hayflick 
MycoAlertTM 
Positives/ 
total runs  
Gel-based PCR 
Positives/total runs 
MycoSensorTM QPCR 
Positives/total runs 
(copies/ml) 
  
Supernatant 
(2x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Supernatant 
(2x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Cell-free 
supernatant  
Supernatant 
(2x104 
cells/ml) 
Cell 
suspension 
(1x104 
cells/ml) 
Supernatant 
(2x104) 
cells/ml 
Cell 
suspension 
(1x104) 
cells/ml 
100  n.c. n.c.  n.c. n.c.  5/5  5/5 3/3  3/3 (1x108) 3/3 (4.6x105) 
10-1  n.c. 9x103  n.c. n.c.  5/5  5/5 2/3  3/3 (1.9x106) 3/3 (6x104) 
10-2  n.c. 1x103  n.c. 9x103  5/5  5/5 1/3  3/3 (2.4x104) 3/3 (3.2x103) 
10-3  7.2x103 6.8x102  9x103 n.e.  0/5  5/5 0/3  5/5 (1.2x104) 0/3 
10-4  6.7x102 6x101  1x103 1.3x103  0/5  1/5 0/3  2/5/ (1.5x103) 0/3 
10-5  1x102 0  1.2x102 0  0/5  0/5 0/3  1/5 (8x102) 0/3 
10-6  1x101 0  5x100 0  0/5  0/5 0/3  0/5 0/3 
10-7*  0 0  0 0  0/5  0/5 0/3  0/5 0/3 
 
n.c.: not counted because the colonies were too dense, n.e.: could not be evaluated 
*dilutions from 10-7 to 10-10 gave negative results with all methods 
Results  55 
 
mES cell culture 
 To determine if mycoplasmas have an effect on mES cell culture, the 
morphology, the growth rate and the viability of mycoplasma-infected and control 
TBV2 mES cells were investigated over 20 passages by use of murine feeder cells. 
The morphology was determined by observing the size of ES cell colonies and the 
development of embryoid bodies (cell aggregates which implicates in vitro 
differentiation of the mES cells). The growth rate was determined by calculating the 
total number of mES cells which included dead, apoptotic and live cells in the 
supernatant, in the washing solution and in trypsinized cell suspensions. The total 
number of viable mES cells in trypsinized cell suspensions was determined using 
trypan blue staining. The numbers of mES cells were extrapolated at each passage. 
 
Morphology of TBV2 mES cells 
 The results obtained for morphology are shown in Figure 15. Control mES 
cells led to the growth of medium to large, multicellular, and well-shaped ES cell 
colonies up to the passage P13+15 (Figure 15, A, B, C). Up to passage P13+20, 
control mES cells produced very large colonies (Figure 15, D). Mycoplasma-infected 
mES cells led to the growth of very small, small and medium colonies up to the 
passage P13+20 (Figure 15, E, black arrow, F, G, H) which appeared flatter than the 
colonies obtained from the control group. No embryoid bodies were observed for the 
two experimental groups over the 20 passages of culture. 
 
Growth and viability of TBV2 mES cells 
 The results obtained for the growth and viability of mycoplasma-infected and 
control mES cells are shown in Table 4 and Figure 16. A total of 4.16x105 control 
TBV2 mES cells was seeded at P13 and increased to 1.2x1022 at passage P13+20 
(Table 4). The number of dead and apoptotic cells at each passage was calculated 
by the difference of the total number to the number of trypsinized cells and was on 
average 18%. The viability of the trypsinized cells was 89% to 100% over the 20 
passages of culture. With respect to the mycoplasma-infected cultures, 4.16x105 of 
TBV2 mES cells were seeded at passage P13, inoculated with M. hominis, M. 
fermentans and M. orale and the cell number was 3.9x1015 at passage P13+20.  
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Figure 15 Morphology of control (A, B, C, D) and mycoplasma-infected (E, F, G, H) TBV2 
murine ES cell colonies at passages P13+5 (A, E), P13+10 (B, F), P13+15 (C, G), and P13+20 (D, 
H), respectively. Black arrow: colonies of TBV2 murine ES cells, white arrow: murine 
embryonic feeder cells. Scale bar = 100 µm. 
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The average number of dead and apoptotic cells was 27% whereas the viability 
obtained in trypsinized cell suspensions was 74% to 95%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Growth rates and viability of control and mycoplasma-infected TBV2 mES cells over 
20 passages (P13+1 to P13+20). 
 
 
Detection of mycoplasmas in TBV2 mES cell cultures 
 The presence of mycoplasmas in TBV2 mES cell cultures was determined by 
agar culture, the MycoAlertTM assay, the gel-based PCR, and the MycoSensorTM 
QPCR assay. The results are shown in Table 5. The number of cells found in the 
mycoplasma-infected supernatants ranged from 2.6x104 to 1x105 mES cells per ml. 
 Plating of cell-containing control supernatant from passages P13+5, P13+10, 
P13+15, and P13+20 on Friis and PH-Hayflick agar plates did not lead to growth of 
mycoplasmas. Plating of mycoplasma-infected cell-containing supernatants from the 
respective passages led to growth of mycoplasmas on both Friis and PH-Hayflick 
agar plates. The colony forming units (CFUs) on agar plates were too dense to allow 
counting. 
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Table 4 Growth rates and viability of control and mycoplasma-infected TBV2 murine ES cells 
*Numbers of cells were extrapolated, £: the total number of cells was enumerated from the supernatants, washes and trypsinized cell suspensions 
Passages  Total number of TBV2 mES cells*£ Number of TBV2 ES cells* in trypsinized cell suspensions 
Viability of TBV2 mES cells* in 
trypsinized cell suspension (%) 
P13 +  Control  Mycoplasma-infected Control 
Mycoplasma-
infected Control 
Mycoplasma-
infected 
1  2.4x106  2.7x106  1.6x106  1.6x106  1.6x106 (100)  1.5x106 (95) 
2  7.4x106  7.9x106  4.9x106  5.4x106  4.7x106 (95)  4.7x106 (86) 
3  3.8x107  1.6x107  3.4x107  1.0x107  3.3x107 (95)  9.2x106 (85) 
4  2.0x108  2.8x107  1.7x108  1.8x107  1.6x108 (97)  1.5x107 (87) 
5  1.3x109  5.6x107  1.0x109  4.2x107  9.5x108 (95)  3.7x107 (89) 
6  1.8x1010  1.7x108  1.7x1010  1.3x108  1.5x1010 (89)  1.2x108 (94) 
7  8.5x1010  4.2x108  7.3x1010  3.6x108  7.3x1010 (100)  2.7x108 (74) 
8  8.9x1011  2.6x109  7.8x1011  2.3x109  6.9x1011 (89)  2.0x109 (89) 
9  8.4x1012  1.3x1010  7.7x1012  1.1x1010  7.0x1012 (91)  9.6x109 (89) 
10  3.4x1013  3.1x1010  2.9x1013  2.5x1010  2.7x1013 (91)  2.0x1010 (80) 
11  2.9x1014  7.5x1010  2.5x1014  3.7x1010  2.4x1014 (96)  3.2x1010 (86) 
12  1.3x1015  1.0x1011  7.9x1014  6.3x1010  7.6x1014 (97)  5.7x1010 (90) 
13  8.0x1015  2.2x1011  6.0x1015  1.0x1011  5.8x1015 (96)  8.7x1010 (85) 
14  4.5x1016  4.5x1011  3.2x1016  3.1x1011  3.0x1016 (93)  2.9x1011 (93) 
15  4.3x1017  1.3x1012  3.6x1017  7.8x1011  3.4x1017 (95)  6.8x1011 (88) 
16  4.2x1018  4.8x1012  3.8x1018  4.4x1012  3.6x1018 (95)  3.7x1012 (84) 
17  2.8x1019  3.5x1013  2.4x1019  2.8x1013  2.3x1019 (95)  2.7x1013 (95) 
18  2.5x1020  2.0x1014  2.2x1020  1.8x1014  2.0x1020 (90)  1.6x1014 (94) 
19  1.9x1021  8.3x1014  1.7x1021  6.5x1014  1.6x1021 (96)  5.8x1014 (89) 
20  1.5x1022  4.5x1015  1.2x1022  3.9x1015  1.1x1022 (96)  3.6x1015 (93) 
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 The MycoAlertTM detection assay was performed for all 20 passages of the 
control and mycoplasma-infected mES cells. Control supernatants were all negative 
and the ratio B/A was between 0.4 and 0.9. The MycoAlertTM assay gave positive 
results for mycoplasma-infected samples for all 20 passages. The ratio B/A at 
passage P13+1 was 2.6 whereas for the next passages and up to passage P13+19, 
the ratio B/A ranged between 10.2 and 51.7 (Table 5). At passage P13+20, the ratio 
B/A was 5.7. 
 The gel-based PCR was performed for all 20 passages of the 2 experimental 
groups. Control samples gave no PCR products and no bands were observed on 
agarose gel while PCR products and bands on agarose gel were observed from all 
20 passages of mycoplasma-infected samples. Furthermore, positive PCR products 
were used for mycoplasma-species identification with Restriction Fragment Length 
Polymorphism (RFLP). At passage P13+1, only M. hominis and M. orale were 
detected whereas from passage P13+2 to P13+20 M. hominis, M. fermentans and M. 
orale were detected. 
 The MycoSensorTM QPCR assay was performed with mycoplasma positive 
cell-containing supernatants and cell suspension samples from passages P13+5, 
P13+10, P13+15 and P13+20. The supernatants from the respective passages 
contained 2.9x104, 3.7x104, 9.2x104 and 7x104 mES cells, respectively, whereas the 
cell suspensions contained 1x104 mES cells per ml. The MycoSensorTM QPCR assay 
detected 5.5x107 and 5.8x106, 1.7x108 and 4.9x105, 3.2x107 and 1x105, and 6x106 
and 6.5x103 mycoplasma genome copies in cell-containing supernatants and in cell 
suspensions at passages P13+5, P13+10, P13+15 and P13+20, respectively. 
Consequently, a total of 5.8x102, 49, 10 and 1 mycoplasmas was adhered to or 
invaded 1 mES cell at the respective passages. 
 
Karyotype of TBV2 mES cells 
 The karyotype of mycoplasma-free TBV2 mES cells was examined at passage 
P13+2. Furthermore, control and mycoplasma-infected TBV2 mES cells at passages 
P13+5, P13+10, P13+15 and P13+20 were examined using Spectral Karyotyping 
(SKY). The results are shown in Table 6. At passage P13+2, 15 metaphases were 
studied. A total of 9 metaphases showed a normal karyotype (60%) having {40, XY} 
chromosomes and 6 of them showed numeric aberrations including 2 tetraploid 
metaphases. Absence of chromosome X appeared twice (13%), whereas absence of 
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Table 5 Detection of mycoplasmas in supernatants and cell suspensions of TBV2 mES cell cultures by four methods 
Passages  Agar culture (CFUs/ml) MycoAlert
TM 
detection assay  Gel-based PCR  
MycoSensorTM 
QPCR assay 
P13 + 
Number of 
TBV2 mES 
cells in 
supernatant/
ml 
 Friis/PH-Hayflick  
Friis/PH-
Hayflick    
Cell-
containing 
supernatant 
(genome 
copies/ml) 
 
Cell 
suspension 
(1x104 
cells/ml) 
  Mycoplasma-infected  Control  
Mycoplasma
-infected  Control  
Mycoplasma
-infected  Control  
Mycoplasma
-infected  
Mycoplasma
-infected  
Mycoplasma
-infected 
1  1.0x105  n.d  n.d  0.74 (-)  2.6 (+)  -  +*  n.d  n.d 
2  6.3x104  n.d  n.d  0.68 (-)  36.5 (+)  -  +**  n.d  n.d 
3  2.6x104  n.d  n.d  0.71 (-)  51.7 (+)  -  +  n.d  n.d 
4  4.0x104  n.d  n.d  0.78 (-)  34.9 (+)  -  +  n.d  n.d 
5  2.9x104  -/-  +/+†  0.66 (-)  37.9 (+)  -  +  5.5x107  5.8x106 
6  2.6x104  n.d  n.d  0.65 (-)  18.2 (+)  -  +  n.d  n.d 
7  3.0x104  n.d  n.d  0.76 (-)  23.0 (+)  -  +  n.d  n.d 
8  2.9x104  n.d  n.d  0.63 (-)  34.0 (+)  -  +  n.d  n.d 
9  3.0x104  n.d  n.d  0.68 (-)  28.7 (+)  -  +  n.d  n.d 
10  3.7x104  -/-  +/+†  0.62 (-)  42.3 (+)  -  +  1.7x108  4.9x105 
11  4.0x104  n.d  n.d  0.64 (-)  18.6 (+)  -  +  n.d  n.d 
12  7.6x104  n.d  n.d  0.63 (-)  10.8 (+)  -  +  n.d  n.d 
13  9.3x104  n.d  n.d  0.41 (-)  17.9 (+)  -  +  n.d  n.d 
14  8.0x104  n.d  n.d  0.49 (-)  16.2 (+)  -  +  n.d  n.d 
15  9.2x104  -/-  +/+†  0.61 (-)  12.3 (+)  -  +  3.2x107  1.0x105 
16  3.3x104  n.d  n.d  0.88 (-)  10.2 (+)  -  +  n.d  n.d 
17  5.3x104  n.d  n.d  0.90 (-)  17.6 (+)  -  +  n.d  n.d 
18  5.0x104  n.d  n.d  0.86 (-)  14.8 (+)  -  +  n.d  n.d 
19  4.0x104  n.d  n.d  0.72 (-)  16.6 (+)  -  +  n.d  n.d 
20  7.0x104  -/-  +/+†  0.50 (-)  5.7 (+)  -  +  6.0x106  6.5x103 
n.d: not done, +: positive, -: negative, †: Colony forming units (CFUs) were not counted, *:P13+1: Restriction Fragment Length Polymorphism (RFLP) assay detected 
only M. hominis and M. orale, **P13+2 to P13+20: Restriction Fragment Length Polymorphism assay detected M. hominis, M. fermentans, M. orale. 
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chromosome  2, 3, 6 and 17 appeared once. A trisomy 10 was observed in 1 
metaphase. 
 From the control TBV2 mES cells at passage P13+5, 18 metaphases were 
studied, 11 of which were normal (60%) and 7 showed an abnormal karyotype with 
numeric aberrations. A total of 1 tetraploid metaphase was observed. Absence of 
chromosome Y appeared twice while 2 metaphases had only 31 chromosomes in 
which both chromosome 8 were absent. Trisomy 11 and 6 was observed once.  
 From the mycoplasma-infected TBV2 mES cells at passage P13+5, 16 
metaphases were studied. A total of 9 metaphases was normal (56%) and 7 were 
abnormal with numeric aberrations. In 1 metaphase, both X and Y chromosomes 
were absent whereas absence of chromosome Y, 4, 6, and 11 was observed once. 
Trisomy 1 appeared twice and trisomy 16 and 18 once. 
 From the control TBV2 mES cells at passage P13+10, 15 metaphases were 
studied. A total of 3 metaphases was normal (20%) and 12 showed an abnormal 
karyotype. The Y chromosome was absent in 2 metaphases (13%), and trisomy 1, 8, 
11 and 14 appeared in 5 (33%), 1 (7%), 3 (20%) and 2 (13%) metaphases, 
respectively. Absence of chromosome 15 and 18 as well as an acentric fragment of 
the chromosome 17 {41, XY; ace(17)} appeared once. From mycoplasma-infected 
TBV2 mES cells of the respective passage 15 metaphases were studied. A total of 
10 metaphases showed a normal karyotype (67%) and 5 were abnormal. Absence of 
chromosome Y and trisomy 1 was observed once (7%). A balanced translocation 
between the chromosomes 10 and 18, which were attached to each other at the 
centromeres {t(10;8)(cen-cen)} was observed in 1 metaphase. Deletions of 
chromosome 7 and 10 segregated at the A2 and B3 bands up to the terminal end of 
the chromatids, respectively, were observed once (7%). 
 At passage P13+15, 15 control metaphases were studied. A total of 5 
metaphases was normal (33%) and 10 showed numeric aberrations. Absence of 
chromosomes Y and 18 was observed once (7%), whereas trisomy 1, 6, 8, 11, 14, 
and 16 appeared in a total of 3 (20%), 1 (7%), 2 (13%), 3 (20%), 2 (13%) and 1 (7%) 
metaphases, respectively. A total of 18 metaphases was studied from mycoplasma-
infected TBV2 mES cells of the respective passage. A normal karyotype appeared in 
6 metaphases (33%). The 12 abnormal metaphases showed trisomy 1, 6, and 13 in 4 
(22%), 3 (17%) and 1 (6%) cases, respectively, whereas absence of chromosome 7, 
9, 13, 14, 17, and 19 appeared once (6%). Both chromosomes 17 were absent from 
1 metaphase. Deletions of chromosome 4, 11 and 15 segregated at the C5, D3 and 
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C bands and up to the terminal end of the chromatids, respectively, were observed 
once. A translocation between chromosome 3 and 7 and 5 and 9 was present in 1 
metaphase at which the derivative fragment of chromosome 7 from the C3 band up 
to the terminal end of the chromatids was connected to the segregated chromosome 
3 at the G3 bands, whereas 5 and 9 chromosomes were connected to each other at 
the centromeres. 
 For control TBV2 mES cells at passage P13+20, 18 metaphases were studied. 
A total of 6 metaphases was normal (33%) and 12 were abnormal. Absence of 
chromosome 3, 5, 10 was observed in 1 (6%), 2 (11%) and 1 (6%) metaphase, 
respectively, whereas trisomy 1 and 11 appeared in 5 (28%) and 3 (17%) 
metaphases, respectively. In a case of trisomy 11, a balanced translocation was 
observed between the chromosomes 11 which were joined to each other at the 
centromeres. A deletion of chromosome 15 segregated at the C2 band and up to the 
terminal end of the chromatids, and a translocation between chromosome 3 and 4 at 
which the derivative fragment of chromosome 4, segregated at the E1 band and up 
to the terminal end of the chromatids, was connected to the segregated chromosome 
3 at the H4 bands, were also observed. Twenty metaphases were studied from 
mycoplasma-infected TBV2 mES cells of the respective passage. A total of 4 
metaphases was normal (20%) (Figure 17, A) and 16 showed abnormal karyotype. 
Absence of chromosome Y, 11 and 7 was observed in 3 (15%), 1 (5%) and 1 (5%) 
metaphases, respectively, whereas trisomy 1 (Figure 17, B), 6, and 11 was observed 
in 5 (25%), 2 (10%) and 1 (5%) metaphases, respectively. An acentric fragment of 
chromosome 1 {41,XY;ace(1)} was observed once. Balanced translocations were 
observed between chromosomes 1, and between the chromosomes 5 and 14, which 
were connected to each other at the centromeres, respectively. Unbalanced 
translocations were observed between the chromosomes 14 and 4 at which the 
derivative fragment from chromosome 4, segregated at the E1 band up to the 
terminal end of the chromatids, was connected to the chromosome 14 at the E4 
band. An insertion between chromosome 11 and 19 {41,XY;der11(B5-ter) 
;ins(11;19)(B5-ter;cen-A9} was observed in 1 metaphase (5%) (Figure 17, B). 
Deletions of chromosome 1, 6, 10, 11, and 12, segregated at the E4, C3, B3, A2 and 
D1 bands up to the terminal end of the chromatids, respectively, were observed once 
(Figure 17, C).  
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Table 6 Spectral karyotypic analysis of control and mycoplasma-infected TBV2 mES cells 
TBV2 mES cells  Number of metaphases studied Aberrant karyotype 
Passage  Total Abnormal  
P13+2 mycoplasma-free  15 6 {39,Y}, {38,Y;-17}, {39,XY;-2}, {41,XY;+10}, {79,XXYY;-3}, {79,XXYY;-6} 
P13+5 control 
 
18 7 {41,XY;+6;}, {39,XY;-3}, {38,X;-14;}, {39,XY;-17;}, {31,XY;-3;-6;-7;-8;-8;-9;-11;-17;-19}, {31,X;-5;-8;-8;-9;-15;-16;-17;-19}, {78,YY;+11;-12} 
P13+5 mycoplasma-infected  16 7 {2x41,XY+1;}, {38;}, {39,X;}, {39,XY;-11;}, {38,XY;-4;-6;}, {42,XY;+16;+18;}  
P13+10 control 
 
15 12 {2x39,X}, {3x41,XY;+1}, {41,XY;+8}, {2x41,XY;+11}, {40,XY;+1;-18}, {41,XY;+6; +14;-15}, {41,XY;ace(17)}, {41,XY;+1;+11;+14} 
P13+10 mycoplasma-infected  15 5 {39,X}, {41,XY;+1}, {39,XY;t(10;18)(cen;cen}, {40,XY;d7(A2-ter)}, {40,XY;d10(B3-ter)} 
P13+15 control 
 
15 10 {39,X}, {2x41,XY;+11}, {40,XXY;-18}, {41,XY;+1}, {42,XY;+1;+14}, {42,XY;+8;+12}, {41,XY;+8}, {41,XY;+6}, {43,XY;+1;+11;+14,+16} 
P13+15 mycoplasma-infected 
 
18 12 
{2x41,XY;+1}, {41,XY;+6}, {41,XY;+13}, {39, XY; -3}, {40,XY;+1;-14}, {41,XY;d4(C5-ter);+6}, 
{39,XY;d15(D3-ter);-19}, {40,XY;d11(D-ter)}, {35,Y;+1;-7;-9;-13;-17;-17}, {40,XY;der(3;7);t(3;7)(cen- 
G3;C-ter);-17;+6}, {39, XY; t(5;9)(cen-cen)} 
P13+20 control 
 
18 12 {2x41,XY;+1}, {2x41,XY;+11}, {39,XY;-5}, {39,XY;-10}, {40,XY;+1,-5}, {40,XY;+11;d15(D2-ter)}, {40,XY;+1;-3;amp 16}, {40,XY;amp14}, {41,XY;t(11;11)(cen;cen)}, {41,XY;+1;t(3;4)(H4;E1-ter)}  
P13+20 mycoplasma-infected 
 
20 16 
{2x39,X}, {41,XY;+1}, {40,X;+1}, {39,XY;-11}, {41,XY;ace(1)}, {40,XY;+1;-7}, {41,XY;t(1;1)(cen;cen)}, 
{39,XY;t(5;14)(cen-cen)}, {40,XY;d12(D1-ter)}, {41,XY;+6;d10(B3-ter)}, {41,XY;+6;d6(C3-ter)}, 
{40,XY;d1(E4-ter)}, {40,XY;t(14;4)(E5;E1-ter)}, {41,XY;der 11(B5-ter) ;ins(11;19)(B5-ter;cen-A)}, 
{42,XY;+1;d11(A2-ter); (11;11)(cen;cen)} 
-, +: numeric aberrations, ace: acentric fragment, cen: centromere, t: translocation, d: deletion, ter: terminal end, der: derivative, ins: insertion, amp: amplification, A2, B3, 
C5, D3, D, G3, C, D1, C3, E4, E5, E1, A, B5: regions of chromosome bands based on the mouse ideogram 
(http://www.pathology.washington.edu/research/cytopages/idiograms/mouse/ #374). 
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Figure 17 Spectral karyotyping of mycoplasma-infected TBV2 mES cells at passage P13+20 (A, 
B, C). A: normal karyotype {40, XY}. B: Trisomy 1 {41,XY;+1}, ins {41,XY;der 11(B5-
ter);ins(11;19)(B5-ter;cen-A)}, the segregated fragment of chromosome 11 at the B5 band and up 
to the terminal end of the chromatids was inserted between the A and B bands of the 
chromosome 19 (aberrations are shown in white frames). C: d10 (B3-ter), chromosome 10 was 
deleted in both chromatids at point B3 (white frame). 
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Differentiation status of TBV2 mES cells 
 The differentiation status of the control and mycoplasma-infected TBV2 mES 
cells was determined at passages P13+6, P13+11, P13+16 and P13+21, respectively, 
using flow cytometric analysis (FACS) and double labeling with antibodies against the 
markers OCT-4 and SSEA-1. The results are shown in Figure 18.  
 A total of 84.8% of the control TBV2 mES cells at passage P13+6 was positive 
for both OCT-4 and SSEA-1 markers, an additional 5.06% and 4.66% was positive only 
for OCT-4, and only for SSEA-1, respectively, and 5.49% was negative for both markers 
(Figure 18, A). Mycoplasma-infected TBV2 mES cells at the same passage were 
positive for OCT-4 and SSEA-1 markers at a rate of 46.3%, whereas 10% was positive 
only for OCT-4, 24.4% was positive only for SSEA-1, and 19.2% was negative for both 
markers (Figure 18, E). 
 At passage P13+11, 86.7% of the control TBV2 mES cells were positive for both 
OCT-4 and SSEA-1 markers, 10.3% were positive only for OCT-4, 1.13% only for 
SSEA-1 and 1.94% were negative for both markers (Figure 18, B). Mycoplasma-
infected TBV2 mES cells at the same passage were positive for OCT-4 ad SSEA-1 
markers at a rate of 83%, whereas 11.3% were positive only for OCT-4, 1.92% were 
positive only for SSEA-1, and 3.81% were negative for both markers (Figure 18, F). 
 A total of 87.8% of the control TBV2 mES cells at passage P13+16 was positive 
for both OCT-4 and SSEA-1 markers, 7.86% was positive only for OCT-4, 2.05% only 
for SSEA-1 and 2.3% was negative for both markers (Figure 18, C). Mycoplasma-
infected TBV2 mES cells at the same passage were positive for both OCT-4 and SSEA-
1 markers at a rate of 78%, whereas 14.3% were positive only for OCT-4, 2.2% were 
positive only for SSEA-1 and 5.5% were negative for both markers (Figure 18, G). 
 At passage P13+21, 78% of the control TBV2 mES cells were positive for both 
OCT-4 and SSEA-1 markers, 18.4% were positive only for OCT-4, 1.82% were positive 
only for SSEA-1 and 1.79% was negative for both markers (Figure 18, D). Mycoplasma-
infected TBV2 mES cells at the same passage were positive for both OCT-4 and SSEA-
1 markers at a rate of 69.4%, whereas 20.1% were positive only for OCT-4, 3.63% were 
positive only for SSEA-1 and 6.89% were negative for both markers (Figure 18, H). 
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Figure 18 Determination of pluripotency of control (A, B, C, D) and mycoplasma-infected (E, F, G, 
H) TBV2 mES cells at passages P13+6, P13+11, P13+16 and P13+21 using flow cytometric analysis 
(FACS) and antibodies against the differentiation markers OCT-4 and anti-SSEA-1.  
 
 
Results of embryo transfers, chimera production and germ line transmission 
 Mycoplasma-free TBV2 mES cells at passage P13+2 and control and 
mycoplasma-infected TBV2 mES cells at passages P13+5, P13+10, P13+15 and 
P13+20 were injected into CD-1 blastocysts, and the embryos were transferred in CD-1 
pseudopregnant recipients. The number of litters, the percentage of chimeric pups and 
the contribution to the germ line were determined. The contribution of TBV2 mES cells 
to somatic tissues and to the germ line of chimeras was determined by coat and eye 
colour, and breeding of chimeric progeny with C57/BL6 (B6) mice, respectively. Each 
chimera was mated twice with B6 mice. Reproductive and germ line transmission (GLT) 
results are shown in Table 7. 
 At passage P13+2, 6 out of 9 recipients littered and 32% of the embryos injected 
resulted in the birth of 40 live pups. A total of 13 chimeras (11 males and 2 females) 
was obtained from 5 out of 6 litters, 12 (10 males and 2 females) of which showed GLT  
 67 
Table 7 Results obtained from embryo transfers after injection of control and mycoplasma-infected TBV2 mES cells into blastocysts 
Parameter  P13+1  P13+5  P13+10  P13+15  P13+20 
  Mycoplasma-free  Control  
Mycoplasma-
infected  Control  
Mycoplasma-
infected  Control  
Mycoplasma-
infected  Control  
Mycoplasma-
infected 
Pups born /embryos 
transferred (%) 
 40/126 (32)  38/84 (45)  25/112 (22)  
31/112 
(27)  67/196 (34)  
34/154 
(22)  48/196 (24)  
30/98 
(31)  59/224 (26) 
Litters/No. of transfers 
performed 
 6/9  6/6  4/8  5/8  10/14  6/11  9/14  5/7  10/16 
Litters with chimeras  
(No. of mice) 
 5/6 (13)  6/6 (10)  3/4 (10)  4/5 (10)  10/10 (28)  5/6 (11)  8/9 (22)  4/5 (9)  8/10 (23) 
♂/♀ chimeras  11/2  8/2  9/1  10/0  24/4  9/2  17/5  4/5  19/4 
Litters with GLT*   5/5  6/6  3/3  4/4  7/10  3/5±  8/8  5/5  8/8 
GL chimeras/total no. 
of chimeras (%) 
 12/13± (92)  9/10 (90)  5/10 (50)  7/9† (78)  15/24† (62)  6/11
± 
(55)  12/20
† (60)  7/9 (78)  18/22† (81) 
♂ GL chimeras/ 
♂ chimeras  
 10/11†  7/8  5/9  7/9  15/21  6/9±  9/15  2/4  15/18 
♀ GL chimeras/ 
♀ chimeras 
 2/2  2/2  0/1  0/0  0/3  0/2±  3/5  5/5  3/4 
GL pups/pups born (%)  103/139 (74)  
94/146 
(64)  45/108 (42)  
91/92 
(98)  
154/258 
(60)  
67/89 
(75)  
161/192 
(83)  
89/115 
(77)  
172/239 
(72) 
GL pups/pups born 
from ♂ chimeras  
 85/116  68/99  45/108  91/92  134/212  67/89  110/134  36/52  128/183 
GL pups/pups born 
from ♀ chimeras  
 18/23  26/47  0/0  0/0  0/46  0/0  51/58  53/63  44/56 
*GLT: Germ line transmission, GL: germ line, ♂: male, ♀: female, †: pups were sacrificed or died before weaning, ±: incomplete data 
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(92%). Breeding of chimeric progeny with B6 mice resulted until now in 139 live pups, 
103 (74%) of which were germ line pups. This experiment is still in progress. 
 At passage P13+5, all 6 recipients littered and 45% of the embryos injected with 
control mES cells resulted in 38 live pups. A total of 10 chimeras (8 males and 2 
females) was obtained from all 6 litters and 9 out of 10 chimeras (7 males and 2 
females) showed GLT (90%). The number of pups born from chimera breeding with B6 
mice was 146, 94 of which were germ line pups (64%). With respect to the embryos 
injected with mycoplasma-infected mES cells of the respective passage, 4 out 8 
recipients littered and 22% resulted in 25 live pups. A total of 10 chimeras (9 males and 
1 female) was obtained from 3 out of 4 litters and 5 males showed GLT (50%). The 
number of pups born from chimera breeding with B6 mice was 108, 45 of which were 
germ line pups (42%). Statistical analysis with the Fischer’s test showed significant 
differences between the 2 experimental groups for the number of litters born (p<0.05), 
the number of pups born (p<0.001), the GLT (p<0.07) and the number of germ line pups 
(p<0.001). The (p<0.07) value is borderline due to the small number of chimeras in the 
2 groups. 
 At passage P13+10, 5 out of 8 recipients littered and 27% of the embryos 
injected with mES cells resulted in 31 live pups. A total of 10 male chimeras was 
obtained from 4 out of 5 litters and 7 out of 9 remaining chimeras showed GLT (78%). 
The number of pups born from chimera breeding with B6 mice was 92, 91 of which were 
germ line pups (98%). With respect to the embryos injected with mycoplasma-infected 
mES cells of the respective passage, 10 out of 14 recipients littered and 34% resulted in 
67 live pups. A total of 28 chimeras (24 males and 4 females) was obtained from all 10 
litters and 15 males out of the 24 remaining chimeras contributed to the germ line 
(62%). The number of pups born from chimera breeding with B6 mice was 258, 154 of 
which were germ line pups (60%). 
 At passage P13+15, 6 out of 11 recipients littered and 22% of the embryos 
injected with control mES cells resulted in 34 live pups. A total of 11 chimeras (9 males 
and 2 females) was obtained from 5 out of 6 litters and 6 males out of the 11 chimeras 
showed until now GLT (55%). The number of pups born from chimera breeding with B6 
mice was 89, 67 of which were germ line pups (75%). With respect to the embryos 
injected with mycoplasma-infected mES cells of the respective passage, 9 out of 14 
recipients littered and 24% resulted in 48 live pups. A total of 22 chimeras (17 males 
and 5 females) was obtained from 8 and out of 9 litters and 12 (9 males and 3 females) 
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out of the 20 remaining chimeras showed GLT (60%). The number of pups born from 
chimera breeding with B6 mice was 192, 161 of which were germ line pups (83%). This 
experiment is still in progress. 
 At passage P13+20, 5 out of 7 recipients littered and 31% of the embryos 
injected with control mES cells resulted in 30 live pups. A total of 9 chimeras (4 males 
and 5 females) was obtained from 4 out of 5 litters and 7 out of 9 chimeras (2 males and 
5 females) showed GLT (78%). The number of pups born from chimera breeding with 
B6 mice was 115, 89 of which were germ line pups (77%). With respect to the embryos 
injected with mycoplasma-infected mES cells of the respective passage, 10 out of 16 
recipients littered and 26% resulted in 59 live pups. A total of 23 chimeras (19 males 
and 4 females) was obtained from 8 out of 10 litters and 18 out of the 22 remaining 
chimeras showed GLT (81%). The numbers of pups born from chimera breeding with 
B6 mice was 239, 172 of which were germ line pups (72%). 
 
Appearance and clinical signs of chimeras 
 A number of chimeras resulting from blastocysts that were injected with 
mycoplasma-infected mES cells showed morphological and clinical signs which are 
summarized in Table 8 and are shown in Figure 19 (A, B). A total of 10 (36%) (8 males 
and 2 females), 5 (23%) (males) and 5 (22%) (4 males and 1 female) chimeras 
produced from mycoplasma-infected TBV2 mES cells at the P13+10, P13+15 and 
P13+20 passages, respectively, was smaller in size with deformed extremities and had 
difficulties in moving (Figure 19, A). They showed retarded development and were 
underweight.  
 The weekly weight of 22, 35, 32, and 20 male mice and 2, 9, 12, and 10 female 
mice, including chimeric and wild type CD-1 mice produced from control and 
mycoplasma-infected TBV2 mES cells at passages P13+1, P13+10, P13+15 and 
P13+20 was determined, respectively. The weight of the male mice is presented in 
Figure 20 (A-D). The male chimeras that showed retarded development were constantly 
lighter and, at the age of 13 weeks, weighed 15 to 20 g less than the healthy chimeras 
and wild type mice. Statistical analysis which obtained using the t-test showed 
significant differences between the group of the diseased mice compared to the other 
groups of mice (p<0.0001). Similarly, reduced weight was observed for diseased female 
chimeras (n=3). Furthermore, 11 (39%) (10 males and 1 female), 7 (22%) (males) and 
12 (52%) (10 males and 2 females) chimeras produced from mycoplasma-infected 
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Table 8 Chimeras with morphological and clinical signs of disease 
Parameter  P13+1  P13+5  P13+10  P13+15  P13+20 
  Mycoplasma-free  Control  
Mycoplasma-
infected  Control  
Mycoplasma-
infected  Control  
Mycoplasma-
infected  Control  
Mycoplasma-
infected 
Litters with 
chimeras having 
clinical and 
morphological 
signs/No. of litters 
 0/6  0/6  0/4  0/5  8/10  0/6  5/9  0/5  7/10 
Small chimeras/ 
chimeras born (%) 
 0/14  0/10  0/10  0/10  10/28 (36)  0/12  5/22 (23)  0/9  5/23 (22) 
♂/♀small chimeras  0/0  0/0  0/0  0/0  8/2  0/0  5/0  0/0  4/1 
Chimeras with 
nasal discharge 
/chimeras born (%) 
 0/14  0/10  0/10  0/10  11/28 (39)  0/12  7/22 (32)  0/9  12/23 (52) 
♂/♀chimeras with 
nasal discharge 
 0/0  0/0  0/0  0/0  10/1  0/0  7/0  0/0  10/2 
Small chimeras 
with nasal 
discharge 
/chimeras born (%) 
 0/14  0/10  0/10  0/10  8/28 (29)  0/12  5/22 (23)  0/9  4/23 (17) 
♂/♀ small chimeras 
with nasal 
discharge 
 0/0  0/0  0/0  0/0  7/1  0/0  5/0  0/0  4/0 
♂: male, ♀: female 
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Figure 19 Appearance and clinical signs of disease of 4 week-old chimeric pups. A: Chimeric 
pups produced after blastocyst injection with mycoplasma-infected TBV2 cells at the passage 
P13+15. Some chimeras showed a significantly delayed development; they were smaller with 
shorter extremities and were underweight compared to chimeric pups of the same age (mouse 
no. 1 and 2). Clinical signs of disease included nasal discharge (B, mouse no. 2) starting at the 
third week of age. 
 
TBV2 mES cells at passages P13+10, P13+15 and P13+20, respectively, developed 
hemorrhagic disorders and showed chronic nasal discharge which started at the age 
of 3 weeks. These symptoms were observed during the study and alternated 
between strong hemorrhages and mild serum secretion (Figure 19, B). A total of 8 
(29%) (7 males and 1 female), 5 (23%) (males), and 4 (17%) (males) chimeras 
produced from mycoplasma-infected TBV2 mES cells at passages P13+10, P13+15 
and P13+20, respectively, was smaller, showed retarded development and had nasal 
discharge (Table 8). 
 
Pathological and histological analysis of chimeras 
 A total 2, 1, and 3 male chimeric mice with clinical signs and 3 (1 chimeric and 
2 wild type mice), 5 (2 chimeric and 3 wild type mice), and 1 control chimeric and wild 
type mice were X-rayed and examined histologically at the age of 2, 7 and 16 weeks, 
respectively. The sections of internal organs were stained with hematoxylin-eosin 
while sections of the nasal cavity obtained from 3 different levels as well as sections 
of the humerus and the femur were stained with hematoxylin-eosin and Van Gieson 
stainings. The histological results and the X-Rays are shown in Figures 21-27.  
 At the age of 2 weeks, control chimeric and wild type mice weighed 7, 8.1 and 
10.8 g and were 6 cm long, respectively, whereas chimeric mice with clinical signs 
B A 
no. 1 no. 2 no. 3 no. 4 no. 2no. 2
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Figure 20 Development of male mice and weekly weight data up to the 13th week of age. Mice 
were produced by injecting control and mycoplasma-infected TBV2 mES cells at the P13+1, 
P13+10, P13+15 and P13+20 passages into blastocysts and performing embryo transfer. 
Clinically affected chimeras at passages P13+10, P13+15 and P13+20 showed statistically 
significant differences (p<0.0001). 
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weighed 3.7 and 4.8 g, were 4 and 5 cm long and had yellow nasal secretion, 
respectively. The histological examination showed a mild pneumonia in 1 chimeric 
mouse. 
 At the age of 7 weeks, control mice weighed 32.4 ± 2.6 g , and were 20.5 ± 0.2 
cm long, respectively, while the chimeric mouse with clinical signs weighed 17.1 g, 
was 15 cm long and had strong hemorrhagic nasal discharge (Figure 19, A and B). 
Histological examination detected a mild pneumonia in a wild type mouse and a 
tubular atrophy of the testicles (Figure 23) in a clinically healthy chimeric mouse 
obtained after blastocyst injection with mycoplasma-infected mES cells. For the 
clinically affected chimeric mouse with clinical signs, histological examination 
revealed a lymphocytic cellular smear at the epithelial surface of the nasal septum 
(Figure 21, E and 22), mild pneumonia (Figure 24), monorchidy and tubular atrophy 
of the testicles (Figure 23), follicles and increased erythropoiesis of the spleen, and 
arthritis at the knee and shoulder joint which resulted in osteoarhtropathia deformans 
and destruction of the normal articular structures, including metaphyseal joint 
surfaces, the joint space and the joint capsule, respectively (Figure 27, C-H). The 
chondroblasts of the growth plate showed hyperproliferation and lacked column-like 
orientation and organization (Figure 27, D). The results obtained from the X-Ray 
analysis were concordant with the results obtained for the histological examination. 
Control mice showed no abnormalities (Figure 25, A and 26, E), whereas severe 
deformation of the limbs was observed for the chimeric mouse with clinical signs. The 
alterations affected predominantly the humerus and the femur but also other long 
bones which were shortened, irregularly formed and distorted with the diaphyseal 
bone density being reduced, having a thickened bony cortex and exostotic 
deformations (Figure 25, B and 26, F). Metaphysis of the proximal humerus and 
distal femur were severely deformed, including metaphyseal flaring, patchy lyrics 
changes and osteogartilaginous loose bodies. 
 At the age of 16 weeks, control chimeric mice (clinically healthy chimeric 
mouse obtained after blastocyst injection with mycoplasma-infected mES cells) 
weighed 36.9 g and was 20.8 cm long, while chimeric mice with clinical signs 
weighed 28.7 ± 1.6 g, were 18.1 ± 0.5 cm long, and had hemorrhagic nasal 
discharge, respectively. Histological examination of control chimeric mouse revealed 
a mild pneumonia, follicular hyperplasia of the spleen, and increased hematopoiesis 
of the liver, whereas for chimeric mice with clinical signs a mild pneumonia and 
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kidney hydronefrosis was present in one mouse, and follicular hyperplasia of the 
spleen and osteoarthropathia were present in all 3 mice, respectively. X-Ray analysis 
of the 16 week-old control mouse showed no alterations (Figure 25, C and 26, G). 
Clinical affected chimeric mice showed similar appearance as that obtained in the 7-
week old chimeric mouse with clinical signs which were characterized by irregular 
and bending deformation of the humeral diaphysis and the olecranon ulnae but no 
loosen bodies (reossification). Deformation of the femur was less pronounced as 
compared to the humerus and the shoulder joint of the 7 week old mouse with clinical 
signs, which presented an incongruent articular neoformation of the shoulder, elbow, 
and knee with metaphyseal flaring (Figure 25, D and 26, H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 Section of the nasal septum from 7 week-old clinically healthy (A, B, C) and 
clinically affected chimeric mouse (D, E, F) obtained after blastocyst injection with 
mycoplasma-infected mES cells, respectively (rostral 125x; middle 125x; and caudal 160x; 
hematoxylin-eosin). Cellular smear was detected at sections of clinically affected chimeric 
mouse (E, black arrow). 
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Figure 22 A, B: Middle sections of the nasal septum of 7 week-old clinically healthy (A) and 
affected (B) chimeric mice. Larger magnifications of Figure 21, B, and E (320x, hematoxylin-
eosin). Clinically affected chimeric mouse (B) showed cellular alterations of the mucosa and 
the submucosal layers (arrows). Deposits of cellular smear with numerous lymphocytes 
covering the mucosa (arrowhead).  
 
 
 
 
 
 
 
 
 
 
 
Figure 23 Histological appearances of the testicles. A: Normal spermatogenesis of a 7 week-
old mouse generated with control TBV2 mES cells (100x, hematoxylin-eosin staining). B: 
Testicles atrophy with arrest of the germ cell development and abundant fatty cells of a 7 week-
old chimeric mouse generated with mycoplasma-infected TBV2 mES cells (100x, hematoxylin-
eosin).  
 
 
Results    76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Histologically appearance of lung tissue of clinically affected chimeric mice. Acute 
pneumonia with granulocytes and macrophages from a 16 week-old chimeric mouse with 
clinical signs at different magnifications. (A: 160x, B: 320x, C: 640x, hematoxylin-eosin) Scale 
bar = 10 mm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
Results    77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 X-Rays of the humerus (A, B, C, D). A, C: Appearance of the humerus from 7 and 16 
week-old control chimeric mice. B, D: humeral diaphysis of 7 and 16 week-old clinically 
affected chimeric mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 X-Rays of the femur (E, F, G, H). E, G: Appearance of the femur from 7 and 16 week-
old control chimeric mice. F, H: femoral diaphysis of 7 and 16 week-old clinically affected 
chimeric mice. 
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Figure 27 A: Histological appearance of the knee of a 7 week-old control chimeric mice (20x, 
hematoxylin-eosin), Gp: Growth plate, M: Metaphysis, B: Chondroblasts in the tibioproximal 
growth plate, presenting a well-organized column-like appearance (320x, hematoxylin-eosin). 
Deformed knee (C, D, E) and shoulder joint (F, G, H) obtained from the 7 week-old chimeric 
mouse with clinical signs, respectively. C, F: Metaphyseal structures are completely 
disorganized and a part of the metaphysis is absent (black arrow, 20x, Van Giesson), Gp: 
Growth plate, M: Metaphysis. C, D, F, G: Fibrocartilaginous masses are proliferating within the 
joint, lacking orientation and organization (D: 320x, G: 160x, Van Giesson). E: arthritis in knee 
resulted in osteoarthropathia deformans appeared in sections C and D (200x, hematoxylin-
eosin). H: irregular line of the humeral growth plate (40x, hematoxylin-eosin). 
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Immunological analyses 
 The levels of IgG1, IgG2a, IgG3, IgM, and IgA immunoglobulins, anti-DNA 
antibodies (Abs), rheumatoid factor (Abs), and the number of T-, B- and NK-T cells 
were determined from the plasma of 56 mice aging 13 to 18 weeks, by use of a bead 
array based system (bioplex assay), ELISA, and flow cytometric analysis (FACS). 
The mice were divided into 5 groups: group A constituted 9 chimeric mice obtained 
after blastocyst injection with control mES cells, group B constituted 13 clinically 
healthy chimeric mice obtained after blastocyst injection with mycoplasma-infected 
mES cells, group C constituted 13 chimeric mice with clinical signs of disease, 
obtained after blastocyst injection with mycoplasma-infected mES cells, group D 
constituted 10 control CD-1 wild type mice from our core breeding unit, and group E 
constituted 11 non-chimeric mice obtained after blastocyst injection with 
mycoplasma-infected mES cells. The results obtained from the respective groups 
were analyzed statistically using the t-test and significant differences were observed 
which are shown in Figure 28 and Table 9.  
 The plasma levels of IgG1, IgG2a, and IgM were 5.4x102, 2.8x102, and 
1.9x103 µg/ml for group A. For group B the levels were 4.6x102, 5.4x102, and 2.2x103 
µg/ml, and for group C values were 1.2x103, 7.1x102, 2.2x103 µg/ml, respectively. 
The levels of anti-DNA antibodies and rheumatoid factor were 0.6 and 0.3 OD for 
group A, 0.7 and 0.4 OD for group B, and 0.8 and 0.4 OD for group C, respectively. 
Comparison of group A (control group) to group B (clinically healthy chimeras 
produced with mycoplasma-infected mES cells) showed significant differences for 
IgM (p<0.05) and rheumatoid factor (p<0.01). Comparison of group A to group C 
(clinically affected chimeras produced with mycoplasma-infected mES cells) showed 
significant differences for IgG1 (p<0.001), IgG2a (p<0.05), IgM (p<0.05), anti-DNA 
antibodies (p<0.05), and rheumatoid factor (p<0.01). The IgG1 levels were 
significantly different between group B and group C (p<0.001) (Figure 28). There 
were no significant differences in the levels of IgG3 and IgA obtained between 
groups A, B and C (p>0.05). Between the group D (control CD-1 wild type mice) and 
group E (non-chimeric mice produced after the injection of mycoplasma-infected 
mES cells into blastocysts), no statistically significant differences could be revealed 
for the above-mentioned immunoglobulins (p>0.05). 
 The results obtained for the white blood cells are shown in Table 9. There 
were significant differences between group A (control chimeric mice) and group B 
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(clinically healthy chimeric mice produced after the injection of mycoplasma-infected 
mES cells into blastocysts), group A and group C (clinically affected chimeric mice 
produced after the injection of mycoplasma-infected mES cells into blastocysts), but 
not between group B and group C. The proportions of T-regulatory cells 
(CD4+>CD3+>CD25+), NK-T cells (NK-U52A>CD3+), and gdT-cells 
(CD3+>gdTCR+) in group B and group C were decreased compared to group A, 
whereas the proportions of a subset of cytotoxic T-cells (CD8a+CD4->CD3+CD44-
CD62l-) and cells expressing Gr1 marker (CD19-/Gr1+CD11b-) were increased. 
Furthermore, several non T-cell leukocyte subsets were altered between the groups. 
In the non T-cell compartment (B-cells or granulocytes) bivariate gating revealed 
differences within the CD44/CD62L subsets. Similar results were observed between 
group E (non-chimeric mice produced after the injection of mycoplasma-infected 
mES cells into blastocysts) and group D (CD-1 wild type mice). 
 
 
 
 
 
 
 
 
 
 
 
 
  A vs. B: IgM (p<0.05) 
  A vs. C: IgG1 (p<0.001), IgG2 (p<0.05), IgM (p<0.05) 
  B vs. C: IgG1 (p<0.001) 
 
Figure 28 Immunoglobulin levels obtained from the examination of plasma. A, B, C: group A 
(control chimeric mice n =9), group B (chimeric mice without clinical signs n = 13), group C 
(chimeric mice with clinical signs n = 13) 
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Table 9 Immunological screening of chimeric mice 
Group A*: control chimeric mice, Group B£: clinically healthy chimeric mice produced with mycoplasma-infected mES cells, Group C‡: clinically affected chimeric mice 
produced with mycoplasma-infected mES cells, n.s: not significant, # (>): parent gate. Parameters of the parent gate are presented in the order of gating hierarchy, 
(/): parameters of leukocyte clusters into cell population, (%)†: values present percentages of parent gate, and/or CD45+ cells if indicated 
Parameters (>, /) #  Group A* (n = 9) 
Group 
B£ 
(n = 13) 
Group 
C‡ 
(n = 13) 
Group A 
vs. 
Group B 
Group A 
vs. 
Group C 
Group B 
vs. 
Group C 
    p-value p-value p-value 
Non duplets>living cells>CD45+>CD19-/Gr1+CD11b- (%)†  0.4 ± 0.1  0.8 ± 0.2  1.1 ± 0.2  p<0.05  p<0.01  n.s 
Non duplets>living cells>CD45+>CD19-> non 
granulocytes/NK-U5A2, freq. of 45+ (%)†  4.7 ± 0.3  3.3 ± 0.2  3.4 ± 0.2  p<0.01  p<0.01  n.s 
Non duplets>living cells>CD45+/CD19->non granulocytes/NK-
U5A2,CD3+, freq. of 45+ (%) 
 1.3 ± 0.1  0.5 ± 0.1  0.5 ± 0.1  p<0.001  p<0.001  n.s 
Non duplets>living cells>CD45+>CD3+/gdTCR+, freq. of 45+ 
(%)† 
 0.7 ± 0.1  0.3 ± 0.0  0.4 ± 0.1  p<0.001  p<0.01  n.s 
Non duplets>living cells>CD45+>CD4+, CD8-/CD3+, CD25+ 
(%)† 
 4.9 ± 0.3  2.8 ± 0.3  3.2 ± 0.3  p<0.001  p<0.01  n.s 
Non duplets>living cells>CD45+>CD8a+, CD4-/CD3+, CD44-
CD62l-(%)† 
 18.7 ± 2.6  30.2 ± 1.7  28.2 ± 3  p<0.05  p<0.01  n.s 
Non duplets>living cells>CD45+/CD4-, CD8a-, CD44+, 
CD62L- (%)† 
 5.7 ± 0.3  8 ± 0.5  9.3 ± 1  p<0.001  p<0.01  n.s 
Non duplets>living cells>CD45+/CD4-, CD8a-, CD44-, 
CD62L+ (%)† 
 12 ± 1.8  10 ± 1.2  6 ± 1  n.s  p<0.05  n.s 
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5. DISCUSSION 
 The aim of this thesis was to investigate the effects of mycoplasma 
contamination on mES cell cultures, the germ line transmission, and the resulting 
chimeric progeny. 
 Since mES cells were experimentally infected, appropriate methods were 
established for reliable detection of mycoplasmas in the ES cell cultures. Therefore, 
in a first step of this thesis, the agar culture, the MycoAlertTM assay, the gel-based 
PCR, and the MycoSensorTM QPCR were evaluated concurrently with regards to the 
limit of detection (LOD) of M. hominis, M. fermentans and M. orale in cell culture 
supernatants and in cells. Due to the diversity of mycoplasma species with respect to 
their properties and growth, samples of supernatants containing apoptotic and dead 
cells and cell suspensions containing viable cells were used for agar culture and 
PCRs. The present data show that each method was able to detect mycoplasmas in 
the undiluted samples while differences were obvious with respect to analysis of the 
dilutions where agar culture and the MycoSensorTM QPCR were the most sensitive 
methods. 
 For detection of M. hominis in cell-containing supernatants and dilutions, the 
MycoSensorTM QPCR assay was the most sensitive method detecting mycoplasmas 
up to the 10-6 dilution, followed by Friis agar culture, PH-Hayflick agar culture, the 
gel-based PCR, and the MycoAlertTM assay being 101, 102, 104 and 105 times more 
sensitive, respectively. With respect to reproducibility, where all 3 to 5 runs were 
positive, the MycoSensorTM QPCR assay was 103 and 102 times more sensitive than 
the gel-based PCR and the MycoAlertTM assay, respectively. Analysis of cell 
suspensions and dilutions for M. hominis showed that the MycoSensorTM QPCR 
assay was again the most sensitive method detecting mycoplasmas up to the 10-4 
dilution, followed by PH-Hayflick agar culture, Friis agar culture and the gel-based 
PCR being 101, 102 and 104 times more sensitive, respectively. Where all 3 runs 
were positive, in contrast to the gel-based PCR, the MycoSensorTM QPCR assay 
gave reproducible results. 
 For detection of M. fermentans in cell-containing supernatants and dilutions, 
Friis agar culture was the most sensitive method detecting mycoplasmas up to the 
10-4 dilution, followed by the MycoSensorTM QPCR assay, the gel-based PCR, and 
the MycoAlertTM assay being 101, 103, and 104 times more sensitive, respectively. 
Where all 3 to 5 runs were positive, the MycoSensorTM QPCR assay was 10 times 
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more sensitive than both the gel-based PCR and the MycoAlertTM assay. Analysis of 
cell suspensions and dilutions for M. fermentans revealed that Friis agar culture was 
again the most sensitive method detecting mycoplasmas up to the 10-4 dilution, 
followed by the MycoSensorTM QPCR assay, PH-Hayflick agar culture, and the gel-
based PCR being 101, 102 and 103 times more sensitive, respectively. Where all 3 
runs were positive, the MycoSensorTM QPCR assay was 102 times more sensitive 
than the gel-based PCR assay. 
 For detection of M. orale in cell-containing supernatants and dilutions, Friis 
and PH-Hayflick agar culture were the most sensitive methods detecting 
mycoplasmas up to the 10-6 dilution, followed by the MycoSensorTM QPCR assay, the 
gel-based PCR, and the MycoAlertTM assay being 101, 102 and 104 times more 
sensitive, respectively. Where all 3 to 5 runs were positive, the MycoSensorTM QPCR 
assay was equally sensitive to the gel-based PCR and 10 times more sensitive than 
the MycoAlertTM assay. Analysis of cell suspensions and dilutions for M. orale 
showed that Friis and PH-Hayflick agar culture were the most sensitive methods 
detecting mycoplasmas up to the 10-4 dilution, followed by the MycoSensorTM QPCR 
assay and the gel-based PCR being 102 times more sensitive. Where all 3 runs were 
positive, the MycoSensorTM QPCR assay was 102 times more sensitive than the gel-
based PCR assay. 
 In this study, due to quantification of the mycoplasmas present, samples were 
inoculated directly on agar plates omitting culture in broth (Uphoff 1992, Uphoff, 
1992). With the exception of PH-Hayflick agar plates inoculated with cell-containing 
supernatants and dilutions on which M. fermentans failed to grow, agar culture was 
the most sensitive method for detection of M. fermentans and M. orale. Failure of M. 
fermentans to grow on PH-Hayflick agar in this study confirms previous reports 
(Blanchard 1993, Serin 2001) and may be due to the lack of appropriate growth 
conditions (Drexler 2000). Mycoplasmas often show an elongated lag phase and 
slower or no growth as a compensatory survival mechanism. Incubation in broth is 
essential for counteracting the long lag phase, allowing replication of mycoplasmas. 
In this study, Friis agar culture was conducive to the growth of M. fermentans despite 
omission of the broth phase. However, for PH-Hayflick culture, incubation in broth 
seems to be mandatory for growth of M. fermentans. Therefore, it is recommended to 
use both types of culture media for more reliable results with supernatants (Uphoff, 
1992). The viable cells in the cell suspension provided the cell-associated M. 
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fermentans with the necessary nutrients, allowing growth on PH-Hayflick agar. In 
contrast, the cells that were found in the supernatants failed to support growth of M. 
fermentans most likely since they are apoptotic or dead. 
 Using both agar culture and PCRs, more mycoplasmas were detected in the 
cell-containing supernatants than in the corresponding dilution of the cell 
suspensions confirming that M. hominis and M. orale are present mostly in cell 
culture supernatants. Friis agar culture and the PCRs detected M. fermentans 
equally in cell-containing supernatants and in cell suspensions. However, for PH-
Hayflick agar culture, only cell suspensions led to growth of colonies. These 
observations confirm that M. fermentans is mainly a cell-associated species found 
mostly attached to or in the cells. The present data also show that detection of 
mycoplasmas in cell cultures is more reliable when both cell-containing supernatants 
and viable cells are analyzed. 
In the present study, the in-house established gel-based PCR used is based 
on previous reports (Uphoff 2002, Uphoff 2002) with modified annealing and 
amplification times, number of cycles and master mix. The primers used anneal to 
gene sequences coding for conserved 16S rRNA of several different mycoplasma 
species, allowing specific detection of mycoplasmal DNA (Uphoff 2005). In addition, 
the mycoplasma species present was identified by restriction fragment length 
polymorphism. The present data reveal that the gel-based PCR showed the highest 
sensitivity for M. orale, followed by M. fermentans and M. hominis. Based on the 
quantification data generated by the MycoSensorTM QPCR, the LOD per reaction for 
the cell-containing supernatant and the cell suspension, respectively, was 30 and 60 
genomic copies of M. orale, 5.8x102 and 3.2x102 genomic copies of M. fermentans, 
and 6.8x104 and 3.2x104 genomic copies of M. hominis. Where all 3 to 5 runs were 
positive for the supernatant dilutions, the gel-based PCR detected 1.6x106, 6x103 
and 4.8x102 copies of M. hominis, M. fermentans, and M. orale per reaction, 
respectively. In contrast, for cell suspension dilutions, the gel-based PCR gave 
reproducible results only for M. fermentans and M. orale with 3.2x103 and 9.2x103 
copies per reaction, respectively. 
Published LODs of gel-based PCRs are 1 to 2 copies of the target DNA from 
13 mycoplasma species (Sung 2006), 1 organism of M. pneumoniae (Vojdani 1998), 
12 to 18 organisms of M. hominis (Blanchard 1993), 1 CFU of 4 mycoplasma species 
including M. fermentans and M. orale (Harasawa 1993), 8.8 CFUs of M. hominis 
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(Stellrecht 2004), 102 CFUs (Harasawa 2005), and 10 to 90 CFUs of M. hominis, M. 
fermentans, and M. orale (Tang 2000). In the present study, the sensitivity of the gel-
based PCR for detection of M. orale and M. fermentans was similar to that of 
previous works (Harasawa 1993, Tang 2000, Harasawa 2005) but lower than that 
reported for detection of M. hominis (Blanchard 1993, Stellrecht 2004, Sung 2006). 
 The MycoSensorTM QPCR showed the highest sensitivity of all methods for 
analysis of M. hominis, detecting as little as 8 copies per reaction. For M. fermentans 
and M. orale, the MycoSensorTM QPCR was the second most sensitive method after 
agar culture, detecting 7 and 80 copies per reaction, respectively. Where all 3 to 5 
runs were positive, the MycoSensorTM QPCR detected in supernatant dilutions 
1.3x104, 2.9x103 and 1.2x103 copies of M. hominis, M. fermentans, and M. orale per 
reaction, respectively. For cell suspensions, the MycoSensorTM QPCR detected 
1.9x103, 2.4x102, and 3.2x102 copies of M. hominis, M. fermentans, and M. orale per 
reaction, respectively. 
 The melting temperatures were similar for all three mycoplasma species, lying 
between 80.1°C and 82°C, thus hindering differentiation between species, as 
previously reported (Harasawa 2005). The efficiency of the real-time PCR was 1.98 
to 2 showing that the quantity of DNA doubled in each cycle. Published LODs of the 
real-time PCR are 10, 5, and 5 genome copies of M. genitalium per reaction 
(Svenstrup 2005, Yoshida 2002, Dupin 2003), respectively, 10 genomic copies of M. 
hominis (Baczynska 2004), and 10 CFUs per assay (Harasawa 2005). The SYBR 
green-based real-time PCR detected 100 fg of mycoplasmal genomic DNA from M. 
hominis, M. fermentans and M. orale (Ishikawa 2006). As such, the LODs obtained in 
this study are comparable to those published by the above-mentioned authors. 
 As shown in the present study, each detection method has its own advantages 
and disadvantages which should be considered. Agar culture is highly sensitive; it 
detects viable mycoplasmas, colonies can generally be readily recognized, it is easy 
to perform, and is cost effective. The disadvantages of this method are the long 
incubation time of 2 to 3 weeks and the artifacts that are occasionally observed on 
agar which makes it difficult for the inexperienced observer to distinguish true 
mycoplasma colonies from cell clumps or pseudocolonies arising from crystals and 
air bubbles. In addition, instead of the classical fried-egg colonies certain 
mycoplasmas produce a more diffuse, granular pattern, which makes evaluation 
difficult. Finally, not all mycoplasma species are cultivatable in artificial media  
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(McGarrity 1985, Uphoff 1992, Uphoff 1992, Tully 1996, Drexler 2000, Drexler 2002).  
 The MycoAlertTM assay is easy to perform, simple to interpret and results are 
obtained within 20 minutes. However, the absence of cells for analysis makes the 
MycoAlertTM assay less sensitive for mycoplasmas that are mainly cell-associated. 
 The results of the gel-based PCR can be obtained within hours. The gel-based 
PCR is susceptible to technical artifacts if not performed with extraordinary care 
including strict quality control of reagents, aseptic procedures and appropriate 
laboratory environment (Tully 1996). In general, PCR results should be verified by 
sequencing, restriction analysis or hybridization. The MycoSensorTM QPCR is a 
quantitative assay and is highly sensitive. It is easy to use and interpret, and results 
can be obtained within hours. In addition, it eliminates post-PCR processing and 
carry-over contamination since it employs a closed-tube detection system. 
 European Pharmacopoeia and the FDA still recommend culture in broth and 
agar media as the method of choice for detection of mycoplasmas in cell cultures and 
biological products produced in cell substrates. For mycoplasma species that cannot 
be cultured in artificial media, use of an indicator cell line is proposed as the method 
of choice. The PCR method was also added to this list (CBER/FDA 1993, Pheur, 
2004). 
 For routine diagnostic work with cell cultures, the presence of mycoplasmas 
per se and not necessarily the species is of interest. Although sensitive methods 
bring some advantages, acute and chronic cell culture infections involve at least 106 
to 108 organisms per ml and 100 to 1000 mycoplasmas can be attached to each 
infected cell (Drexler 2002). In the present study, all methods reliably detected the 
presence of mycoplasmas in the undiluted supernatants and cell suspensions. Highly 
sensitive methods are necessary where minute amounts of mycoplasmas are present 
such as in cells that are routinely cultured with antibiotics, which could lead to 
covered contaminations, after antibiotic treatment or screening of imported cells. 
Based on the present data, agar culture and the MycoSensorTM QPCR can be used 
for routine diagnostic work. In addition to the use of supernatants, analysis of viable 
cells would aid in increasing the probability of detecting cell-associated 
mycoplasmas. 
 As infections of cell lines with more than one mycoplasma strain are frequently 
observed (Timenetsky 2006), in the second part of this thesis, the susceptibility of the 
TBV2 mES cells to infection with a combination of M. hominis, M. fermentans, and M. 
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orale and the resulting effects on morphology, growth, viability, karyotype, and 
differentiation status were determined over 20 passages. The influence on Germ Line 
Transmission (GLT) of the infected TBV2 mES cells was evaluated after injection of 
the mES cells into blastocysts, transfer of the injected embryos into pseudopregnant 
recipients, production of chimeras, and breeding of the chimeric progeny with the B6 
mouse strain. 
 The human species M. hominis, M. fermentans and M. orale were chosen 
since they are the most common mycoplasma contaminants of cell cultures (Drexler 
2002). In addition, a recent study including 98 cell lines showed 60% prevalence of 
multiple mycoplasma infections with 2 or more mycoplasma species including those 
used in the present study (Timenetsky 2006). Continuous culture of the inoculated 
cell line indicates that TBV2 mES cells are susceptible to infection with the 
combination of M. hominis, M. fermentans, and M. orale and that mycoplasma-
infected mES cells exhibit a number of severe effects both in vitro and in vivo.  
Control mES cells led to the growth of large to very large mES cell colonies, 
showed an average growth rate of 1:7 per passage and reached a hypothetical 
number of 1.2x1022 trypsinized mES cells at passage P13+20. Subsequent to 
inoculation with M. hominis, M. fermentans, and M. orale at passage P13, all 3 
species were present from passage P13+2 to P13+20, as determined by restriction 
fragment length polymorphism (RFLP) indicating productive infection of the mES 
cells with all 3 mycoplasma strains. The MycoSensorTM QPCR assay detected 
between 1.7x108 (at P13+10) and 6.5x103 (at P13+20) mycoplasma genome copies 
per ml in cell-containing supernatants and in cell suspensions. Thus, an average of 1 
to 580 mycoplasmas adhered to or was present in each mES cell. 
The mycoplasma infection affected the morphology, the growth rate, and the 
viability of the mES cells and led to very small to medium cell colonies. The average 
growth rate was 1:3 per passage up to passage P13+14, increased to 1:6 for 
passages P13+15 to P13+20, and resulted in 3.9x1015 trypsinized mES cells at 
passage P13+20. As such, the number of cells was approximately 7 logs lower than 
that of the control cell line at this passage level. The average viability of the 
mycoplasma-infected mES cells was 85% and thus 10% lower than that of the 
control cell line (95%). Earlier studies showed that M. fermentans increased the 
population doubling time of FL amnion cells from 17.5 to 30 hours (Fogh 1971), 
whereas M. hominis reduced the growth rate of the HAIN-55 human diploid 
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fibroblasts (Sasaki 1981). Other studies demonstrated similar results (Kenny 1963, 
Stanbridge 1969, Stanbridge 1971, McGarrity 1985).  
 The GLT rate of the control mES cells at passage P13+1 was 92%; it 
decreased slightly to 90% at passage P13+5 and further to 78% at passage P13+20, 
showing that extended periods of culture reduced the GLT of the TBV2 mES cells. 
Similar results have been reported for the R1 mES cell line with a 129 genetic 
background (Nagy 1993). With respect to control TBV2 mES cells at passage levels 
P13+6, P13+11, P13+16, and P13+21, 84% expressed both differentiation markers 
OCT-4 and SSEA-1, as determined by flow cytometric analysis (FACS). These data 
agree with those of previous reports, where low OCT-4 expression resulted in a low 
GLT (Buehr 2003, Tielens 2006). Control mES cells showed low euploidy of 20% at 
passage P13+10 and trisomy 1, 6 and 11, indicating that these features did not affect 
the GLT of mES cells or the chimeric progeny. In contrast, previous studies reported 
that various mES cell lines failed to contribute to the germ line, when euploidy was 
less than 50%. Moreover, sterility, polydactylia, and eye anomalies were detected in 
the progeny (Longo 1997, Guo 2005). Two more studies showed that trisomy 8 had 
no effects on the differentiation potential of the mES cells but influenced the GLT (Liu 
1997, Park 1998). The reason for the high GLT of the control TBV2 mES cells 
observed even at late passages in the present study could be due to the fact that 15 
to 20 mES cells were injected into each blastocyst, indicating that there were 
sufficient ES cells capable of contributing to the germ line. The number of mES cells 
injected has been shown to markedly influence GLT as previously reported (Brown 
1992) where 8 to 12 mES cells with a diameter of 7 to 13 µm resulted in 18.5% of 
chimeric mice, whereas blastocyst injections with 3 to 5 and 5 to 8 mES cells resulted 
in 0% and 7.4% chimeric mice, respectively. 
 Germ line transmission of mycoplasma-infected mES cells at passage P13+5, 
which was the strongest infected passage, was only 50%. This effect was less 
pronounced at P13+10 and P13+15, where GLT was 62% and 60%, respectively. At 
passage level P13+20, at which approximately 1 mycoplasma attached to each mES 
cell, GLT was 81% and similar to that obtained for control mES cells at the same 
passage. The low GLT rates were most likely due to the effects of mycoplasmas on 
various cell parameters. Based on the MycoSensorTM QPCR assay, approximately 
1.2x104 to 15 mycoplasmas were injected together with the mES cells into each 
blastocyst between passages P13+5 and P13+20, respectively. Since each recipient 
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received 14 blastocysts, approximately 1.6x105 to 210 mycoplasmas were 
transferred to the recipients via the blastocysts at the four respective passages. 
Karyotypic analysis of mycoplasma-infected and control mES cell metaphases 
revealed numeric aberrations and a number of non-clonal chromosomal aberrations, 
which were first observed at passage P13+10 and increased with further passages. 
Previous studies in a human amnion cell line showed that chronic mycoplasma 
contamination led to gradual reduction of the chromosome number (Fogh 1965), 
whereas other studies reported that M. hominis, M. fermentans, M. orale, A. laidlawii 
and Ureoplasmas resulted in chromosome breaks, rearrangements, and 
translocations (Paton 1965, Stanbridge 1969, Kundsin 1971, Tsai, 1995). The 
duration of an infection with mycoplasmas plays an important role in the 
establishment of reversible or irreversible effects with clonal or non-clonal 
chromosomal aberrations. Reversible chromosomal aberrations caused by M. 
fermentans were described in the mouse embryo cell line C3H in the first 7 to 11 
weeks of infection; they became irreversible 5 weeks later (Tsai 1995). Even though 
no influence on GLT or on the resulting chimeras was observed in the present study 
after 6 weeks of infection, it is subject of speculation whether irreversible clonal 
chromosomal aberrations occur in mES cells after longer periods of mycoplasma 
infection and whether consequences on GLT of the mES cells and the genome of the 
resulting chimeric progeny are brought about at later time points. This, however, is 
rather irrelevant, since mES cells with high passage numbers are generally no longer 
used for transgenesis. 
 Mycoplasma-infected mES cells at passage P13+6 showed expression of both 
OCT-4 and SSEA-1 at a rate of 46%, 10% expressed only OCT-4 and 24% 
expressed only SSEA-1; 20% expressed neither OCT-4 nor SSEA-1. At further 
passages, OCT-4 and SSEA-1 levels were comparable to those of control mES cells. 
The low OCT-4 expression rate observed at passage P13+6 correlated with the low 
GLT of mycoplasma-infected mES cells. A previous study reported that changes in 
culture conditions led to reduced OCT-4 expression of the IOUD2 murine ES cell line 
(Faherty 2005). In this study, suboptimal culture conditions were very likely 
generated due to mycoplasma consumption of essential nutrients and other 
components of the media, as well as by changes of the pH due to high metabolic 
activity, especially in the early stages of the infection.  
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 At passage P13+5, a smaller numbers of pups were born and low GLTs were 
observed, probably due to the heavy mycoplasma infection. A previous study showed 
that mycoplasma contamination led to reductions in the number of chimeras born, 
percentage of male progeny and average contribution of ES cells to tissues (Bradley 
1987). It was further reported that infection could be transmitted from mES cells to 
the embryo where mycoplasmas replicate uncontrollably, resulting in embryo death 
and that the level of cell contamination could affect the number and quality of the 
chimeras born (Bradley 1987).  
 Chimeric progeny from mycoplasma-infected mES cells at passages P13+10 
to P13+20 showed abnormal morphology and signs of disease. In contrast, no effects 
were observed in chimeric progeny produced with mycoplasma-infected mES cells at 
passage P13+5 even though GLT was lowest at this passage. This may be due to a 
strong immunological reaction of the recipients to the large amount of mycoplasma 
antigens at passage P13+5. At later passage levels, when less antigen was 
transferred to the blastocysts immunological interactions between the host and 
mycoplasma-containing mES cells could be the reason for the development of 
disease. The development of morphological and clinical effects in chimeric progeny 
may depend on the mycoplasma species, since M. hominis and M. fermentans are 
highly pathogenic, whereas M. orale act as a pathogen only under certain conditions. 
Moreover, it appears to be individually controlled by the recipients’ defense 
mechanisms, since healthy and affected chimeras with morphological and clinical 
signs were observed in the same litters. 
 Morphological alterations and diseased mice were present in the chimeric 
progeny but not in the F1 generation after breeding of chimeras with B6 mice, 
indicating that the disease developed as a consequence of infection rather than due 
to genetic reasons. Histological analysis and the X-rays of affected progeny 
suggested that dwarfism and locomotory problems are due to alterations in the 
growth plate, arthritis and generalized osteoarthropathia as a consequence of 
mycoplasma infection of the joints.  
 Generalized mycoplasma infection in the chimeras resulted in retarded 
development and affected chimeras were significantly lighter than their healthy mates 
weighing 30 g or less until 13 weeks of age. The contribution of mES cells to the 
somatic tissues of the affected chimeras was 5 to 95%, excluding the possibility that 
the 129 mouse genetic background of the mES cells is the reason for this condition. 
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Furthermore, generalized mycoplasma infection induced subtle changes in the 
proportions of leukocyte subsets in peripheral blood of the adult chimeras produced 
with mycoplasma-infected mES cells, a decrease in T-regulatory cells, gdTCR cells, 
NK-T cells, and changes in the levels of IgG1, IgG2a, and IgM. Furthermore, the 
levels of DNA and rheumatoid antibodies were elevated in some of the affected 
chimeric mice. 
 Nasal hemorrhagic discharge was observed in 30 chimeras from 3 weeks of 
age during the whole experimental period. The severity of the clinical signs, the 
quality (hemorrhagic, serum) and the quantity (strong or mild) of the secretion varied 
and the condition was not contagious or life-threatening. The nasal epithileum was 
also affected and the clinical smear observed was infiltrated with lymphocytes, 
indicating a chronic situation. Acute pneumonia with granulocyte infiltration of the 
lungs as well as hydronephrosis and follicular hyperplasia of the spleen with 
increased erythropoiesis were observed probably due to nasal discharge as a result 
of aspiration and bronchiolar obstruction and hemorrhagic compensatory and 
immunological mechanisms, respectively. 
 There are many studies which show the interactions of mycoplasmas with 
various cell types in vitro and in vivo and their implication as causative factors, co 
factors or opportunistic agents in human diseases (Baseman 1997, Nicolson 1999). 
Mycoplasmas exhibit host and tissue specificities. As such, they are able to enter the 
host cells, multiply, and survive within phagocytic and non-phagocytic cells for a long 
period of time showing slow growth rates. They develop mechanisms of mimicry 
showing antigenic variability and the ability to suppress the host’s immune responses 
(Razin 1998, Rottem 2003, Nicolson 1999). As a result, mycoplasmal infections have 
a chronic and persisting nature and the host is unable to suppress these infections 
through immune and non-immune responses (Nicolson 1999). 
 The presence of M. hominis and M. fermentans in synovial fluids of the human 
joints was reported previously, implicating the involvement of these 2 mycoplasma 
species in the development of human arthritis and chronic arthritic conditions 
including rheumatoid arthritis (Schaeverbeke 1997, Haier 1999, Nicolson 1999, 
Henrich 1998, Razin1998, Johnson 2000, Boesen 2001, Gilroy 2001, Yavlovich 
2001, Waites 2005, Yavlovich 2006). It was reported that in cases of chronic active 
arthritis the lipoprotein surface of M. hominis Vaa antigen changes in structure and its 
expression, thus affecting the adhering properties of M. hominis and enhancing 
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evasion of host-mediated immunity (Henrich 1993, Razin 1998, Nicolson 1999, 
Boesen 2001). In animal models, experimental arthritis was induced in rabbits by M. 
fermentans after intratracheal and intrasynovial application (Rivera 2002). 
Furthermore, M. fermentans was found alone or in combination with other 
mycoplasma species in synovial fluids and the blood of patients with rheumatoid 
arthritis (Schaeverbeke 1997, Haier 1999, Nicolson 1999), suggesting that even 
though the underlying causes of rheumatoid arthritis remain unknown, mycoplasmas 
could play a role as co-factor in this desease. In experimental rat and mice models of 
rheumatoid arthritis, M. arthritidis-related superantigens compromised T-cells and 
resulted in autoimmune arthritis, while release of substances from the same species 
of the same animal model including oxygen radicals, chemotactic and aggregating 
substances acted on polymorphonuclear granulocytes (Kirchhoff 1989, Nicolson 
1999).  
 Mycoplasmas activate or suppress the host’s immune system and induce the 
production of interleukins, TNF-α, interferon-γ (INF-γ) and other inflammatory 
mediators (McGarrity 1985, Muhlradt 1991, Drexler 2000, Rottem 2003). Earlier 
studies showed that they affect macrophages, lymphocytes and the balance between 
the Th1 and Th2 populations of CD4+ T-cells, thus influencing the direction of the 
subsequent effector phases of the immune response, as well as increasing natural 
killer cell activity (Rottem 1998, Razin 1998, Rottem 2003). Mycoplasma-infected 
fibroblast cells were also shown to produce IL-13. IL-13 was shown to be produced 
by CD4+, CD8+ cells, neutrophils, and other non-immune cells, and has a down-
regulating activity on macrophages. Moreover, IL-13 stimulates B-cells for IgG1 and 
IgE production. As a result, down-regulating cytokines influence T-cell proliferation 
and the balance between CD4+ Th1 and Th2 phenotypes (Zurita-Salinas 1996, 
Razin, 1998). As previously described, M. fermentans suppressed the interferon-γ 
(INF-γ) expression of major histocompatibility complex (MHC) class II molecules on 
macrophages and resulted in impaired antigen presentation to helper T-cells in an 
animal model (Frisch 1996). Additionally, M. fermentans induced apoptosis of T-cells 
initiated by concanavalin A (Shibata 1997). Furthermore, the mycoplasmal lipoprotein 
spiralin stimulated in vitro proliferation of human peripheral blood mononuclear cells 
and murine splenocytes, resulting in the production of proinflammatory cytokines 
(Brenner 1997), whereas the MALP-2 lipoprotein of M. fermentans stimulated in vitro 
and in vivo the production of chemokines and induced inflammatory effect and 
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endotoxin cross tolerance in mouse models (Urbaschek 1987, Deiters 1999, 
Luhrmann 2002, Deiters 2003). As a result of mycoplasmal properties and their 
ability to invade the cells, infections showed persistence and mycoplasmas are found 
in high incidences in the blood and tissues of patients with chronic illnesses, resulting 
in various clinical conditions (Nicolson 1999).  
 In our study, the clinical signs of the affected chimeras indicate a chronic 
inflammatory situation. The immunological analyses revealed differences in the 
proportion of certain T-cells subsets especially regulatory T-cells, NK-T and gdTCR 
cells, differences in the subsets of CD8a+ cells, increased CD44+ expression in the 
non T-cell compartment and increased immunoglobulin levels, which are in 
agreement with several of the above-mentioned studies. The increased levels of anti-
DNA Abs and rheumatoid factor in chimeras produced of mycoplasma-infected mES 
cells suggest activated, however, not as yet identified autoimmune mechanisms. 
Interestingly, the immunological data of the clinically healthy and affected chimeras 
produced with mycoplasma-infected mES cells revealed no significant differences in 
the clinically-affected chimeras, except for an increased IgG1 level. Different levels of 
Ig classes and IgG isotypes could be due to genetic variation of various inbred 
mouse strains or due to different activated status of the immune system (Sant'Anna 
1985). The profile of the subclasses reflects the general direction of T helper cell 
differentiation. Th2-directed responses correlate with higher IgG1 levels, whereas 
Th1 bias towards IgG2a (Stevens 1988, Adler 2007). The levels of immunoglobulins 
of the clinically affected chimeras were generally increased compared to the other 
groups, suggesting a higher infection status, which could be responsible for the 
development of the clinical signs. No mycoplasmas were detected in nasal secretion 
and plasma samples of 8 week-old affected chimeras using the agar culture and the 
MycosensorTM QPCR. However, further efforts to detect mycoplasmas in the chimeric 
mice are continuing. Based on the present data, osteoarthropathia, nasal discharge 
and cachexia of the affected chimeras could be due either to the presence of 
mycoplasmas in the organism or to autoimmune reactions. Further investigations into 
the etiopathological cause of the nasal discharge are part of the current work. 
 Since mES cells were infected with 3 different mycoplasma species the 
present results cannot be ascertained to a particular species. To elucidate these 
effects, mES cells should be infected with a single species. At our laboratory, 
attempts to work with the E14 ES cell line, which is permanently infected with M. 
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hominis, resulted in a lower number of chimeras with a GLT of 40% in comparison to 
E14 Tg2a mycoplasma-free ES cells which show a GLT of 80%. However, the 
chimeras obtained were normal, in contrast to some obtained in the present study. 
This observation, the knowledge based on the effects of a M. fermentans infection on 
humans and the fact that M. orale is pathogenic only under certain conditions 
implicate that M. fermentans plays a major role in the phenotype of the chimeras 
obtained in the present study. 
 In view of the increasing use of mES cell lines in biomedical research for the 
production of transgenic und knock-out mice and the present data, it is of paramount 
importance to screen mES cells for mycoplasmas prior to their use. In this way, one 
can contribute to animal welfare since the number of mice used would be reduced 
and misinterpretation of experimental results and phenotypic characteristics is 
avoided.  
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6. Summary 
 
 In biomedical research, murine ES (mES) cells are used for the production of 
transgenic and knock-out mice which serve as animal models for human and animal 
diseases. The extensive exchange of mES cells between laboratories increases the risk 
of contaminations since mES cell lines are often used without determination of their 
microbiological status. Mycoplasmas can influence various cell parameters and 
ultimately, the interpretation of experimental data. In cell cultures, mycoplasma 
contaminations are 15 to 35% worldwide with extreme incidences of 65 to 80%. In this 
study, the objective was to determine the effects of mycoplasmas on mES cells during 
in vitro culture, the germ line transmission (GLT) of mES cells, and the resulting 
chimeric progeny. For reliable detection of mycoplasmas in mES cell cultures, 4 
detections methods were evaluated concurrently with regards to the limit of detection of 
the human species M. hominis, M. fermentans, and M. orale in cell culture supernatants 
and in cells. The mES cell line TBV2 (129/SvPas) was inoculated at passage P13 with 
the above-mentioned mycoplasma species and cultured over 20 passages, whereby the 
growth rate, viability, the karyotype, and the differentiation status of the mES cells were 
determined. Furthermore, the GLT was examined after injection of mES cells at 
passages P13+5, P13+10, P13+15, and P13+20 into Crl:CD1 (Icr) blastocysts, transfer 
of the embryos in Crl:CD1 (Icr) pseudopregnant recipients and breeding of the resulting 
chimeras with C57BL/6 mice. 
The data show that each method was able to detect mycoplasmas while agar 
culture and the MycoSensorTM QPCR were the most sensitive methods compared to the 
in-house established PCR and the MycoAlertTM assay. mES cells became infected with 
all three mycoplasma species, showing reduced growth rate and viability compared to 
control mES cells. Spectral karyotypic analysis of both control and infected mES cells 
revealed numeric aberrations with trisomies 1, 6, and 11. In addition, mycoplasma-
infected mES cells showed a number of non-clonal chromosomal aberrations, which 
increased with the duration of infection. The pluripotential status of the control mES 
cells, determined by double staining with the differentiation markers anti-OCT-4 and 
anti-SSEA-1 and flow cytometric analysis (FACS), showed that control mES cells were 
highly pluripotent, expressing both markers at passages P13+6 (84.8%), P13+11 
(86.7%), P13+16 (87.8%), and P13+21 (78%). Mycoplasma-infected mES cells were 
less pluripotent at passage P13+6 (46.3%), where the infection was strongest, and 
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pluripotency at passages P13+11, P13+16, and P13+21 was 83%, 78%, and 69.4%, 
respectively. As a result, the GLT of mycoplasma-infected mES cells at passage P13+5 
was most affected (50%) with reductions in the number of litters obtained (50%) and in 
the numbers of pups born (22%) compared to the number of embryo transfers 
performed. In comparison, the control group showed 90% GLT at passage P13+5, with 
100% litters and 45% pups born. Furthermore, 30 out of 73 chimeras obtained from 
blastocyst injection with mycoplasma-infected mES cells at passages P13+10 to 
P13+20 showed a phenotype with nasal discharge, osteoarthropathia, and cachexia. 
The same phenotype was not observed in the F1 generation after breeding of chimeras 
with C57BL/6 mice. For chimeras generated with mycoplasma-infected mES cells, 
immunological analysis of murine plasma by the bead array based assay (bioplex), 
ELISA and flow cytometric analysis (FACS) showed reduced proportions of T-cells and 
increased levels of IgG1, IgG2a and IgM as well as increased levels of anti-DNA and 
rheumatoid antibodies, suggesting the presence of infection and/or an autoimmune 
situation. 
 In view of the increasing use of mES cell lines in biomedical research for the 
production of transgenic und knock-out mice and the present data, it is of paramount 
importance to screen mES cells for mycoplasmas prior to their use. In this way, one can 
contribute to animal welfare since the number of mice used would be reduced and 
misinterpretation of experimental results and phenotypic characteristics are avoided. 
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7. Zusammenfassung 
 
Mykoplasmakontamination von murinen embryonalen Stammzellen: 
Nachweissensitivität, Einfluss auf Zytogenetik, Keimbahntransmission und 
Chimärennachkommen 
 
 Murine embryonale Stammzellen (mES Zellen) werden in der biomedizinischen 
Forschung zur Herstellung von transgenen und knock-out Mäusen, die als Tiermodelle 
für Pathogenesestudien dienen, eingesetzt. Mit zunehmendem Austausch von mES 
Zellen zwischen Laboratorien steigt auch die Gefahr ihrer mikrobiellen Kontamination, 
insbesondere mit Mykoplasmen. Dadurch werden verschiedene Zellparameter 
verändert und die Interpretation von experimentellen Daten beeinflusst. Weltweit 
kommen Mykoplasmen in 15 bis 35% der Zellkulturen vor und erreichen eine Prävalenz 
von mitunter bis zu 80%.  
Ziel der vorliegenden Arbeit war es, die Einflüsse von Mykoplasmen auf mES 
Zellen bezüglich zellbiologischer Parameter, auf die Keimbahntransmission und die 
daraus resultierenden Chimären zu untersuchen. Dazu wurden mES Zellen der Linie 
TBV2 (129/SvPas) bei Passage P13 mit den bei Zellkulturen prävalenten Stämmen M. 
hominis, M. fermentans und M. orale inokuliert und über 20 Passagen kultiviert.  
Von den untersuchten Nachweismethoden waren die Agarkultur und die 
MycoSensorTM QPCR die sensitivsten, gefolgt von einer selbst dafür etablierten PCR 
und dem MycoAlertTM Assay. Mycoplasma-infizierte mES Zellen zeigten eine niedrigere 
Wachstumsrate und geringere Vitalität im Vergleich zu Kontrollzellen. Die 
Karyotypisierung von nicht-infizierten und infizierten mES Zellen zeigte eine Reihe von 
chromosomalen Aberrationen einschließlich Trisomie 1, 6 und 11. Bei den infizierten 
mES Zellen wurden außerdem mehrere non-klonale chromosomale Aberrationen 
festgestellt, die mit der Infektionsdauer zunahmen. Die durch eine Doppelmarkierung 
der Differenzierungsmarker OCT-4 und SSEA-1 und mittels FACS ermittelte Pluripotenz 
nicht-infizierter mES Zellen lag zwischen Passage P13+6 und P13+21 bei 84.8 - 78%. 
Bei Mykoplasma-infizierten mES Zellen lag sie bei Passage P13+6 mit der stärksten 
Infektion bei 46.3%, während sie bei Passage P13+11, P13+16 bzw. P13+21 jeweils 
83%, 78% bzw. 69.4% betrug. Die Keimbahntransmission Mykoplasma-infizierter mES 
Zellen lag bei Passage P13+5 bei 50% mit 22% Nachkommen, bei den Kontrollen lag 
sie bei 90%, mit 100% Würfen und 45% Nachkommen. In 30 von 73 Chimären der F1 
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Generation, die durch die Blastozysteninjektion mit Mykoplasma-infizierten mES Zellen 
von Passage P13+10 bis P13+20 entstanden, wurden Nasenausfluss, 
Osteoarthropathie, und Kachexie festgestellt. Bei Rückverpaarungen der Chimäre mit 
C57BL/6 Mäusen wurden keine Veränderungen festgestellt. F1 Chimären, die aus 
Mykoplasma-infizierten mES Zellen entstanden, zeigten eine Reduktion der Proportion 
von T-Zellen und eine Erhöhung der IgG1-, IgG2a-, IgM-, anti-DNA- und 
rheumatypischen Antikörper-Spiegel. Diese Ergebnisse deuten auf die Anwesenheit 
einer Infektion und/oder einen autoimmunen Zustand hin. 
 Ausgehend vom zunehmenden Einsatz von mES Zellen in der biomedizinischen 
Forschung bei der Herstellung von transgenen und knock-out Mäusen und den 
vorliegenden Daten ist es unabdingbar, mES Zellen vor ihrer Verwendung auf eine 
Kontamination mit Mykoplasmen zu überprüfen und kontaminierte Zellen zu verwerfen. 
Dadurch kann der Bedarf an Versuchstieren reduziert und langfristig ein Beitrag zum 
Tierschutz geleistet werden. Schließlich vermeiden derartige Kontrollmaßnahmen 
falsche Interpretationen von experimentellen und Phänotypisierungsergebnissen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials  99 
 
8. MATERIALS 
 
The following antibodies, chemicals, equipment, enzymes, kits, materials, hormones, 
anaesthetics, and reagents were used for this project. 
 
Antibodies 
Alexa Fluor 700/   BioLegend, San Diego, CA, USA 
rat anti-mouse CD45 
Alexa fluor 610/   BioLegend, San Diego, CA, USA 
rat anti-mouse CD45 
Anti-BiotinCy-5   Rockland, Biomol, Hamburg, Germany 
Anti-Biotin Cy-5.5   Rockland, Biomol, Hamburg, Germany 
Anti-digoxigenin   Roche Diagnostics, Mannheim, Germany 
Anti-DNA Abs (LPR control) Jackson Labs, Maine, USA 
Anti-mouse CD16/CD32  Pharmingen, BD, Heidelberg, Germany 
Anti-mouse Polyvalent  Biozol Diagnostica GmbH, Eching, Germany 
Immunoglobulins-AP 
Anti-Oct 3/4    R and D Systems Inc., Minneapolis, USA 
Anti-SSEA-1    R and D Systems Inc., Minneapolis, USA 
APC-Alexa 750/   Caltag Laboratories GmbH, Hamburg, German 
rat anti-mouse B220 
APC-Alexa 750/   Caltag Laboratories GmbH, Hamburg, Germany 
rat anti-mouse CD8a 
APC rat anti-mouse CD5  Pharmingen, BD, Heidelberg, Germany 
DNA (LPR-control)   Jackson Labs, Maine, USA 
FITC rat anti-mouse CD44 Pharmingen, BD, Heidelberg, Germany 
FITC rat anti-mouse IgD  Pharmingen, BD, Heidelberg, Germany 
Mouse IgM APC   Pharmingen, BD, Heidelberg, Germany 
PE anti-mouse CD4 (L3T4) Pharmingen, BD, Heidelberg, Germany 
PB rat anti-mouse CD3  eBioscience, San Diego, CA, USA 
PB rat anti-mouse CD11b  Caltag Laboratories GmbH, Hamburg, German 
PE-Alexa Fluor 610/  Caltag Laboratories GmbH, Hamburg, German 
rat anti-mouse CD4 
PE armenian hamster/  Pharmingen, BD, Heidelberg, Germany 
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anti-mouse γδTCR  
PerCpCy55 rat anti-mouse CD4 Pharmingen, BD, Heidelberg, Germany 
PE-Cy7 rat anti-mouse CD62L eBioscience, San Diego, CA, USA 
PE-Cy7 rat anti-mouse CD19 Pharmingen, BD, Heidelberg, Germany 
PE rat anti-mouse NK-T/NK Pharmingen, BD, Heidelberg, Germany 
RH factor (LPR control)  Dr Bruno Lukow, LMU, Germany 
 
Chemicals 
Acetic acid CH3COOH  Merck, Darmstadt, Germany 
Acid violet    Merck, Darmstadt, Germany 
Chloral hydrate   Merck, Darmstadt, Germany 
Citric acid    Merck, Darmstadt, Germany 
Colcemid 10µg/ml   Roche Diagnostic GmbH, Mannheim, Germany 
DAPI 1mg/ml   Sigma-Aldrich Chemie GmbH, Steinheim, Germany  
EMA (500 mg/ml) Mol. Bioprobes, InvitrogenTM, Karlsruhe, Germany 
Eosin     Medite, Burgdorf, Germany 
Ethanol    Merck, Darmstadt, Germany 
Ethidium bromide   Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
FeCl3     Merck, Darmstadt, Germany 
Formamide    Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Formalin    Sigma-Aldrich Chemie GmbH, Steinhein, Germany 
HCl     Merck, Darmstadt, Germany  
KAl(SO4) 12H2O   Merck, Darmstadt, Germany 
KCl      Neolab GmbH, Heidelberg, Germany 
KCl     Merck, Darmstadt, Germany 
KH2PO4    Merck, Darmstadt, Germany 
Methanol CH3OH   Merck, Darmstadt, Germany 
MgCl2     Merck, Darmstadt, Germany 
MgCl2 (50 mM)   InvitrogenTM, Carlsbad, CA, USA 
MgCl26H2O    Sigma-Aldrich Chemie GmbH, Steinhein, Germany 
MgSO4    Merck, Darmstadt, Germany 
NaCl     Merck, Darmstadt, Germany  
NaH2PO4    Merck, Darmstadt, Germany 
Na2HPO4    Merck, Darmstadt, Germany 
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NaJO3    Merck, Darmstadt, Germany 
NaN3     Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
NaOH     Merck, Darmstadt, Germany 
NH4Cl     Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Nitric acid    Merck, Darmstadt Germany 
Nonidet P40 Fluka, Sigma-Aldrich Chemie GmbH Germany 
Paraffin w/o DMSO   Merck, Darmstadt, Germany 
PI (2 mg/ml)    Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Picric acid    Merck, Darmstadt Germany 
Phenol Red 1%   Sigma-Aldrich Chemie GmbH, Steinheim, Germany  
Sodium azide   Merck, Darmstadt, Germany 
Sodium citrate   Merck, Darmstadt, Germany  
Tris-HCl    Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Trypan blue dye   Biochrom AG, Berlin, Germany 
Xylol     Merck, Darmstadt, Germany 
 
Equipment 
Applied Biosystem 7500  
Real-time PCR System  Applied Biosystem, Singapore 
Biometra Thermocycler  Biometra, Germany 
Bio-Plex reader   Biorad, Hercules, CA, USA 
Centrifuge     Eppendorf, Hamburg, Germany 
Centrifuge    Hettich Universal 30 F, Tuttingen, Germany 
Centrifuge 5415 D   Eppendorf, Hamburg, Germany 
Eppendorf centrifuge 5804 Eppendorf, Hamburg, Germany 
FACS LSR II    BD, San Diego, USA 
Heated block HLC   HBT 130, Bovenden, Germany 
Heraeus Megafuge 2.0  Hereaus GmbH, Hanau, Germany 
Incubator    Queue Systems Inc., Ashville, USA 
Incubator    Binder, Tuttingen, Germany 
Luminometer Microlumat LB 96P Berthold Technologies, Bad Wildbad, Germany 
Microinjection manipulator  Leitz DM IRB, Leica, Bensheim, Germany 
Microm 355    Walldorf, Germany  
Plate shaker    Heidolph, Schwabach, Germany 
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Shaker, Multifuge 3 S-R  Hereaus, Hanau, Germany 
Stereoscopic microscope  Leica, Bensheim, Germany 
Thermomixer compact  Eppendorf, Hamburg, Germany 
Vacuum Infiltrations Processsor Sakura Finetek GmbH, Heppenheim, Germany 
Vacuum manifold   Biorad, Hercules, CA, Germany 
TECAN SUNRISETM reader TECAN GmbH, Crailsheim, Germany 
TECAN washer   TECAN GmbH, Crailsheim, Germany  
Tomtec-Robot Quadra 3  Biozym Scientific GmbH, Oldendorf, Germany 
 
Enzymes 
Platinum Taq DNA Polymerase InvitrogenTM, Carlsbad, CA, USA 
Poly-L-Lysine   Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
RNase A    Fermentas, St. Leon-Rot, Germany  
Trypsin/EDTA   Biochrom AG, Berlin, Germany 
Xba I, Hpa II, and Hae III  InvitrogenTM, Carlsbad, CA, USA 
 
Kits 
Bio Plex assay kit   Biorad, Hercules, CA, USA  
Foxp3 Staining Buffer set  eBioscience, San Diego, CA, USA 
MycoSensorTM QPCR Assay kit Stratagene, La Jolla, CA, USA 
MycoAlertTM Assay Control Set Lonza Verviers, Liege, Belgium 
MycoAlertTM assay kit  Lonza Verviers, Liege, Belgium 
MycoSensorTM QPCR Assay kit Stratagene, La Jolla, CA, USA 
Wizard Clean-Up System  Promega, Mannheim, Germany  
 
Materials 
Auto clips 9 mm   Clay Adams, BD Company, NJ., USA 
Cryo tube vials   NuncTM, Roskilde, Denmark 
Coverslips    Menzel, Braunschweig, Germany 
Coverslips    IDL GmbH, Nidderau, Germany  
Cryo tube vials   NuncTM, Roskilde, Denmark 
Culture dishes CELLSTAR® Greiner Bio-One GmbH, Frickenhausen, Germany 
Dilution plates   Greiner Bio-One GmbH, Frickenhausen, Germany 
ELISA plates    NuncTM, Roskilde, Denmark 
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Eppendorf tubes   Eppendorf, Hamburg, Germany 
Falcon tubes    Becton Dickinson and Company, N.J., USA 
Falcon Petri dishes   BD and Company, Sparks, USA 
Injection pipettes   BioMedical Instruments, Zöllnitz, Germany 
Haemocytometer Hycor Biomedical Inc., Kassel, Germany 
IVCs     VentiRacks™; BioZone, Margate, UK 
Makrolon® cages    
MillexTM Filter 0.22 µm  Millipore, Carrigtwohill, Co. Cork, Ireland 
Mineral oil    Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Needle, 27-gauge   Braun, Melsungen, Germany 
Petri dishes    NuncTM, Roskilde, Denmark 
Petri dishes    NunclonTM Surface, NuncTM, Roskilde, Denmark 
Rubber cement   Fixogum, Marabu, Tamm, Germany 
Standardized mouse diet1314 Altromin, Lage, Germany  
Super frost object slide  Neolab Migge GmbH, Munich, Germany 
Super Frost plus slides  Roth, Karlsruhe, Germany 
Tubes     Sarstedt, Mumbrecht, Germany 
Vectashield mounting medium Vector Laboratories, Burlingame, CA, USA  
Vicryl 4-0     Johnson and Johnson Intl., Woluwe, Belgium 
Wood shavings    Altromin, Lage, Germany  
96-well white microplate  NuncTM, Roskilde, Denmark 
96-well white microplate  Applied Biosystems, Singapore 
 
Hormones and anaesthetics  
 
Equine chorionic gonadotropin Intergonan® 1000 I.U, Intervet, Germany 
Human chorionic gonadotropin Ovogest® 1500 I.U, Intervet, Germany  
Ketavet® 100 mg/ml  Pfizer, Karlsruhe, Germany 
Sedaxylan 20 mg/ml  WDT, Garbsen, Germany  
Vetranquil 1%   Ceva GmbH, Düsseldorf, Germany 
Vetalgin® 500 mg/ml  Intervet GmbH, Unterschleißheim, Germany 
 
Reagents 
Agar No.1    Oxoid, Hampshire, England 
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Agarose    Biozym Scientific GmbH, Oldendorf, Germany 
Bacto brain heart infusion  Oxoid, Hampshire, England 
Blotting Blocker Dry Milk  Biorad, Hercules, CA, USA 
BSA     Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Calf thymus DNA   Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
DEAE-Dextran 1%   Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
DifcoTM Bacto PPLO-Agar  BD and Company, Sparks, USA 
DifcoTM Bacto PPLO-Broth BD and Company, Sparks, USA 
DMEM (1x)    Gibco, InvitrogenTM, Paisley, UK 
DMEM     Biochrom, Berlin, Germany 
DMSO 99.5% GC   Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
DNase I (100 mg)   Roche Diagnostics, Mannheim, Germany 
DNA solution   Takara BIO Inc., Japan  
dNTP     Fermentas, St- Leon-Rot, Germany 
EDTA     Roth, Karsruhe, Germany 
Ethanol    Merck, Darmstadt, Germany  
Eukitt mounting medium  Kindler, Freiburg, Germany 
Fetal calf serum   Seromed, Biochrom, Berlin, Germany 
Fetal calf serum for ES cells  PANTM, BIOTECH GmbH, Aidenbach, Germany 
Glutamine 200 mM   Biochrom, Berlin, Germany 
HBSS     Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Heat-inactivated horse serum Gibco, InvitrogenTM, Auckland, New Zealand 
Heat-inactivated porcine serum Gibco, InvitrogenTM, Auckland, New Zealand 
Heparin (25.000 I.U)  Roche, Mannheim, Germany 
Inactivated fetal calf serum  Seromed, Biochrom, Berlin, Germany 
LIF     Chemicon International Inc., CA, USA 
Loading buffer   Fermentas, St. Leon-Rot, Germany 
Mitomycin C (1 mg/ml)  Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Mouse Spectral Karyotyping Applied Spectral Imaging, Edingen, Germany 
M2 Medium    Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Non-essential amino acids Biochrom, Berlin, Germany 
PBS     Biochrom, Berlin, Germany 
PBS     Gibco, InvitrogenTM, Auckland, New Zeeland 
PCR buffer (10 x)   InvitrogenTM, Carlsbad, CA, USA 
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Penicillin-Streptomycin  Gibco, InvitrogenTM, Paisley, UK 
React® 2 and 8 buffer  InvitrogenTM, Carlsbad, CA, USA 
p-Nitrophenyl Phosphate tabs Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Tween® 20    Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium Chloride 0.9%  Fresenius Kabi GmbH, Homburg v. d. H., Germany 
Yeast extracts 25%w/v  Fluka, Sigma-Aldrich Chemie GmbH, Germany 
β-Mercaptoethanol   Gibco, InvitrogenTM, Paisley, UK 
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9. List of abbreviations  
Abs      Antibodies 
amp      amplification 
AP      alkaline phosphatase 
APC      allophycocyanin 
ATP      adenosine triphosphate 
BSA      bovine serum albumin 
CFU      colony forming unit 
Cy      cyanine 
d      day 
d      deletion 
DAPI      diamidinophenylindole 
der      derivation 
DEAE      diethylaminoethyldextran 
DIA      differentiation inhibitoring factor 
DNA      deoxyribonucleic acid 
dNTP      deoxynucleotides 
D-MEM     Dulbeccos’s Modified Eagle’s Medium 
DMSO     dimethyl sulfoxide 
dpc      days post coitus 
eCG      equine Chorionic Gonadotropin 
EC      embryonic carcinoma 
EDTA      ethylene diamine tetraacetate 
ELISA      Enzyme Linked Immunobsorbent Assay 
EMA      ethidium monoazide 
EMFI      embryonic murine fibroblasts 
ESM      embryonic stem cell medium 
FACS      fluoresence activated cell sorting 
FCS      fetal calf serum 
FeCl3      iron chloride 
FITC      fluorescein isothiocyanate  
g      gram 
G      gauge 
G+C      guanine+cytosine 
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GLT      germ line transmission 
GPI      glucosephosphate isomerase 
h      hour 
HBSS      hank’s balanced salt solution 
hCG      human chorionic gonadotropin 
HIV      Human immunodeficiency virus 
ICM      inner cell mass 
IL      Interleukin 
ins      insertion 
IU      international unit 
i.p      intraperitoneal 
KAl(SO4)     potassium aluminium sulfate 
kb      kilo base 
KH2PO4     mono potassium phosphate 
KCl      potassium chloride 
l      liter 
LIF      leukemia inhibitory factor 
LOD      limit of detection 
MALP      macrophage activating lpoprotein 
µg      microgram 
µl      microliter 
ml      mililiter 
mm      milimeter 
mM      milimole 
M2      wash medium for blastocysts 
MCP      macrophage chemoattractant lipoprotein 
MEFS      murine embryonic fibroblasts 
mES      murine embryonic stem cells 
MgCl2      magnesium chloride 
MgSO4     magnesium sulfate 
MIP      macrophage inflammatory protein 
MMC      mitomycin C 
MRA      mycoplasmal removal agent 
mRNA     messenger ribonucleic acid 
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NaCl      sodium chloride 
Na2HPO4     disodium hydrogen phosphate 
NaH2PO4     monosodium phosphate 
NaJO3      sodium iodate 
NaN3      sodium azide 
NaOH      sodium hydroxide 
n.d      not done 
NH4CH     ammonium chloride 
Nr.      number 
Oct-4      Octamer-binding protein-4 
OD      optical density 
PBS      phosphate buffered saline 
PCR      polymerase chain reaction 
PerCp      peridinin chlorophyll protein  
PGCs      primordial germ cells 
PE      phycoerythrine 
PI      propidium iodide 
PN      phosphate nonidet 
PNM      phosphate nonidet with dry milk 
POU      pit (pituitary), oct (octamer), unc 
PPLO      pleuropneumonia like organisms 
QPCR     quantitative polymerase chain reaction 
RH      rheumatoid 
RNA      ribonucleic acid 
s.c      subcutaneously 
SSC      standard saline citrate 
SSEA      stage specific embryonic antigen 
SKY      spectral karyotyping 
t      translocation 
ter      terminal end of chromatid 
TNF-α      tumor necrosis factor-α 
Tm      melting temperature 
Tris-HCl     hydroxymethyl aminomethane hydrochloride 
Vaa      variable adherence associated 
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